Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006; 26:1730-44.
Saadat M. Haplotype analysis of XRCC1 (at codons 194 and 399) and susceptibility to breast cancer, a meta-analysis of the literatures. Breast Cancer Res Treat 2010; 124:785-91.
Saare M, Belousova A, Punab M et al. Androgen receptor gene haplotype is associated with male infertility. Int J Androl 2008; 31:395-402.
Saari TI, Grönlund J, Hagelberg NM et al. Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone. Eur J Clin Pharmacol 2010; 66:387-97.
Saari TI, Laine K, Bertilsson L, Neuvonen PJ, Olkkola KT. Voriconazole and fluconazole increase the exposure to oral diazepam. Eur J Clin Pharmacol 2007; 63:941-9.
Sabahi Z, Salek R, Heravi RE, Mosaffa F, Avanaki ZJ, Behravan J. Association of gastric cancer incidence with MDR1 gene polymorphism in an ethnic Iranian population. Indian J Cancer 2010; 47:317-21.
Sabatti C, Service SK, Hartikainen AL et al. Genome-wide association analysis of metabolic traits in a birth cohort from a founder population. Nat Genet 2009; 41:35-46.
SabbaghY, Carpenter TO, Demay MB. Hypophosphatemia leads to rickets by impairing caspase-mediated apoptosis of hypertrophic chondrocytes. Proc Nat Acad Sci USA 2005; 102:9637-42.
Sabeva NS, McPhaul CM, Li X, Cory TJ, Feola DJ, Graf GA. Phytosterols differentially influence ABC transporter expression, cholesterol efflux and inflammatory cytokine secretion in macrophage foam cells. J Nutr Biochem 2011; 22:777-83.
Sabl JF, Laird CD. Epigene conversion: a proposal with implications for gene mapping in humans. Am J Hum Genet 1992; 50:1171-7.
Sabnis GJ, Goloubeva O, Chumsri S, Nguyen N, Sukumar S, Brodie AM. Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole. Cancer Res 2011; 71:1893-903.
Sabol SZ, Hamer DH. An improved assay shows no association between the CYP2A6 gene and cigarette smoking behavior. Behav Genet 1999; 29:257-61.
Sabol SZ, Hu S, Hamer D. A functional polymorphism in the monoamine oxidase A gene promoter. Hum Genet 1998; 103:273-9.
Sabol SZ, Nelson ML, Fisher C et al. A genetic association for cigarette smoking behavior. Health Psychol 1999; 18:7-13.
Sabolovic N, Heydel JM, Li X et al. Carboxyl nonsteroidal anti-inflammatory drugs are efficiently glucuronidated by microsomes of the human gastrointestinal tract. Biochim Biophys Acta 2004; 1675:120-9.
Saccucci P, Meloni GF, Verrotti A et al. A study of three polymorphic sites of the ADA gene in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2010; 23:283-90.
Saçkesen C, Karaaslan C, Keskin O et al. The effect of polymorphisms at the CD14 promoter and the TLR4 gene on asthma phenotypes in Turkish children with asthma. Allergy 2005; 60:1485-92.
Sackmann S, Lichtenauer U, Shapiro I, Reincke M, Beuschlein F. Aldosterone producing adrenal adenomas are characterized by activation of calcium/calmodulin-dependent protein kinase (CaMK) dependent pathways. Horm Metab Res 2011; 43:106-11.
Sacks PG, Zhao ZL, Kosinska W, Fleisher KE, Gordon T, Guttenplan JB. Concentration dependent effects of tobacco particulates from different types of cigarettes on expression of drug metabolizing proteins, and benzo(a)pyrene metabolism in primary normal human oral epithelial cells. Food Chem Toxicol 2011; 49:2348-55.
Sachse C, Brockmöller J, Bauer S, Reum T, Roots I. A rare insertion of T226 in exon 1 of CYP2D6 causes a frameshift and is associated with the poor metabolizer phenotype: CYP2D6*15. Pharmacogenetics 1996; 6:269-72.
Sachse C, Brockmöller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60:284-95.
Sachse C, Brockmoller J, Bauer S, Roots I. Functional significance of a C-to-A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Brit J Clin Pharm 1999; 47:445-9.
Sachse C, Brockmöller J, Hildebrand M, Müller K, Roots I. Correctness of prediction of the CYP2D6 phenotype confirmed by genotyping 47 intermediate and poor metabolizers of debrisoquine. Pharmacogenetics 1998; 8:181-5.
Sachs-Erisson N, Sawyer K, Corsentino E, Collins N, Steffens DC. The moderating effect of the APOE [small element of] 4 allele on the relationship between hippocampal volume and cognitive decline in older depressed patients. Am J Geriatr Psychiatry 2011; 19:23-32.
Sachse-Seeboth C, Pfeil J, Sehrt D et al. Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. Clin Pharmacol Ther 2009; 85:273-6.
Sádaba B, Campanero MA, Quetglas EG, Azanza JR. Clinical relevance of sirolimus drug interactions in transplant patients. Transplant Proc 2004; 36:3226-8.
Sadahiro S, Suzuki T, Maeda Y et al. Molecular determinants of folate levels after leucovorin administration in colorectal cancer. Cancer Chemother Pharmacol 2010; 65:735-42.
Sadeque AJ, Fisher MB, Korzekwa KR, Gonzalez FJ, Rettie AE. Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid. J Pharmacol Exp Ther 1997; 283:698-703.
Sadick H, Hage J, Goessler U et al. Mutation analysis of “Endoglin” and “Activin receptor-like kinase” genes in German patients with hereditary hemorrhagic telangiectasia and the value of rapid genotyping using an allele-specific PCR-technique. BMC Med Genet 2009; 10:53.
Sadler BM, Gillotin C, Lou Y et al. Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir. Antimicrob Agents Chemother 2001; 45:3663-8.
Sadrieh N, Snyderwine EG. Cytochromes P450 in cynomolgus monkeys mutagenically activate 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) but not 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx). Carcinogenesis 1995; 16:1549-55.
Sadzuka Y, Inoue C, Hirooka S, Sugiyama T, Umegaki K, Sonobe T. Effects of theanine on alcohol metabolism and hepatic toxicity. Biol Pharm Bull 2005; 28:1702-6.
Saeki M, Kurose K, Hasegawa R, Tohkin M. Functional analysis of genetic variations in the 5’-flanking region of the human MDR1 gene. Mol Genet Metab 2011; 102:91-8.
Saeki M, Kurose K, Tohkin M, Hasegawa R. Identification of the functional vitamin D response elements in the human MDR1 gene. Biochem Pharmacol 2008; 76:531-42.
Saeki M, Ozawa S, Saito Y et al. Three novel single nucleotide polymorphisms in UGT1A10. Drug Metab Pharmacokinet 2002; 17:488-90.
Saeki M, Saito Y, Jinno H et al. Single nucleotide polymorphisms and haplotype frequencies of UGT2B4 and UGT2B7 in a Japanese population. Drug Metab Dispos 2004; 32:1048-54.
Saeki M, Saito Y, Jinno H et al. Genetic polymorphisms of UGT1A6 in a Japanese population. Drug Metab Pharmacokinet 2005; 20:85-90.
Saeki M, Saito Y, Jinno H et al. Genetic variations and haplotypes of UGT1A4 in a Japanese population. Drug Metab Pharmacokinet 2005; 20:144-51.
Saeki M, Saito Y, Jinno H et al. Haplotype structures of the UGT1A gene complex in a Japanese population. Pharmacogenomics J 2006; 6:63-75.
Saeki M, Saito Y, Jinno H et al. Three novel single nucleotide polymorphisms in UGT1A9. Drug Metab Pharmacokinet 2003; 18:146-9.
Sáenz López P, Vázquez Alonso F, Romero JM et al. Polymorphisms in inflammatory response genes in metastatic renal cancer. Actas Urol Esp 2009; 33:474-81.
Saetre P, Lundmark P, Wang A et al. The tryptophan hydroxylase 1 (TPH1) gene, schizophrenia susceptibility, and suicidal behavior: a multi-centre case-control study and meta-analysis. Am J Med Genet B Neuropsychiatr Genet 2010; 153:387-96.
Saewong T, Ounjaijean S, Mundee Y et al. Effects of green tea on iron accumulation and oxidative stress in livers of iron-challenged thalassemic mice. Med Chem 2010; 6:57-64.
Safa AR, Stern RK, Choi K et al. Molecular basis of preferential resistance to colchicine in multidrug-resistant human cells conferred by Gly185-to-Val185 substitution in P-glycoprotein. Proc Nat Acad Sci USA 1990; 87:7225-9.
Safaei R, Howell SB. Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol 2005; 53:13-23.
Safar ME, Millasseau S, Mahmud A, Blacher J. Relations between large artery structure and function and aldosterone. J Hypertens 2011; 29:1676-83.
Safarinejad MR, Shafiei N, Safarinejad S. The role of endothelial nitric oxide synthase (eNOS) T-786C, G894T, and 4a/b gene polymorphisms in the risk of idiopathic male infertility. Mol Reprod Dev 2010; 77:720-7.
Safranow K, Rzeuski R, Binczak-Kuleta A et al. ADA*2 allele of the adenosine deaminase gene may protect against coronary artery disease. Cardiology 2007; 108:275-81.
Sage AP, Lu J, Atti E et al. Hyperlipidemia induces resistance to PTH bone anabolism in mice via oxidized lipids. J Bone Miner Res 2011; 26:1197-206.
Sagen JV, Raeder H, Hathout E et al. Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6. 2: patient characteristics and initial response to sulfonylurea therapy. Diabetes 2004; 53:2713-8.
Saghir SA, Zhang F, Rick DL, Kan L, Bus JS, Bartels MJ. In vitro metabolism and covalent binding of ethylbenzene to microsomal protein as a possible mechanism of ethylbenzene-induced mouse lung tumorigenesis. Regul Toxicol Pharmacol 2010; 57:129-35.
Sagud M, Mück-Seler D, Mihaljević-Peles A et al. Catechol-O-methyl transferase and schizophrenia. Psychiatr Danub 2010; 22:270-4.
Saha L, Kaur S, Saha PK. Pharmacotherapy of polycystic ovary syndrome – an update. Fundam Clin Pharmacol 2011. doi:10. 1111/j. 1472-8206. 2010. 00916. x.
Saha S, Engström L, Mackerlova L, Jakobsson PJ, Blomqvist A. Impaired febrile responses to immune challenge in mice deficient in microsomal prostaglandin E synthase-1. Am J Physiol Regul Integr Comp Physiol 2005; 288:1100-7.
Saha S, Guillily MD, Ferree A et al. LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. J Neurosci 2009; 29:9210-8.
Sahai J. Risks and synergies from drug interactions. AIDS 1996; 10 Suppl 1:21-5.
Sahan-Firat S, Jennings BL, Yaghini FA et al. 2,3’,4,5’-Tetramethoxystilbene prevents deoxycorticosterone-salt-induced hypertension: contribution of cytochrome P-450 1B1. Am J Physiol Heart Circ Physiol 2010; 299:1891-901.
Sahi J, Black CB, Hamilton GA et al. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos 2003; 31:439-46.
Sahi J, Hamilton G, Sinz M et al. Effect of troglitazone on cytochrome P450 enzymes in primary cultures of human and rat hepatocytes. Xenobiotica 2000; 30:273-84.
Sahi J, Milad MA, Zheng X et al. Avasimibe induces CYP3A4 and multiple drug resistance protein 1 gene expression through activation of the pregnane X receptor. J Pharmacol Exp Ther 2003; 306:1027-34.
Sahi J, Shord SS, Lindley C, Ferguson S, LeCluyse EL. Regulation of cytochrome P450 2C9 expression in primary cultures of human hepatocytes. J Biochem Mol Toxicol 2009; 23:43-58.
Sahi J, Sinz MW, Campbell S et al. Metabolism and transporter-mediated drug-drug interactions of the endothelin-A receptor antagonist CI-1034. Chem Biol Interact 2006; 159:156-68.
Sahney S. A review of calcium channel antagonists in the treatment of pediatric hypertension. Paediatr Drugs 2006; 8:357-73.
Sahu R, Boddula R, Sharma P et al. Genetic analysis of the SRD5A2 gene in Indian patients with 5alpha-reductase deficiency. J Pediatr Endocrinol Metab 2009; 22:247-54.
Sai K, Kaniwa N, Ozawa S, Sawada JI. A new metabolite of irinotecan in which formation is mediated by human hepatic cytochrome P-450 3A4. Drug Metab Dispos 2001; 29:1505-13.
Sai K, Saeki M, Saito Y et al. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther 2004; 75:495-500.
Sai K, Saito Y, Fukushima-Uesaka H et al. Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients. Cancer Chemother Pharmacol 2008; 62:529-37.
Sai K, Saito Y, Itoda M et al. Genetic variations and haplotypes of ABCC2 encoding MRP2 in a Japanese population. Drug Metab Pharmacokinet 2008; 23:139-47.
Sai K, Saito Y, Maekawa K et al. Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients. Cancer Chemother Pharmacol 2010; 66:95-105.
Sai K, Saito Y, Tatewaki N et al. Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients. Br J Clin Pharmacol 2010; 70:222-33.
Sai K, Saito Y. Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs. Expert Opin Drug Metab Toxicol 2011; 7:967-88.
Sai Y, Dai R, Yang TJ et al. Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450. Xenobiotica 2000; 30:327-43.
Said A, Garnick JJ, Dieterle N, Peres E, Abidi MH, Ibrahim RB. Sirolimus-itraconazole interaction in a hematopoietic stem cell transplant recipient. Pharmacotherapy 2006; 26:289-95.
Saidi S, Mahjoub T, Almawi WY. Aldosterone synthase gene (CYP11B2) promoter polymorphism as a risk factor for ischaemic stroke in Tunisian Arabs. J Renin Angiotensin Aldosterone Syst 2010; 11:180-6.
Saidi S, Mallat SG, Almawi WY, Mahjoub T. Association between renin-angiotensin-aldosterone system genotypes and haplotypes and risk of ischemic stroke of atherosclerotic etiology. Acta Neurol Scand 2009; 119:356-63.
Saif MW, Ezzeldin H, Vance K, Sellers S, Diasio RB. DPYD*2A mutation: the most common mutation associated with DPD deficiency. Cancer Chemother Pharmacol 2007; 60:503-7.
Saihan Z, Li Z, Rice J et al. Clinical and biochemical effects of the E139K missense mutation in the TIMP3 gene, associated with Sorsby fundus dystrophy. Mol Vis 2009; 15:1218-30.
Saint-Martin C, Arnoux JB, de Lonlay P, Bellanné-Chantelot C. KATP channel mutations in congenital hyperinsulinism. Semin Pediatr Surg 2011; 20:18-22.
Sainz J, Rudolph A, Hein R et al. Association of genetic polymorphisms in ESR2, HSD17B1, ABCB1, and SHBG genes with colorectal cancer risk. Endocr Relat Cancer 2011; 18:265-76.
Saito H, Dhanasekaran P, Baldwin F, Weisgraber KH, Phillips MC, Lund-Katz S. Effects of polymorphism on the lipid interaction of human apolipoprotein E. J Biol Chem 2003; 278:40723-9.
Saito H, Osumi M, Hirano H, Shin W, Nakamura R, Ishikawa T. Technical Pitfalls and Improvements for High-speed Screening and QSAR Analysis to Predict Inhibitors of the Human Bile Salt Export Pump (ABCB11/BSEP). AAPS J 2009; 11:581–9.
Saito J, Fukushima H, Nagase H. Inhibitory effect of magnolol on Trp-P-2-induced DNA damage in various organs in mice. Phytother Res 2009; 23:901-5.
Saito M, Hirata-Koizumi M, Matsumoto M, Urano T, Hasegawa R. Undesirable effects of citrus juice on the pharmacokinetics of drugs: focus on recent studies. Drug Saf 2005; 28:677-94.
Saito M, Hirata-Koizumi M, Miyake S, Hasegawa R. Comparison of information on the pharmacokinetic interactions of Ca antagonists in the package inserts from three countries (Japan, USA and UK). Eur J Clin Pharmacol 2005; 61:531-6.
Saito M, Kawana J, Ohno T et al. Population pharmacokinetics of R- and S-carvedilol in Japanese patients with chronic heart failure. Biol Pharm Bull 2010; 33:1378-84.
Saito M, Yasui-Furukori N, Kaneko S. Clinical pharmacogenetics in the treatment of schizophrenia. Nihon Shinkei Seishin Yakurigaku Zasshi 2005; 25:129-35.
Saito S, Iida A, Sekine A et al. Catalog of 238 variations among six human genes encoding solute carriers ( hSLCs) in the Japanese population. J Hum Genet 2002; 47:576-84.
Saito S, Iida A, Sekine A et al. Catalog of 680 variations among eight cytochrome p450 (CYP) genes, nine esterase genes, and two other genes in the Japanese population. J Hum Genet 2003; 48:249-70.
Saito S, Kato J, Hiraoka S et al. DNA methylation of colon mucosa in ulcerative colitis patients: Correlation with inflammatory status. Inflamm Bowel Dis 2011; 17:1955-65.
Saito T, Takahashi Y, Hashimoto H, Kamataki T. Novel transcriptional regulation of the human CYP3A7 gene by Sp1 and Sp3 through nuclear factor kappa B-like element. J Biol Chem 2001; 276:38010-22.
Saito Y, Katori N, Soyama A et al. CYP2C8 haplotype structures and their influence on pharmacokinetics of paclitaxel in a Japanese population. Pharmacogenet Genomics 2007; 17:461-71.
Saitoh A, Capparelli E, Aweeka F et al. CYP2C19 genetic variants affect nelfinavir pharmacokinetics and virologic response in HIV-1-infected children receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2010; 54:285-9.
Sáiz PA, Morales B, G-Portilla MP et al. Apolipoprotein E genotype and schizophrenia: Further negative evidence. Acta Psychiart Scand 2002; 105:71-5.
Saiz PA, Susce MT, Clark DA et al. An investigation of the alpha1A-adrenergic receptor gene and antipsychotic-induced side-effects. Hum Psychopharmacol 2008; 23:107-14.
Sakaeda T, Fujino H, Komoto C et al. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm Res 2006; 23:506-12.
Sakaeda T, Iwaki K, Kakumoto M et al. Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs. J Pharm Pharmacol 2005; 57:759-64.
Sakai W, Swisher EM, Karlan BY et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008; 451:1116-20.
Sakamoto N, Yamamoto T, Moriwaki Y et al. Identification of a new point mutation in the human xanthine dehydrogenase gene responsible for a case of classical type I xanthinuria. Hum Genet 2001; 108:279-83.
Sakata N, Hoshii Y, Nakamura T et al. Colocalization of apolipoprotein AI in various kinds of systemic amyloidosis. J Histochem Cytochem 2005; 53:237-42.
Sakata S, Fujiwara M, Ohtsuka K et al. ATP-binding cassette transporters in primary central nervous system lymphoma: decreased expression of MDR1 P-glycoprotein and breast cancer resistance protein in tumor capillary endothelial cells. Oncol Rep 2011; 25:333-9.
Saksena S, Goyal S, Raheja G et al. Upregulation of P-glycoprotein by probiotics in intestinal epithelial cells and in the dextran sulfate sodium model of colitis in mice. Am J Physiol Gastrointest Liver Physiol 2011; 300:1115-23.
Sakuma T, Shimojima T, Miwa K, Kamataki T. Cloning CYP2D21 and CYP3A22 cDNAs from liver of miniature pigs. Drug Metab Dispos 2004; 32:376-8.
Sakura H, Wat N, Horton V, Millns H, Turner RC, Ashcroft FM. Sequence variations in the human Kir6. 2 gene, a subunit of the beta-cell ATP-sensitive K-channel: no association with NIDDM in while Caucasian subjects or evidence of abnormal function when expressed in vitro. Diabetologia 1996; 39:1233-6.
Sakurai A, Onishi Y, Hirano H et al. Quantitative structure-activity relationship analysis and molecular dynamics simulation to functionally validate nonsynonymous polymorphisms of human ABC transporter ABCB1 (P-glycoprotein/MDR1). Biochemistry 2007; 46:7678-93.
Sakurai A, Tamura A, Onishi Y, Ishikawa T. Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCG2: therapeutic implications. Expert Opin Pharmacother 2005; 6:2455-73.
Sakurai K, Enomoto K, Amano S. The combined effect of Paclitaxel and toremifene therapy for estrogen receptor positive and aromatase inhibitor resistant metastatic breast cancer. Gan To Kagaku Ryoho 2010; 37:2246-8.
Sakurai M, Higashide T, Takahashi M, Sugiyama K. Association between genetic polymorphisms of the prostaglandin F2alpha receptor gene and response to latanoprost. Ophthalmology 2007; 114:1039-45.
Sakuta R, Goto Y, Nonaka I, Horai S. An A-to-G transition at nucleotide pair 11084 in the ND4 gene may be an mtDNA polymorphism. Am J Hum Genet 1993; 53:964-5.
Sakuyama K, Sasaki T, Ujiie S et al. Functional characterization of 17 CYP2D6 allelic variants (CYP2D6. 2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57). Drug Metab Dispos 2008; 36:2460-7.
Salas R, Main A, Gangitano DA et al. Nicotine relieves anxiogenic-like behavior in mice that overexpress the read-through variant of acetylcholinesterase but not in wild-type mice. Mol Pharmacol 2008; 74:1641-8.
Salcido CD, Larochelle A, Taylor BJ, Dunbar CE, Varticovski L. Molecular characterisation of side population cells with cancer stem cell-like characteristics in small-cell lung cancer. Br J Cancer 2010; 102:1636-44.
Saldivar JS, Lu KH, Liang D et al. Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients. Gynecol Oncol 2007; 107:223-9.
Saleh EM, El-Awady RA, Abdel Alim MA, Abdel Wahab AH. Altered expression of proliferation-inducing and proliferation-inhibiting genes might contribute to acquired doxorubicin resistance in breast cancer cells. Cell Biochem Biophys 2009; 55:95-105.
Salerno AG, Patrício PR, Berti JA, Oliveira HC. Cholesteryl ester transfer protein (CETP) increases postprandial triglyceridaemia and delays triacylglycerol plasma clearance in transgenic mice. Biochem J 2009; 419:629-34.
Salgueiro N, Veiga I, Fragoso M et al. Mutations in exon 14 of dihydropyrimidine dehydrogenase and 5-Fluorouracil toxicity in Portuguese colorectal cancer patients. Genet Med 2004; 6:102-7.
Salimi S, Firoozrai M, Zand H et al. Endothelial nitric oxide synthase gene Glu298Asp polymorphism in patients with coronary artery disease. Ann Saudi Med 2010; 30:33-7.
Salinas-Sánchez AS, Sánchez-Sánchez F, Donate-Moreno MJ et al. GSTT1, GSTM1, and CYP1B1 gene polymorphisms and susceptibility to sporadic renal cell cancer. Urol Oncol 2011. doi:10. 1016/j. urolonc. 2010. 10. 001.
Salmela KS, Kessova IG, Tsyrlov IB, Lieber CS. Respective roles of human cytochrome P-4502E1, 1A2, and 3A4 in the hepatic microsomal ethanol oxidizing system. Alcohol Clin Exp Res 1998; 22:2125-32.
Salmela KS, Tsyrlov IB, Lieber CS. Azide inhibits human cytochrome P -4502E1, 1A2, and 3A4. Alcohol Clin Exp Res 2001; 25:253-60.
Salmén T, Heikkinen AM, Mahonen A et al. Early postmenopausal bone loss is associated with PvuII estrogen receptor gene polymorphism in Finnish women: effect of hormone replacement therapy. J Bone Miner Res 2000; 15:315-21.
Salminen KA, Leppänen J, Venäläinen JI et al. Simple, direct, and informative method for the assessment of CYP2C19 enzyme inactivation kinetics. Drug Metab Dispos 2011; 39:412-8.
Salminen KA, Meyer A, Jerabkova L et al. Inhibition of human drug metabolizing cytochrome P450 enzymes by plant isoquinoline alkaloids. Phytomedicine 2011; 18:533-8.
Salomon JJ, Ehrhardt C. Nanoparticles attenuate P-glycoprotein/MDR1 function in A549 human alveolar epithelial cells. Eur J Pharm Biopharm 2011; 77:392-7.
Salpea KD, Gable DR, Cooper JA et al. The effect of WNT5B IVS3C>G on the susceptibility to type 2 diabetes in UK Caucasian subjects. Nutr Metab Cardiovasc Dis 2009; 19:140-5.
Salphati L, Lee LB, Pang J, Plise EG, Zhang X. Role of P-glycoprotein and breast cancer resistance protein-1 in the brain penetration and brain pharmacodynamic activity of the novel phosphatidylinositol 3-kinase inhibitor GDC-0941. Drug Metab Dispos 2010; 38:1422-6.
Salphati L, Plise EG, Li G. Expression and activity of the efflux transporters ABCB1, ABCC2 and ABCG2 in the human colorectal carcinoma cell line LS513. Eur J Pharm Sci 2009; 37:463-8.
Salsali M, Holt A, Baker GB. Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6. Cell Mol Neurobiol 2004; 24:63-76.
Saltzman BS, Yamamoto JF, Decker R et al. Association of genetic variation in the transforming growth factor beta-1 gene with serum levels and risk of colorectal neoplasia. Cancer Res 2008; 4:1236-44.
Salva M, Jansat JM, Martínez-Tobed A, Palacios JM. Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab Dispos 2003; 31:404-11.
Salvarani C, Zizzi F, Macchioni P et al. Clinical response to auranofin in patients with psoriatic arthritis. Clin Rheumatol 1989; 8:54-7.
Salvatore CA, Moore EL, Calamari A et al. Pharmacological properties of MK-3207, a potent and orally active calcitonin gene-related peptide receptor antagonist. J Pharmacol Exp Ther 2010; 333:152-60.
Sallee FR, DeVane CL, Ferrell RE. Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency. J Child Adolesc Psychopharmacol 2000; 10:27-34.
Sallinen J, Haapalinna A, Viitamaa T, Kobilka BK, Scheinin M. Adrenergic alpha2C-receptors modulate the acoustic startle reflex, prepulse inhibition, and aggression in mice. J Neurosci 1998; 18:3035-42.
Sam SS, Thomas V, Reddy KS, Surianarayanan G, Chandrasekaran A. Gene-gene interactions of drug metabolizing enzymes and transporter protein in the risk of upper aerodigestive tract cancers among Indians. Cancer Epidemiol 2010; 34:626-33.
Samaia HB, Mari JJ, Vallada HP et al. A prion-linked psychiatric disorder. Nature 1997; 390:241.
Samarajeewa NU, Ham S, Yang F, Simpson ER, Brown KA. Promoter-specific effects of metformin on aromatase transcript expression. Steroids 2011; 76:768-71.
Sameer AS, Shah ZA, Syeed N, Rasool R, Afroze D, Siddiqi MA. NAD(P)H:quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and colorectal cancer predisposition in the ethnic Kashmiri population. Asian Pac J Cancer Prev 2010; 11:209-13.
Samer CF, Daali Y, Wagner M et al. Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. Br J Pharmacol 2010; 160:919-30.
Samer CF, Piguet V, Dayer P, Desmeules JA. Genetic polymorphism and drug interactions: their importance in the treatment of pain. Can J Anaesth 2005; 52:806-21.
Samimi G, Safaei R, Katano K et al. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin Cancer Res 2004; 10:4661-9.
Samimi G, Varki NM, Wilczynski S, Safaei R, Alberts DS, Howell SB. Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients. Clin Cancer Res 2003; 9:5853-9.
Samnegård A, Silveira A, Lundman P et al. Serum matrix metalloproteinase-3 concentration is influenced by MMP-3 -1612 5A/6A promoter genotype and associated with myocardial infarction. J Intern Med 2005; 258:411-9.
Sampaio AS, Fagerness J, Crane J et al. Association between polymorphisms in GRIK2 gene and obsessive-compulsive disorder: A family-based study. CNS Neurosci Ther 2011; 17:141-7.
Sampaio MF, Hirata MH, Hirata RD et al. AMI is associated with polymorphisms in the NOS3 and FGB but not in PAI-1 genes in young adults. Clin Chim Acta 2007; 377:154-62.
Sampayo R, Lavandera JV, Batlle A, Buzaleh AM. Sevoflurane: its action on heme metabolism and Phase I drug metabolizing system. Cell Mol Biol 2009; 55:140-6.
Sampayo-Reyes A, Hernández A, El-Yamani N et al. Arsenic induces DNA damage in environmentally exposed Mexican children and adults. Influence of GSTO1 and AS3MT polymorphisms. Toxicol Sci 2010; 117:63-71.
Sams C, Cocker J, Lennard MS. Biotransformation of chlorpyrifos and diazinon by human liver microsomes and recombinant human cytochrome P450s (CYP). Xenobiotica 2004; 34:861-73.
Sams C, Mason HJ, Rawbone R. Evidence for the activation of organophosphate pesticides by cytochromes P450 3A4 and 2D6 in human liver microsomes. Toxicol Lett 2000; 116:217-21.
Samson M, Libert F, Doranz BJ et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382:722-5.
Samuels Y, Wang Z, Bardelli A et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304:554.
Samuelsson K, Bergström MA, Jonsson CA, Westman G, Karlberg AT. Diphenylthiourea, a common rubber chemical, is bioactivated to potent skin sensitizers. Chem Res Toxicol 2011; 24:35-44.
San L, Arranz B. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. Eur Psychiatry 2008; 23:396-402.
Sanada N, Gotoh Y, Shimazawa R, Klinge CM, Kizu R. Repression of activated aryl hydrocarbon receptor-induced transcriptional activation by 5alpha-dihydrotestosterone in human prostate cancer LNCaP and human breast cancer T47D cells. J Pharmacol Sci 2009; 109:380-7.
Sanak M, Simon HU, Szczeklik A. Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet 1997; 350:1599-600.
Sanan DA, Weisgraber KH, Russell SJ et al. Apolipoprotein E associates with beta-amyloid peptide of Alzheimer’s disease to from novel monofibrils: isoform apoE4 associates more efficiently than apoeE4. J Clin Invest 1994; 94:860-9.
Sánchez Hellín V, Gutiérrez Rodero F. Toxicogenetics of antiretroviral treatment (II): neurotoxicity, hepatotoxicity, lactic acidosis, kidney damage, and other adverse effects of antiretroviral drugs. Enferm Infecc Microbiol Clin 2008; 26 Suppl 6:24-33.
Sánchez I, Mahlke C, Yuan J. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 2003; 421:373-9.
Sánchez MB, Herranz JL, Leno C et al. Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy. Seizure 2010; 19:93-101.
Sánchez RI, Wang RW, Newton DJ et al. Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos 2004; 32:1287-92.
Sanchez V, Dong JJ. Alteration of lipid metabolism in cells infected with human cytomegalovirus. Virology 2010; 404:71-7.
Sanchez-Alavez M, Klein I, Brownell SE et al. Night eating and obesity in the EP3R-deficient mouse. Proc Nat Acad Sci USA 2007; 104:3009-14.
Sánchez-Borges M, Acevedo N, Vergara C et al. The A-444C polymorphism in the leukotriene C4 synthase gene is associated with aspirin-induced urticaria. J Investig Allergol Clin Immunol 2009; 19:375-82.
Sánchez-Cuén J, Aguilar-Medina M, Arámbula-Meraz E et al. ApoB-100, ApoE and CYP7A1 gene polymorphisms in Mexican patients with cholesterol gallstone disease. World J Gastroenterol 2010; 16:4685-90.
Sandanaraj E, Jada SR, Shu X et al. Influence of UGT1A9 intronic I399C>T polymorphism on SN-38 glucuronidation in Asian cancer patients. Pharmacogenomics J 2008; 8:174-85.
Sandanaraj E, Lal S, Selvarajan V et al. PXR pharmacogenetics: association of haplotypes with hepatic CYP3A4 and ABCB1 messenger RNA expression and doxorubicin clearance in Asian breast cancer patients. Clin Cancer Res 2008; 14:7116-26.
Sandberg M, Johansson I, Christensen M, Rane A, Eliasson E. The impact of CYP2C9 genetics and oral contraceptives on cytochrome P450 2C9 phenotype. Drug Metab Dispos 2004; 32:484-9.
Sandberg M, Yasar U, Strömberg P, Höög JO, Eliasson E. Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase. Br J Clin Pharmacol 2002; 54:423-9.
Sandee D, Morrissey K, Agrawal V et al. Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro. Pharmacogenet Genomics 2010; 20:677-86.
Sander LE, Lorentz A, Sellge G et al. Selective expression of histamine receptors H1R, H2R, and H4R, but not H3R, in the human intestinal tract. Gut 2006; 55:498.
Sanders AR, Duan J, Gejman PV. DNA variation and psychopharmacology of the human serotonin receptor 1B (HTR1B) gene. Pharmacogenomics 2002; 3:745-62.
Sanders RJ, Ofman R, Dacremont G, Wanders RJ, Kemp S. Characterization of the human omega-oxidation pathway for omega-hydroxy-very-long-chain fatty acids. FASEB J 2008; 22:2064-71.
Sanders RJ, Ofman R, Duran M, Kemp S, Wanders RJ. Omega-oxidation of very long-chain fatty acids in human liver microsomes. Implications for X-linked adrenoleukodystrophy. J Biol Chem 2006; 281:13180-7.
Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med 2005; 7:97-104.
Sandford AJ, Zhu S, Bai TR, Fitzgerald JM, Paré PD. The role of the C-C chemokine receptor-5 Delta32 polymorphism in asthma and in the production of regulated on activation, normal T cells expressed and secreted. J Allergy Clin Immunol 2001; 108:69-73.
Sandford B, Bown M, London N, Sayers R. The role of the CCR5 Delta32 polymorphism in abdominal aortic aneurysms. Int J Immunogenet 2009; 36:199-205.
Sandhu RS, Prescilla RP, Simonelli TM, Edwards DJ. Influence of goldenseal root on the pharmacokinetics of indinavir. J Clin Pharmacol 2003; 43:1283-8.
Sandilands A, Yeo G, Brown MJ, O’Shaughnessy KM. Functional responses of human beta1 adrenoceptors with defined haplotypes for the common 389R>G and 49S>G polymorphisms. Pharmacogenetics 2004; 14:343-9.
Sandrim VC, Palei AC, Luizon MR, Izidoro-Toledo TC, Cavalli RC, Tanus-Santos JE. eNOS haplotypes affect the responsiveness to antihypertensive therapy in preeclampsia but not in gestational hypertension. Pharmacogenomics J 2010; 10:40-5.
Sandström R, Karlsson A, Knutson L, Lennernäs H. Jejunal absorption and metabolism of R/S-verapamil in humans. Pharm Res 1998; 15:856-62.
Sandström R, Knutson TW, Knutson L, Jansson B, Lennernäs H. The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans. Br J Clin Pharmacol 1999; 48:180-9.
Sandwall P, Lo MW, Jonzon B et al. Lack of polymorphism of the conversion of losartan to its active metabolite E-3174 in extensive and poor metabolizers of debrisoquine (cytochrome P450 2D6) and mephenytoin (cytochrome P450 2C19). Eur J Clin Pharmacol 1999; 55:279-83.
Sane RS, Buckley DJ, Buckley AR, Nallani SC, Desai PB. Role of human pregnane X receptor in tamoxifen- and 4-hydroxytamoxifen-mediated CYP3A4 induction in primary human hepatocytes and LS174T cells. Drug Metab Dispos 2008; 36:946-54.
Sanga M, Younis IR, Tirumalai PS et al. Epoxidation of the methamphetamine pyrolysis product, trans-phenylpropene, to trans-phenylpropylene oxide by CYP enzymes and stereoselective glutathione adduct formation. Toxicol Appl Pharmacol 2006; 211:148-56.
Sanghani SP, Quinney SK, Fredenburg TB, Davis WI, Murry DJ, Bosron WF. Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3. Drug Metab Dispos 2004; 32:505-11.
Sangiuolo F, D’Apice MR, Gambardella S, Di Daniele N, Novelli G. Toward the pharmacogenomics of cystic fibrosis-an update. Pharmacogenomics 2004; 5:861-78.
Sangrajrang S, Sato Y, Sakamoto H et al. Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women. Int J Cancer 2009; 125:837-43.
Sangrajrang S, Sato Y, Sakamoto H, Ohnami S, Khuhaprema T, Yoshida T. Genetic polymorphisms in folate and alcohol metabolism and breast cancer risk: a case-control study in Thai women. Breast Cancer Res Treat 2010; 123:885-93.
Sangviroon A, Panomvana D, Tassaneeyakul W, Namchaisiri J. Pharmacokinetic and pharmacodynamic variation associated with VKORC1 and CYP2C9 polymorphisms in Thai patients taking warfarin. Drug Metab Pharmacokinet 2010; 25:531-8.
Sani G, Kotzalidis GD, Simonetti A et al. Development of asymptomatic pancreatitis with paradoxically high serum clozapine levels in a patient with schizophrenia and the CYP1A2*1F/1F genotype. J Clin Psychopharmacol 2010; 30:737-9.
Sankaranarayanan S, Holahan MA, Colussi D et al. First demonstration of cerebrospinal fluid and plasma A beta lowering with oral administration of a beta-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates. J Pharmacol Exp Ther 2009; 328:131-40.
Sano O, Kobayashi A, Nagao K et al. Sphingomyelin-dependence of cholesterol efflux mediated by ABCG1. J Lipid Res 2007; 48:2377-84.
Sansom OJ, Meniel VS, Muncan V et al. Myc deletion rescues Apc deficiency in the small intestine. Nature 2007; 446:676-9.
Santamarina-Fojo S, Peterson K, Knapper C et al. Complete genomic sequence of the human ABCA1 gene: analysis of the human and mouse ATP-binding cassette A promoter. Proc Nat Acad Sci USA 2000; 97:7987-92.
Santana A, Salido E, Torres A, Shapiro LJ. Primary hyperoxaluria type 1 in the Canary Islands: a conformational disease due to I244T mutation in the P11L-containing alanine:glyoxylate aminotransferase. Proc Natl Acad Sci USA 2003; 100:7277-82.
Santhanam U, Ray A, Sehgal PB. Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc Natl Acad Sci USA 1991; 88:7605-9.
Santiago C, Ruiz JR, Buxens A et al. Trp64Arg polymorphism in ADRB3 gene is associated with elite endurance performance. Br J Sports Med 2011; 45:147-9.
Santibáñez M, Bolumar F, García AM. Occupational risk factors in Alzheimer’s disease: a review assessing the quality of published epidemiological studies. Occup Environ Med 2007; 64:723-32.
Santorelli FM, Mak SC, El-Schahawi M et al. Maternally inherited cardiomyopathy and hearing loss associated with a novel mutation in the mitochondrial tRNA(Lys) gene (G8363A). Am J Hum Genet 1996; 58:933-9.
Santorelli FM, Tanji K, Manta P et al. Maternally inherited cardiomyopathy: an atypical presentation of the mtDNA 12S rRNA gene A1555G mutation. Am J Hum Genet 1999; 64:295-300.
Santoro S, Santini M, Pepe C et al. Aromatase inhibitor-induced skin adverse reactions: exemestane-related cutaneous vasculitis. J Eur Acad Dermatol Venereol 2011; 25:596-8.
Santos A, Zanetta S, Cresteil T et al. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin Cancer Res 2000; 6:2012-20.
Santos M, do Carmo Costa M, Edite Rio M et al. Genotypes at the APOE and SCA2 loci do not predict the course of multiple sclerosis in patients of Portuguese origin. Mult Scler 2004; 10:153-7.
Santos MJ, Quintanilla RA, Toro A et al. Peroxisomal proliferation protects from beta-amyloid neurodegeneration. J Biol Chem 2005; 280:41057-68.
Santos PC, Soares RA, Santos DB et al. CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population. BMC Med Genet 2011; 12:13.
Santoso S, Kunicki TJ, Kroll H, Haberbosch W, Gardemann A. Association of the platelet glycoprotein Ia C807T gene polymorphism with nonfatal myocardial infarction in younger patients. Blood 1999; 93:2449-53.
Santovito A, Burgarello C, Cervella P, Delpero M. Polymorphisms of cytochrome P450 1A1, glutathione s-transferases M1 and T1 genes in Ouangolodougou (Northern Ivory Coast). Genet Mol Biol 2010; 33:434-7.
Santt O, Baranova H, Albuisson E, Bignon YJ, Lucotte G. Interaction between GSTM1-null and CYP2D6-deficient alleles in the pathogenesis of Parkinson’s disease. Eur J Neurol 2004; 11:247-51.
Sanwald P, David M, Dow J. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists. Drug Metab Dispos 1996; 24:602-9.
Sanyal S, Sandstrom DJ, Hoeffer CA, Ramaswami M. AP-1 functions upstream of CREB to control synaptic plasticity in Drosophila. Nature 2002; 416:870-4.
Sanz MA, Fenaux P, Lo Coco F; European APL Group of Experts. Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence. Haematologica 2005; 90:1231-5.
Saour JN, Shereen AW, Saour BJ, Mammo LA. CYP2C9 polymorphism studies in the Saudi population. Saudi Med J 2011; 32:347-52.
Sapag A, Tampier L, Valle-Prieto A, Quintanilla ME, Moncada C, Israel Y. Mutations in mitochondrial aldehyde dehydrogenase (ALDH2) change cofactor affinity and segregate with voluntary alcohol consumption in rats. Pharmacogenetics 2003; 13:509-15.
Sapi E. The role of CSF-1 in normal physiology of mammary gland and breast cancer: an update. Exp Biol Med 2004; 229:1-11.
Sapienza Peterson AC, Rossant J, Balling R. Degree of methylation of transgenes is independent of gamete of origin. Nature 1987; 328:251-4.
Sapone A, Vaira D, Trespidi S et al. The clinical role of cytochrome p450 genotypes in Helicobacter pylori management. Am J Gastroenterol 2003; 98:1010-5.
Sapp E, Ge P, Aizawa H et al. Evidence for a preferential loss of enkephalin immunoreactivity in the external globus pallidus in low grade Huntington’s disease using high resolution images analysis. Neuroscience 1995; 64:397-404.
Sappal BS, Ghosh SS, Shneider B, Kadakol A, Chowdhury JR, Chowdhury NR. A novel intronic mutation results in the use of a cryptic splice acceptor site within the coding region of UGT1A1, causing Crigler-Najjar syndrome type 1. Mol Genet Metab 2002; 75:134-42.
Sarachana T, Xu M, Wu RC, Hu VW. Sex hormones in autism: androgens and estrogens differentially and reciprocally regulate RORA, a novel candidate gene for autism. PLoS One 2011. doi:10. 1371/journal. pone. 0017116.
Saraeva RB, Paskaleva ID, Doncheva E, Eap CB, Ganev VS. Pharmacogenetics of acenocoumarol: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements. J Clin Pharm Ther 2007; 32:641-9.
Sarantseva SV, Bolshakova OI, Timoshenko SI, Rodin DI, Vitek M, Schwarzman AL. Studying the pathogenesis of Alzheimer’s disease in a Drosophila melanogaster model: Human APP overexpression in the brain of transgenic flies leads to deficit of the synaptic protein synaptotagmin. Russian Journal of Genetics 2009, 45:105-12.
Sarapa N, Britto MR, Mainka MB, Parivar K. The effect of mild and moderate hepatic impairment on the pharmacokinetics of valdecoxib, a selective COX-2 inhibitor. Eur J Clin Pharmacol 2005; 61:247-56.
Sarapa N, Nickens DJ, Raber SR, Reynolds RR, Amantea MA. Ritonavir 100 mg does not cause QTc prolongation in healthy subjects: a possible role as CYP3A inhibitor in thorough QTc studies. Clin Pharmacol Ther 2008; 83:153-9.
Sarginson JE, Lazzeroni LC, Ryan HS, Ershoff BD, Schatzberg AF, Murphy GM Jr. ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression. Pharmacogenet Genomics 2010; 20:467-75.
Saricaoglu H, Yilmaz M, Karkucak M et al. Investigation of ABCB1 gene polymorphism with colchicine response in Behçet’s disease. Genet Mol Res 2011; 10:1-6.
Sarich T, Kalhorn T, Magee S et al. The effect of omeprazole pretreatment on acetaminophen metabolism in rapid and slow metabolizers of S-mephenytoin. Clin Pharmacol Ther 1997; 62:21-8.
Sarikaya D, Bilgen C, Kamataki T, Topcu Z. Comparative cytochrome P450 -1A1, -2A6, -2B6, -2C, -2D6, -2E1, -3A5 and -4B1 expressions in human larynx tissue analysed at mRNA level. Biopharm Drug Dispos 2006; 27:353-9.
Sarkar MA, Vadlamuri V, Ghosh S, Glover DD. Expression and cyclic variability of CYP3A4 and CYP3A7 isoforms in human endometrium and cervix during the menstrual cycle. Drug Metab Dispos 2003; 31:1-6.
Sarkar S, Ravikumar B, Floto RA, Rubinsztein DC. Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies. Cell Death Differ 2009; 16:46-56.
Sarkis R, Honiger J, Chafai N et al. Semiautomatic macroencapsulation of fresh or cryopreserved porcine hepatocytes maintain their ability for treatment of acute liver failure. Cell Transplant 2001; 10:601-7.
Sarlis NJ, Gourgiotis L. Hormonal effects on drug metabolism through the CYP system: perspectives on their potential significance in the era of pharmacogenomics. Curr Drug Targets Immune Endocr Metabol Disord 2005; 5:439-48.
Sarma AV, Dunn RL, Lange LA et al. Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men’s Health Study. Prostate 2008; 68:296-305.
Sartorius LJ, Nagappan G, Lipska BK et al. Alternative splicing of human metabotropic glutamate receptor 3. J Neurochem 2006; 96:1139-48.
Sartorius LJ, Weinberger DR, Hyde TM, Harrison PJ, Kleinman JE, Lipska BK. Expression of a GRM3 splice variant is increased in the dorsolateral prefrontal cortex of individuals carrying a schizophrenia risk SNP. Neuropsychopharmacology 2008; 33:2626-34.
Saruwatari J, Matsunaga M, Ikeda K et al. Impact of CYP2D6*10 on H1-antihistamine-induced hypersomnia. Eur J Clin Pharmacol 2006; 62:995-1001.
Sarwar N, Sandhu MS, Ricketts SL et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010; 375:1634-9.
Sarzynski MA, Jacobson P, Rankinen T et all. Association of GWAS-based candidate genes with HDL-Cholesterol levels before and after bariatric surgery in the Swedish obese subjects study. J Clin Endocrinol Metab 2011; 96:953-7.
Sasaki G, Ogata T, Ishii T et al. Micropenis and the 5alpha-reductase-2 (SRD5A2) gene: mutation and V89L polymorphism analysis in 81 Japanese patients. J Clin Endocrinol Metab 2003; 88:3431-6.
Sasaki K, Murohara T, Ikeda H et al. Evidence for the importance of angiotensin II type 1 receptor in ischemia-induced angiogenesis. J Clin Invest 2002; 109:603-11.
Sasaki M, Kaneuchi M, Sakuragi N, Fujimoto S, Carroll PR, Dahiya R. The polyglycine and polyglutamine repeats in the androgen receptor gene in Japanese and Caucasian populations. Biochem Biophys Res Commun 2003; 312:1244-7.
Sasaki S, Kondo T, Sata F et al. Maternal smoking during pregnancy and genetic polymorphisms in the Ah receptor, CYP1A1 and GSTM1 affect infant birth size in Japanese subjects. Mol Hum Reprod 2006; 12:77-83.
Sasaki S, Watanabe T, Kobunai T, Nagawa H. Effect of cystathionine beta-synthase variant 844ins68bp and methylenetetrahydrofolate reductase A1298C polymorphisms in xenografts on 5-FU efficacy and doubling time. Cancer Lett 2006; 24:256-62.
Sasaki T, Fujikane Y, Ogino Y, Osada K, Sugano M. Hepatic function and lipid metabolism are modulated by short-term feeding of cholesterol oxidation products in rats. J Oleo Sci 2010; 59:503-7.
Sasaki T, Goto E, Konno Y, Hiratsuka M, Mizugaki M. Three novel single nucleotide polymorphisms of the human thiopurine S-methyltransferase gene in Japanese individuals. Drug Met and pharmacokinetics 2006; 4:332-6.
Sasaki T, Horikawa M, Orikasa K et al. Possible relationship between the risk of Japanese bladder cancer cases and the CYP4B1 genotype. Jpn J Clin Oncol 2008; 38:634-40.
Sashio H, Tamura K, Ito R et al. Polymorphisms of the TNF gene and the TNF receptor superfamily member 1B gene are associated with susceptibility to ulcerative colitis and Crohn’s disease, respectively. Immunogenetics 2002; 53:1020-7.
Sassen A, Diermeier-Daucher S, Sieben M et al. Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer. Breast Cancer Res 2009; 11:50.
Sata F, Sapone A, Elizondo G et al. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther 2000; 67:48-56.
Sathishkumar K, Balakrishnan M, Chinnathambi V, Chauhan M, Hankins GD, Yallampalli C. Fetal sex-related dysregulation in testosterone production and their receptor expression in the human placenta with preeclampsia. J Perinatol 2011. doi:10. 1038/jp. 2011. 101.
Sato A, Katada S, Sato M, Kobayashi H. A case of polymyalgia rheumatica with improved steroid-responsibility after discontinuing carbamazepine. No To Shinkei 2004; 56:61-3.
Sato A, Okura Y, Minagawa S et al. Life-threatening serotonin syndrome in a patient with chronic heart failure and CYP2D6*1/*5. Mayo Clin Proc 2004; 79:1444-8.
Sato K, Emi M, Ezura Y et al. Soluble epoxide hydrolase variant (Glu287Arg) modifies plasma total cholesterol and triglyceride phenotype in familial hypercholesterolemia: intrafamilial association study in an eight-generation hyperlipidemic kindred. J Hum Genet 2004; 49:29-34.
Sato K, Kamada T. Regulation of bile acid, cholesterol, and fatty acid synthesis in chicken primary hepatocytes by different concentrations of T0901317, an agonist of liver X receptors. Comp Biochem Physiol A Mol Integr Physiol 2011; 158:201-6.
Sato M, Toné S, Ishikawa T, Purdue PE, Danpure CJ, Minatogawa Y. Functional analysis of the 5’-flanking region of the human alanine:glyoxylate aminotransferase gene AGXT. Biochim Biophys Acta 2002; 1574:205-9.
Sato M, Yokoyama U, Fujita T, Okumura S, Ishikawa Y. The roles of cytochrome p450 in ischemic heart disease. Curr Drug Metab 2011; 12:526-32.
Sato R, Watanabe H, Genma R, Takeuchi M, Maekawa M, Nakamura H. ABCC8 polymorphism (Ser1369Ala): influence on severe hypoglycemia due to sulfonylureas. Pharmacogenomics 2010; 11:1743-50.
Sato S, Someya T, Shioiri O, Koitabashi T, Inoue Y. Involvement of CYP3A4 in the metabolism of bromperidol in vitro. Pharmacol Toxicol 2000; 86:145-8.
Sato T, Ashizawa N, Iwanaga T et al. Design, synthesis, and pharmacological and pharmacokinetic evaluation of 3-phenyl-5-pyridyl-1,2,4-triazole derivatives as xanthine oxidoreductase inhibitors. Bioorg Med Chem Lett 2009; 19:184-7.
Sato T, Ashizawa N, Matsumoto K et al. Discovery of 3-(2-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051 – a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia [corrected]. Bioorg Med Chem Lett 2009; 19:6225-9.
Sato Y, Koshioka S, Kirino Y et al. Role of dipeptidyl peptidase IV (DPP4) in the development of dyslipidemia: DPP4 contributes to the steroid metabolism pathway. Life Sci 2011; 88:43-9.
Satoh J. Interferon -beta therapy in multiple sclerosis. Nippon Rinsho 2006; 64:1297-309.
Satoh K, Nigro P, Zeidan A et al. Cyclophilin a promotes cardiac hypertrophy in apolipoprotein e-deficient mice. Arterioscler Thromb Vasc Biol 2011; 31:1116-23.
Satoh K, Nonaka R, Nakae D, Ogata A. Increase in in utero exposure to a migrant, 4,4’-butylidenebis(6-t-butyl-m-cresol), from nitrile-butadiene rubber gloves on brain aromatase activity in male rats. Biol Pharm Bull 2010; 33:6-10.
Satoh T, Fujita KI, Munakata H et al. Studies on the interactions between drugs and estrogen: analytical method for prediction system of gynecomastia induced by drugs on the inhibitory metabolism of estradiol using Escherichia coli coexpressing human CYP3A4 with human NADPH-cytochrome P450 reductase. Anal Biochem 2000; 286:179-86.
Satoh T, Matsui M, Tamura H. Sulfotransferases in a human colon carcinoma cell line, Caco-2. Biol Pharm Bull 2000; 23:810-4.
Satoh T, Munakata H, Fujita K et al. Studies on the interactions between drug and estrogen. II. On the inhibitory effect of 29 drugs reported to induce gynecomastia on the oxidation of estradiol at C-2 or C-17. Biol Pharm Bull 2003; 26:695-700.
Satoh T, Ura T, Yamada Y et al. Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms. Cancer Sci 2011; 102:1868-1873.
Satoh T, Watanabe Y, Ikarashi N, Ito K, Sugiyama K. Effects of Kampo medicines on P-glycoprotein. Biol Pharm Bull 2009; 32:2018-21.
Satsu H, Hiura Y, Mochizuki K, Hamada M, Shimizu M. Activation of pregnane X receptor and induction of MDR1 by dietary phytochemicals. J Agric Food Chem 2008; 56:5366-73.
Satyanarayana A, Kaldis P. Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms. Oncogene 2009; 28:2925-39.
Satyanarayana CR, Devendran A, Jayaraman M et al. Influence of the genetic polymorphisms in the 5’ flanking and exonic regions of CYP2C19 on proguanil oxidation. Drug Metab Pharmacokinet 2009; 24:537-48.
Satyanarayana Chakradhara Rao U, Devendran A, Satyamoorthy K, Shewade DG, Krishnamoorthy R, Chandrasekaran A. Functional characterization of promoter region polymorphisms of human CYP2C19 gene. Mol Biol Rep 2011; 38:4171-9.
Saudou F, Finkbeiner S, Devys D, Greenberg ME. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 1998; 95:55-66.
Sauer C, Peters FT, Schwaninger AE, Meyer MR, Maurer HH. Investigations on the cytochrome P450 (CYP) isoenzymes involved in the metabolism of the designer drugs N-(1-phenyl cyclohexyl)-2-ethoxyethanamine and N-(1-phenylcyclohexyl)-2-methoxyethanamine. Biochem Pharmacol 2009; 77:444-50.
Sauer JM, Long AJ, Ring B et al. Atomoxetine hydrochloride: clinical drug-drug interaction prediction and outcome. J Pharmacol Exp Ther 2004; 308:410-8.
Sauer JM, Ponsler GD, Mattiuz EL et al. Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. Drug Metab Dispos 2003; 31:98-107.
Sauer M. Re: Beta1 and beta2-adrenergic receptor polymorphisms and idiopathic ventricular arrhythmias. J Cardiovasc Electrophysiol 2008; 19:55.
Sauerborn Klobucar R, Zaja R, Franjević D, Brozović A, Smital T. Presence of ecotoxicologically relevant Pgp and MRP transcripts and proteins in Cyprinid fish. Arh Hig Rada Toksikol 2010; 61:175-82.
Saukko M, Kesäniemi YA, Ukkola O. Leptin receptor Lys109Arg and Gln223Arg polymorphisms are associated with early atherosclerosis. Metab Syndr Relat Disord 2010; 8:425-30.
Saunders AM. Apolipoprotein E and Alzheimer disease: an update on genetic and functional analysis. J Neuropathol Exp Neurol 2000; 59:751-8.
Saunders AM, Schmader K, Breitner JCS et al. Apolipoprotein E epsilon-4 allele distributions in late-onset Alzheimer’s disease and in other amyloid-forming diseases. Lancet 1993; 342:710-1.
Saunders AM, Strittmatter WJ, Schmechel D et al. Association of apolipoprotein E allele E4 with late-onset familial and sporadic Alzheimer’s disease. Neurology 1993; 43:1467-72.
Saussele T, Burk O, Blievernicht JK et al. Selective induction of human hepatic cytochromes P450 2B6 and 3A4 by metamizole. Clin Pharmacol Ther 2007; 82:265-74.
Savaraj N, Wu C, Wangpaichitr M et al. Overexpression of mutated MRP4 in cisplatin resistant small cell lung cancer cell line: collateral sensitivity to azidothymidine. Int J Oncol 2003; 23:173-9.
Savas S, Geraci J, Jurisica I, Liu G. A comprehensive catalogue of functional genetic variations in the EGFR pathway: protein-protein interaction analysis reveals novel genes and polymorphisms important for cancer research. Int J Cancer 2009; 125:1257-65.
Savettieri G, Andreoli V, Bonavita S et al. Apolipoprotein E genotype does not influences the progression of multiple sclerosis. J Neurol 2003; 250:1094-8.
Savikko J, von Willebrand E, Häyry P. Leflunomide analogue FK778 is vasculoprotective independent of its immunosuppressive effect: potential applications for restenosis and chronic rejection. Transplantation 2003; 76:455-8.
Savitz J, Lucki I, Drevets WC. 5-HT(1A) receptor function in major depressive disorder. Prog Neurobiol 2009; 88:17-31.
Savitz JB, Drevets WC. Imaging phenotypes of major depressive disorder: genetic correlates. Neuroscience 2009; 164:300-30.
Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced blood glucose levels, increased insulin levels and improved glucose tolerance in alpha2A-adrenoceptor knockout mice. Eur J Pharmacol 2008; 578:359-64.
Savva J, Maqbool A, White HL et al. Polymorphisms of adrenoceptors are not associated with an increased risk of adverse event in heart failure: a MERIT-HF substudy. J Card Fail 2009; 15:435-41.
Saw J, Brennan DM, Steinhubl SR et al. Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. J Am Coll Cardiol 2007; 50:291-5.
Saw J, Steinhubl SR, Berger PB et al. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 2003; 108:921-4.
Sawada N, Yamamoto K, Yamada S et al. Role of Gln 85 of human CYP27A1 in 25-hydroxyvitamin D(3)-binding and protein folding. Biochem Biophys Res Commun 2007; 355:211-6.
Sawamura N, Morishima-Kawashima M, Waki H et al. Mutant presenilin 2 transgenic mice. A large increase in the levels of Abeta 42 is presumably associated with the low density membrane domain that contains decreased levels of glycerophospholipids and sphingomyelin. J Biol Chem 2000; 275:27901-8.
Sawant AD, Miller EL, Duignan DB et al. Understanding the clinical pharmacokinetics of a GABAA partial agonist by application of in vitro tools. Xenobiotica 2010; 40:476-84.
Sawant RD. Rhabdomyolysis due to an uncommon interaction of ciprofloxacin with simvastatin. Can J Clin Pharmacol 2009; 16:78-9.
Sawczenko A, Azooz O, Paraszczuk J et al. Intestinal inflammation-induced growth retardation acts through IL-6 in rats and depends on the -174 IL-6 G/C polymorphism in children. Proc Natl Acad Sci USA 2005; 102:13260-5.
Saxena R, Shaw GL, Relling MV et al. Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype. Hum Mol Genet 1994; 3:923-6.
Sayed-Tabatabaei FA, Schut AFC, Arias Vasquez A et al. Angiotensin converting enzyme gene polymorphism and cardiovascular morbidity and mortality: the Rotterdam study. J Med Genet 2005; 42:26-30.
Sayers I, Barton S, Rorke S et al. Promoter polymorphism in the 5-lipoxygenase (ALOX5) and 5-lipoxygenase-activating protein (ALOX5AP) genes and asthma susceptibility in a Caucasian population. Clin Exp Allergy 2003; 33:1103-10.
Scahill L. Alpha-2 adrenergic agonists in children with inattention, hyperactivity and impulsiveness. CNS Drugs 2009; 23 Suppl 1:43-9.
Scaia MF, Regueira E, Sassone AG, Volonteri MC, Ceballos NR. The Bidder’s organ of the toad Rhinella arenarum (Amphibia, Anura). Presence of steroidogenic enzymes. J Exp Zool A Ecol Genet Physiol 2011; 315:439-46.
Scarmeas N, Brandt J, Albert M et al. Association between the APOE genotype and psychopathologic symptoms in Alzheimer’s disease. Neurology 2002; 58:1182-8.
Scassellati C, Bonvicini C, Perez J et al. Association study of -1727 A/T, -50 C/T and (CAA)n repeat GSK-3beta gene polymorphisms with schizophrenia. Neuropsychobiology 2004; 50:16-20.
Sciarrone MT, Stella P, Barlassina C et al. ACE and alpha-adducin polymorphism as markers of individual response to diuretic therapy. Hypertension 2003; 41:398-403.
Scinto LFM, Daffner KR, Dressler D et al. A pontial nonivasive neurobiological test for Alzheimer disease. Science 1994; 266:1051-3.
Scollon EJ, Starr JM, Godin SJ, DeVito MJ, Hughes MF. In vitro metabolism of pyrethroid pesticides by rat and human hepatic microsomes and cytochrome p450 isoforms. Drug Metab Dispos 2009; 37:221-8.
Sconce EA, Avery PJ, Wynne HA, Kamali F. Vitamin K epoxide reductase complex subunit 1 (VKORC1) polymorphism influences the anticoagulation response subsequent to vitamin K intake: a pilot study. J Thromb Haemost 2008; 6:1226-8.
Sconce EA, Khan TI, Wynne HA et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106:2329-33.
Scordo MG, Spina E. Cytochrome P450 polymorphisms and response to antipsychotic therapy. Pharmacogenomics 2002; 3:201-18.
Scordo MG, Spina E, Dahl ML, Gatti G, Perucca E. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. Basic Clin Pharmacol Toxicol 2005; 97:296-301.
Scott EE, Halpert JR. Structures of cytochrome P450 3A4. Trends Biochem Sci 2005; 30:5-7.
Scott J, Pache D, Keane G, Buckle H, O’Brien N. Prolonged anticholinergic delirium following antihistamine overdose. Australas Psychiatry 2007; 15:242-4.
Scott J, Poffenbarger PL. Pharmacogenetics of tolbutamide metabolism in humans. Diabetes 1979; 28:41-51.
Scott JA, Incardona JP, Pelkki K, Shepardson S, Hodson PV. AhR2-mediated, CYP1A-independent cardiovascular toxicity in zebrafish (Danio rerio) embryos exposed to retene. Aquat Toxicol 2011; 101:165-74.
Scott LJ, Curran MP, Figgitt DP. Rosuvastatin: a review of its use in the management of dyslipidemia. Am J Cardiovasc Drugs 2004; 4:117-38.
Scott LJ, Figgitt DP. Mitoxantrone: a review of its use in multiple sclerosis. CNS Drugs 2004; 18:379-96.
Scott LJ, Mohlke KL, Bonnycastle LL et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 2007; 316:1341-5.
Scott LM, Durant P, Leone-Kabler S et al. Effects of prior oral contraceptive use and soy isoflavonoids on estrogen-metabolizing cytochrome P450 enzymes. J Steroid Biochem Mol Biol 2008; 112:179-85.
Scott M, DeArmond SJ, Prusiner SB, Ridley RM, Baker HF. Transgenic investigations of species barrier and prion strains. In: Prusiner SB (Ed). Prion biology and diseases. Cold Spring Harbor Laboratory Press, New York, 1999:307-47.
Scott RH, Homfray T, Huxter NL et al. Familial T-cell non-Hodgkin lymphoma caused by biallelic MSH2 mutations. J Med Genet 2007; 44:83.
Scott SA, Edelmann L, Kornreich R, Desnick RJ. Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Am J Hum Genet 2008; 82:495-500.
Scott SA, Khasawneh R, Peter I, Kornreich R, Desnick RJ. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics 2010; 11:781-91.
Scott SA, Martis S, Peter I, Kasai Y, Kornreich R, Desnick RJ. Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness. Pharmacogenomics J 2011. doi:10. 1038/tpj. 2011. 5.
Scott SM, Brown M, Come SE. Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer. Expert Opin Drug Saf 2011; 10:819-26.
Scripture CD, Pieper JA. Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinet 2001; 40:263-81.
Schaaf HS, Parkin DP, Seifart HI et al. Isoniazid pharmacokinetics in children treated for respiratory tuberculosis. Arch Dis Child 2005; 90:614-8.
Schaap FG, van der Gaag NA, Gouma DJ, Jansen PL. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology 2009; 49:1228-35.
Schab M, Janiszewska H, Jarzemski P et al. Frequency of CYP1B1 homozygous genotype 355T/T in prostate cancer families from Poland. Eur J Cancer Prev 2010; 19:31-4.
Schachter F, Faure-Delanef L, Guenot F et al. Genetic association with human longevity at the APOE and ACE loci. Nat Genet 1994; 6:29-32.
Schaefer M, Roots I, Gerloff T. In-vitro transport characteristics discriminate wild-type ABCB1 (MDR1) from ALA893SER and ALA893THR polymorphisms. Pharmacogenet Genomics 2006; 16:855-61.
Schaeffeler E, Eichelbaum M, Brinkmann U et al. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet 2001; 358:383-4.
Schäfer A, Galuppo P, Fraccarollo D et al. Increased cytochrome P4502E1 expression and altered hydroxyeicosatetraenoic acid formation mediate diabetic vascular dysfunction: rescue by guanylyl-cyclase activation. Diabetes 2010; 59:2001-9.
Schafer JA, Kjesbo NK, Gleason PP. Dronedarone: current evidence and future questions. Cardiovasc Ther 2010; 28:38-47.
Schafer JJ, Squires KE. Integrase inhibitors: a novel class of antiretroviral agents. Ann Pharmacother 2010; 44:145-56.
Schäfer M, Rujescu D, Giegling I et al. Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene. Am J Psychiatry 2001; 158:802-4.
Schaffer SD, Yoon S, Zadezensky I. A review of smoking cessation: potentially risky effects on prescribed medications. J Clin Nurs 2009; 18:1533-40.
Schalekamp T, Boink GJ, Visser LE, Stricker BH, de Boer A, Klungel OH. CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring? Clin Pharmacol Ther 2006; 79:511-20.
Schalekamp T, Brassé BP, Roijers JF et al. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin Pharmacol Ther 2006; 80:13-22.
Schalekamp T, Brassé BP, Roijers JF et al. VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement. Clin Pharmacol Ther 2007; 4:529-38.
Schalekamp T, Oosterhof M, van Meegen E et al. Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status. Clin Pharmacol Ther 2004; 76:409-17.
Schalekamp T, van Geest-Daalderop JH, de Vries-Goldschmeding H, Conemans J, Bernsen Mj M, de Boer A. Acenocoumarol stabilization is delayed in CYP2C93 carriers. Clin Pharmacol Ther 2004; 75:394-402.
Scharfetter J. Pharmacogenetics of dopamine receptors and response to antipsychotic drugs in schizophrenia-an update. Pharmacogenomics 2004; 5:691-8.
Scharfetter J, Chaudhry HR, Hornik K et al. Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakastani patients. Eur Neuropsychopharmacol 1999; 10:17-20.
Scharin Täng M, Lindberg E, Grüner Sveälv B, Magnusson Y, Andersson B. Cardiac reserve in the transplanted heart: effect of a graft polymorphism in the beta1-adrenoceptor. J Heart Lung Transplant 2007; 26:915-20.
Scharplatz M, Puhan MA, Steurer J, Bachmann LM. What is the impact of the ACE gene insertion/deletion (I/D) polymorphism on the clinical effectiveness and adverse events of ACE inhibitors?-Protocol of a systematic review. BMC Med Genet 2004; 5:23.
Schauber J, Weiler F, Gostner A et al. Human rectal mucosal gene expression after consumption of digestible and non-digestible carbohydrates. Mol Nutr Food Res 2006; 50:1006-12.
Schebb NH, Franze B, Maul R, Ranganathan A, Hammock BD. In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites. Drug Metab Dispos 2011. doi:10. 1124/dmd. 111. 042283.
Scheen AJ. Pharmacokinetic interactions with thiazolidinediones. Clin Pharmacokinet 2007; 46:1-12.
Scheen AJ. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet 2007; 46:93-108.
Scheen AJ. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. Clin Pharmacokinet 2010; 49:573-88.
Scheffler M, di Gion P, Doroshyenko O, Wolf J, Fuhr U. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines. Clin Pharmacokinet 2011; 50:371-403.
Scheidweiler KB, Ladenheim B, Cadet JL, Huestis MA. Mice lacking multidrug resistance protein 1a show altered dopaminergic responses to methylenedioxymethamphetamine (MDMA) in striatum. Neurotox Res 2010; 18:200-9.
Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S. Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide. Clin Pharmacol Ther 2010; 88:214-22.
Schelleman H, Bilker WB, Brensinger CM, Wan F, Yang YX, Hennessy S. Fibrate/Statin initiation in warfarin users and gastrointestinal bleeding risk. Am J Med 2010; 123:151-7.
Schelleman H, Brensinger CM, Chen J, Finkelman BS, Rieder MJ, Kimmel SE. New genetic variant that might improve warfarin dose prediction in African Americans. Br J Clin Pharmacol 2010; 70:393-9.
Schelleman H, Klungel OH, Witteman JC et al. The influence of the alpha-adducin G460W polymorphism and angiotensinogen M235T polymorphism on antihypertensive medication and blood pressure. Eur J Hum Genet 2006; 14:860-6.
Schelleman H, Klungel OH, Witteman JC et al. Diuretic-gene interaction and the risk of myocardial infarction and stroke. Pharmacogenomics J 2007; 7:346-52.
Schelleman H, Klungel OH, Witteman JC et al. Angiotensinogen M235T polymorphism and the risk of myocardial infarction and stroke among hypertensive patients on ACE-inhibitors or beta-blockers. Eur J Hum Genet 2007; 15:478-84.
Schelleman H, Klungel OH, Witteman JC et al. Interaction between polymorphisms in the renin-angiotensin-system and angiotensin-converting enzyme inhibitor or beta-blocker use and the risk of myocardial infarction and stroke. Pharmacogenomics J 2008; 8:400-7.
Schelleman H, Stricker BH, Verschuren WM et al. Interactions between five candidate genes and antihypertensive drug therapy on blood pressure. Pharmacogenomics J 2006; 6:22-6.
Schellenberg GD, Anderson L, O’dahl S et al. APP(717), APP(693), and PRNP gene mutations are rare in Alzheimer disease. Am J Hum Genet 1991; 49:511-7.
Schenekar T, Winkler KA, Troyer JL, Weiss S. Isolation and characterization of the CYP2D6 gene in Felidae with comparison to other mammals. J Mol Evol 2011; 72:222-31.
Schenk D, Barbour R, Dunn W et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400:173-7.
Schenk PW, van Fessem MA, Verploegh-van Rij S et al. Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients. Mol Psychiatry 2008; 13:597-605.
Schenk PW, van Vliet M, Mathot RA et al. The CYP2C19*17 genotype is associated with lower imipramine plasma concentrations in a large group of depressed patients. Pharmacogenomics J 2010; 10:219-25.
Schennink A, Bovenhuis H, Léon-Kloosterziel KM, van Arendonk JA, Visker MH. Effect of polymorphisms in the FASN, OLR1, PPARGC1A, PRL and STAT5A genes on bovine milk-fat composition. Anim Genet 2009; 40:909-16.
Scheper W, Annaert W, Cupers P, Saftig P, de Strooper B. Function and dysfunction of the presenilins. Alzheimer Report 1999; 2:73-81.
Scherzinger E, Sittler A, Schweiger K et al. Self-assembly of polyglutamine-containing huntingtin into amyloid-like fibrils: implications for Huntington’s disease pathology. Proc Nat Acad Sci USA 1999; 96:4604-9.
Schettert IT, Pereira AC, Lopes NH, Hueb WA, Krieger JE. Association between platelet P2Y12 haplotype and risk of cardiovascular events in chronic coronary disease. Thromb Res 2006; 118:679-83.
Scheurer ME, Amirian E, Cao Y et al. Polymorphisms in the interleukin-4 receptor gene are associated with better survival in patients with glioblastoma. Clin Cancer Res 2008; 14:6640-6.
Schicks J, Synofzik M, Schulte C, Schöls L. POLG, but not PEO1, is a frequent cause of cerebellar ataxia in Central Europe. Mov Disord 2010; 25:2678-82.
Schiepers OJ, Harris SE, Gow AJ et al. APOE E4 status predicts age-related cognitive decline in the ninth decade: longitudinal follow-up of the Lothian Birth Cohort 1921. Mol Psychiatry 2011. doi:10. 1038/mp. 2010. 137.
Schiepers OJ, van Boxtel MP, Harris SE et al. MTHFR polymorphisms and cognitive ageing in the ninth decade: the Lothian Birth Cohort 1921. Genes Brain Behav 2011; 10:354-64.
Schierloh A, Deussing J, Wurst W, Zieglgänsberger W, Rammes G. Corticotropin-releasing factor (CRF) receptor type 1-dependent modulation of synaptic plasticity. Neurosci Lett 2007; 416:82-6.
Schiffelers SL, Blaak EE, Saris WH, van Baak MA. In vivo beta3-adrenergic stimulation of human thermogenesis and lipid use. Clin Pharmacol Ther 2000; 67:558-66.
Schiffer R, Pope LE. Review of pseudobulbar affect including a novel and potential therapy. J Neuropsychiatry Clin Neurosci 2005; 17:447-54.
Schildkraut JM, Goode EL, Clyde MA et al. Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. Cancer Res 2009; 69:2349-57.
Schildkraut JM, Murphy SK, Palmieri RT et al. Trinucleotide repeat polymorphisms in the androgen receptor gene and risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2007; 16:473-80.
Schilthuizen C, Broyl A, van der Holt B, de Knegt Y, Lokhorst H, Sonneveld P. Influence of genetic polymorphisms in CYP3A4, CYP3A5, GSTP1, GSTM1, GSTT1 and MDR1 genes on survival and therapy-related toxicity in multiple myeloma. Haematologica 2007; 92:277-8.
Schilling G, Becher M, Sharp A et al. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Molec Genet 1999; 8:397-407.
Schindowski K, Bretteville A, Leroy K et al. Alzheimer’s disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am J Pathol 2006; 169:599-616.
Schink JA, Loewenstein DA, Raj A et al. Defining mild cognitive impairment: impact of varying decision criteria on neuropsychological diagnostic frequencies and correlates. Am J Geriatr Psychiatry 2010; 18:684-91.
Schinkel AH, Jonker JW. Polymorphisms affecting function of the human organic cation transporter hOCT1 (SLC22A1): what are the consequences? Pharmacogenetics 2002; 12:589-90.
Schinkel AH, Mayer U, Wagenaar E et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Nat Acad Sci USA 1997; 94:4028-33.
Schinzari F, Armuzzi A, de Pascalis B et al. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn’s disease. Clin Pharmacol Ther 2008; 83:70-6.
Schiöth HB, Phillips SR, Rudzish R, Birch-Machin MA, Wikberg JE, Rees JL. Loss of function mutations of the human melanocortin 1 receptor are common and are associated with red hair. Biochem Biophys Res Commun 1999; 260:488-91.
Schipani A, Siccardi M, D’Avolio A et al. Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance. Antimicrob Agents Chemother 2010; 54:5242-50.
Schirmer M, Rosenberger A, Klein K et al. Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes. Pharmacogenomics 2007; 8:443-53.
Schirmer M, Toliat MR, Haberl M et al. Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations. Pharmacogenet Genomics 2006; 16:59-71.
Schjeide BM, McQueen MB, Mullin K et al. Assessment of Alzheimer’s disease case-control associations using family-based methods. Neurogenetics 2009; 10:19-25.
Schlachter K, Gruber-Sedlmayr U, Stogmann E et al. A splice site variant in the sodium channel gene SCN1A confers risk of febrile seizures. Neurology 2009; 72:974-8.
Schläwicke Engström K, Broberg K, Concha G, Nermell B, Warholm M, Vahter M. Genetic polymorphisms influencing arsenic metabolism: evidence from Argentina. Environ Health Perspect 2007; 115:599-605.
Schläwicke Engström K, Nermell B, Concha G, Strömberg U, Vahter M, Broberg K. Arsenic metabolism is influenced by polymorphisms in genes involved in one-carbon metabolism and reduction reactions. Mutat Res 2009; 667:4-14.
Schleinitz D, Klöting N, Böttcher Y et al. Genetic and evolutionary analyses of the human bone morphogenetic protein receptor 2 (BMPR2) in the pathophysiology of Obesity. PLoS One 2011. doi:10. 1371/journal. pone. 0016155.
Schlezinger JJ, Liu D, Farago M et al. A role for the aryl hydrocarbon receptor in mammary gland tumorigenesis. Biol Chem 2006; 387:1175-87.
Schlichtiger J, Pekcec A, Bartmann H et al. Celecoxib treatment restores pharmacosensitivity in a rat model of pharmacoresistant epilepsy. Br J Pharmacol 2010; 160:1062-71.
Schliebs R, Arendt T. The significance of the cholinergic system in the brain during aging and in Alzheimer’s disease. J Neural Transm 2006; 113:1625-44,
Schlienger RG, Klink MH, Eggenberger C, Drewe J. Seizures associated with therapeutic doses of venlafaxine and trimipramine. Ann Pharmacother 2000; 34:1402-5.
Schlienger RG, Shapiro LE, Shear NH. Lamotrigine-induced severe cutaneous adverse reactions. Epilepsia 1998; 39 Suppl 7:22-6.
Schlimmer N, Kratz M, Böhm M, Baumhäkel M. Telmisartan, ramipril and their combination improve endothelial function in different tissues in a murine model of cholesterol-induced atherosclerosis. Br J Pharmacol 2011; 163:804-14.
Schlötzer-Schrehardt U. Genetics and genomics of pseudoexfoliation syndrome/glaucoma. Middle East Afr J Ophthalmol 2011; 18:30-6.
Schmelzer E, Triolo F, Turner ME et al. Three-dimensional perfusion bioreactor culture supports differentiation of human fetal liver cells. Tissue Eng Part A 2010; 16:2007-16.
Schmelzer E, Wauthier E, Reid LM. The phenotypes of pluripotent human hepatic progenitors. Stem Cells 2006; 24:1852-8.
Schmelzle M, Dizdar L, Matthaei H et al. Esophageal cancer proliferation is mediated by cytochrome P450 2C9 (CYP2C9). Prostaglandins Other Lipid Mediat 2011; 94:25-33.
Schmider J, Brockmöller J, Arold G, Bauer S, Roots I. Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine. Pharmacogenetics 1999; 9:725-34.
Schmider J, Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. N-demethylation of amitriptyline in vitro: role of cytochrome P-450 3A (CYP3A) isoforms and effect of metabolic inhibitors. J Pharmacol Exp Ther 1995; 275:592-7.
Schmider J, Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. Inhibition of cytochrome P450 by nefazodone in vitro: studies of dextromethorphan O- and N-demethylation. Br J Clin Pharmacol 1996; 41:339-43.
Schmider J, Greenblatt DJ, von Moltke LL et al. Biotransformation of mestranol to ethinyl estradiol in vitro: the role of cytochrome P-450 2C9 and metabolic inhibitors. J Clin Pharmacol 1997; 37:193-200.
Schmider J, Greenblatt DJ, von Moltke LL, Karsov D, Shader RI. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin p-hydroxylation. Br J Clin Pharmacol 1997; 44:495-8.
Schmidt B, Faymonville T, Gembé E, Joussen N, Schuphan I. Comparison of the biotransformation of the 14C-labelled insecticide carbaryl by non-transformed and human CYP1A1-, CYP1A2-, and CYP3A4-transgenic cell cultures of Nicotiana tabacum. Chem Biodivers 2006; 3:878-96.
Schmidt B, Joussen N, Bode M, Schuphan I. Oxidative metabolic profiling of xenobiotics by human P450s expressed in tobacco cell suspension cultures. Biochem Soc Trans 2006; 34:1241-5.
Schmidt D, Elger CE. What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs? Epilepsy Behav 2004; 5:627-35.
Schmidt DR, Holmstrom SR, Fon Tacer K, Bookout AL, Kliewer SA, Mangelsdorf DJ. Regulation of bile acid synthesis by fat-soluble vitamins A and D. J Biol Chem 2010; 285:14486-94.
Schmidt GA, Hoehns JD, Purcell JL, Friedman RL, Elhawi Y. Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir. J Am Board Fam Med 2007; 20:411-6.
Schmidt L, Duh FM, Chen F et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997; 16:68-73.
Schmidt MV, Deussing JM, Oitzl MS et al. Differential disinhibition of the neonatal hypothalamic- pituitary-adrenal axis in brain-specific CRH receptor 1-knockout mice. Eur J Neurosci 2006; 24:2291-8.
Schmidt R, Baumann F, Hanschmann H, Geissler F, Preiss R. Gender difference in ifosfamide metabolism by human liver microsomes. Eur J Drug Metab Pharmacokinet 2001; 26:193-200.
Schmidt R, Baumann F, Knüpfer H et al. CYP3A4, CYP2C9 and CYP2B6 expression and ifosfamide turnover in breast cancer tissue microsomes. Br J Cancer 2004; 90:911-6.
Schmidt R, Schmidt H, Haybaeck J et al. Heterogeneity in age-related white matter changes. Acta Neuropathol 2011; 122:171-85.
Schmidt RJ, Romitti PA, Burns TL et al. Caffeine, selected metabolic gene variants, and risk for neural tube defects. Birth Defects Res A Clin Mol Teratol 2010; 88:560-9.
Schmidt S, Gastl G, Wolf D. Possible role for gene expression profiling in predicting responses to conventional or targeted drugs in patients with chronic myeloid leukemia. Leuk Lymphoma 2008; 49:643-7.
Schmidt-Arras D, Schwäble J, Böhmer FD, Serve H. Flt3 receptor tyrosine kinase as a drug target in leukemia. Curr Pharm Des 2004; 10:1867-83.
Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME et al. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos 1997; 25:1228-33.
Schmiedlin-Ren P, Thummel KE, Fisher JM, Paine MF, Lown KS, Watkins PB. Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha,25-dihydroxyvitamin D3. Mol Pharmacol 1997; 51:741-54.
Schmiedlin-Ren P, Thummel KE, Fisher JM, Paine MF, Watkins PB. Induction of CYP3A4 by 1 alpha,25-dihydroxyvitamin D3 is human cell line-specific and is unlikely to involve pregnane X receptor. Drug Metab Dispos 2001; 29:1446-53.
Schmitt A, Benninghoff J, Moessner R et al. Adult neurogenesis in serotonin transporter deficient mice. J Neural Transm 2007; 114:1107-19.
Schmitt C, Hofmann C, Riek M, Patel A, Zwanziger E. Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe. Pharmacotherapy 2009; 29:1175-81.
Schmitt C, Riek M, Winters K, Schutz M, Grange S. Unexpected hepatotoxicity of rifampin and saquinavir/ritonavir in healthy male volunteers. Arch Drug Inf 2009; 2:8-16.
Schmitt CA, Heiss EH, Aristei Y, Severin T, Dirsch VM. Norfuraneol dephosphorylates eNOS at threonine 495 and enhances eNOS activity in human endothelial cells. Cardiovasc Res 2009; 81:750-7.
Schmitt U, Lee DE, Herth MM et al. P-glycoprotein influence on the brain uptake of a 5-HT(2A) ligand: [(18)F]MH. MZ. Neuropsychobiology 2011; 63:183-90.
Schmitt-Hoffmann A, Roos B, Maares J et al. Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother 2006; 50:286-93.
Schmitz G, Schmitz-Madry A, Ugocsai P. Pharmacogenetics and pharmacogenomics of cholesterol-lowering therapy. Curr Opin Lipidol 2007; 18:164-73.
Schmitz KJ, Lang H, Frey UH et al. GNAS1 T393C polymorphism is associated with clinical course in patients with intrahepatic cholangiocarcinoma. Neoplasia 2007; 9:159-65.
Schmitz M, Denardin D, Silva TL et al. Association between alpha-2a-adrenergic receptor gene and ADHD inattentive type. Biol Psychiatry 2006; 60:1028-33.
Schnabel C, Sterz K, Müller H, Rehbein J, Wiese M, Hiersemann M. Total synthesis of natural and non-natural Δ(5,6)Δ(12,13)-jatrophane diterpenes and their evaluation as MDR modulators. J Org Chem 2011; 76:512-22.
Schneider E, Ryan TJ. Gamma-glutamyl hydrolase and drug resistance. Clin Chim Acta 2006; 374:25-32.
Schneider H, Lingesleben A, Vogel HP, Garuti R, Calandra S. A novel mutation in the sterol 27-hydroxylase gene of a woman with autosomal recessive cerebrotendinous xanthomatosis. Orphanet J Rare Dis 2010; 5:27.
Schneider J, Bernges U, Philipp M, Woitowitz HJ. GSTM1, GSTT1, and GSTP1 polymorphism and lung cancer risk in relation to tobacco smoking. Cancer Lett 2004; 208:65-74.
Schneider J, Bernges U. CYP1A1 and CYP1B1 polymorphisms as modifying factors in patients with pneumoconiosis and occupationally related tumours: A pilot study. Mol Med Report 2009; 2:1023-8.
Schneider MJ, Fiering SN, Pallud SE, Parlow AF, St Germain DL, Galton VA. Targeted disruption of the type 2 selenodeiodinase gene (DIO2) results in a phenotype of pituitary resistance to T4. Mol Endocrinol 2001; 15:2137-48.
Schnittger S, Gopal Rao VVN, Deutsch U et al. PAX1, a member of the paired box-contains class of developmental control genes, is mapped to human chromosome 20p. 11. 2 by in situ hybridisation (ISH and FISH). Genomics 1992; 14:740-4.
Schober LJ, Khandoga AL, Dwivedi S et al. The role of PGE(2) in human atherosclerotic plaque on platelet EP(3) and EP (4) receptor activation and platelet function in whole blood. J Thromb Thrombolysis 2011; 32:158-66.
Schober W, Pusch G, Oeder S, Reindl H, Behrendt H, Buters JT. Metabolic activation of phenanthrene by human and mouse cytochromes P450 and pharmacokinetics in CYP1A2 knockout mice. Chem Biol Interact 2010; 183:57-66.
Schoedel KA, Tyndale RF. Induction of nicotine-metabolizing CYP2B1 by ethanol and ethanol-metabolizing CYP2E1 by nicotine: summary and implications. Biochim Biophys Acta 2003; 1619:283-90.
Schoenherr CJ, Anderson DJ. The neuron-restrictive silencer factor (NRSF): a coordinate repressor of multiple neuron-specific genes. Science 1995; 267:1360-3.
Scholz I, Oberwittler H, Riedel KD et al. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol 2009; 68:906-15.
Schöller-Gyüre M, Kakuda TN, Woodfall B et al. Effect of steady-state etravirine on the pharmacokinetics and pharmacodynamics of ethinylestradiol and norethindrone. Contraception 2009; 80:44-52.
Schonder KS, Shullo MA, Okusanya O. Tacrolimus and lopinavir/ritonavir interaction in liver transplantation. Ann Pharmacother 2003; 37:1793-6.
Schrag ML, Wienkers LC. Topological alteration of the CYP3A4 active site by the divalent cation Mg(2+). Drug Metab Dispos 2000; 28:1198-201.
Schrag ML, Wienkers LC. Triazolam substrate inhibition: evidence of competition for heme-bound reactive oxygen within the CYP3A4 active site. Drug Metab Dispos 2001; 29:70-5.
Schrag ML, Wienkers LC. Covalent alteration of the CYP3A4 active site: evidence for multiple substrate binding domains. Arch Biochem Biophys 2001; 391:49-55.
Schreiber DH, Anderson TR. Statin-induced rhabdomyolysis. J Emerg Med 2006; 31:177-80.
Schreieck J, Dostal S, von Beckerath N et al. C825T polymorphism of the G-protein beta3 subunit gene and atrial fibrillation: association of the TT genotype with a reduced risk for atrial fibrillation. Am Heart J 2004; 148:545-50.
Schrijver HM, Crusius JB, García-González MA et al. Gender-related association between the TGFB1+869 polymorphism and multiple sclerosis. J Interferon Cytokine Res 2004; 24:536-42.
Schrijver HM, Crusius JB, Uitdehaag BM et al. Association of interleukin-1beta and interleukin-1 receptor antagonist genes with disease severity in MS. Neurology 1999; 52:595-9.
Schrijvers EM, Witteman JC, Sijbrands EJ, Hofman A, Koudstaal PJ, Breteler MM. Insulin metabolism and the risk of Alzheimer disease: the Rotterdam Study. Neurology 2010; 75:1982-7.
Schroder FH. Endocrine treatment of prostate cancer. Prostate Suppl 2000; 10:1.
Schroeder B, Franz B, Hempfling P et al. Polymorphisms within the prion-like protein gene (Prnd) and their implications in human prion diseases, Alzheimer’s disease and other neurological disorders. Hum Genet 2001; 109:319-25.
Schroeder JC, Dinatale BC, Murray IA et al. The uremic toxin 3-indoxyl sulfate is a potent endogenous agonist for the human aryl hydrocarbon receptor. Biochemistry 2010; 49:393-400.
Schroeder WS, Ghobrial L, Gandhi PJ. Possible mechanisms of drug-induced aspirin and clopidogrel resistance. J Thromb Thrombolysis 2006; 22:139-50.
Schroth W, Antoniadou L, Fritz P et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 2007; 25:5187-93.
Schuetz E, Lan L, Yasuda K et al. Development of a real-time in vivo transcription assay: application reveals pregnane X receptor-mediated induction of CYP3A4 by cancer chemotherapeutic agents. Mol Pharmacol 2002; 62:439-45.
Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 1996; 49:311-8.
Schuetz EG, Strom S, Yasuda K et al. Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. J Biol Chem 2001; 276:39411-8.
Schuetz JD, Beach DL, Guzelian PS. Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics 1994; 4:11-20.
Schuetz JD, Connelly MC, Sun D et al. MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 1999; 5:1048-51.
Schuetz JD, Guzelian PS. Isolation of CYP3A5P cDNA from human liver: a reflection of a novel cytochrome P-450 pseudogene. Biochim Biophys Acta 1995; 1261:161-5.
Schuhmacher A, Mössner R, Quednow BB et al. Influence of 5-HT3 receptor subunit genes HTR3A, HTR3B, HTR3C, HTR3D and HTR3E on treatment response to antipsychotics in schizophrenia. Pharmacogenet Genomics 2009; 19:843-51.
Schüle R, Siddique T, Deng HX et al. Marked accumulation of 27-hydroxycholesterol in SPG5 patients with hereditary spastic paresis. J Lipid Res 2010; 51:819-23.
Schults MA, Timmermans L, Godschalk RW et al. Diminished carcinogen detoxification is a novel mechanism for hypoxia-inducible factor 1-mediated genetic instability. J Biol Chem 2010; 285:14558-64.
Schultz DW, Klein ML, Humpert A et al. Lack of an association of apolipoprotein E genepolymorphisms with familial age-related macular degeneration. Arch Opthal 2003; 121:679-83.
Schultz EN, Devadason SG, Khoo SK et al. The role of GSTP1 polymorphisms and tobacco smoke exposure in children with acute asthma. J Asthma 2010; 47:1049-56.
Schultz MJ, Wijnholds J, Peppelenbosch MP et al. Mice lacking the multidrug resistance protein 1 are resistant to Streptococcus pneumoniae-induced pneumonia. J Immun 2001; 166:4059-64.
Schulz E, Gori T, Münzel T. Oxidative stress and endothelial dysfunction in hypertension. Hypertens Res 2011; 34:665-73.
Schulz TG, Neubert D, Davies DS, Edwards RJ. Inducibility of cytochromes P-450 by dioxin in liver and extrahepatic tissues of the marmoset monkey (Callithrix jacchus). Biochim Biophys Acta 1996; 1298:131-40.
Schulz-Jander DA, Casida JE. Imidacloprid insecticide metabolism: human cytochrome P450 isozymes differ in selectivity for imidazolidine oxidation versus nitroimine reduction. Toxicol Lett 2002; 132:65-70.
Schulz-Utermoehl T, Edwards RJ, Boobis AR. Affinity and potency of proinhibitory antipeptide antibodies against CYP2D6 is enhanced using cyclic peptides as immunogens. Drug Metab Dispos 2000; 28:544-51.
Schulz-Utermoehl T, Mountfield RJ, Bywater RP, Madsen K, Jørgensen PN, Hansen KT. Structure-function analysis of human CYP3A4 using a specific proinhibitory antipeptide antibody. Drug Metab Dispos 2000; 28:718-25.
Schulz-Utermoehl T, Mountfield RJ, Madsen K, Jørgensen PN, Hansen KT. Selective and potent inhibition of human CYP2C19 activity by a conformationally targeted antipeptide antibody. Drug Metab Dispos 2000; 28:715-7.
Schulz-Utermoehl T, Spear M, Pollard CR et al. In vitro hepatic metabolism of cediranib, a potent vascular endothelial growth factor tyrosine kinase inhibitor: interspecies comparison and human enzymology. Drug Metab Dispos 2010; 38:1688-97.
Schumacher FR, Cheng I, Freedman ML et al. A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians. Hum Mol Genet 2010; 19:3089-101.
Schupp PJ, Kohlert-Schupp C, Whitefield S et al. Cancer chemopreventive and anticancer evaluation of extracts and fractions from marine macro- and microorganisms collected from Twilight Zone waters around Guam. Nat Prod Commun 2009; 4:1717-28.
Schurhoff F, Krebs MO, Szoke A et al. Apolipoprotein E in schizophrenia: a French association study and meta-analysis. Am J Med Genet B Neuropsychiatr Genet 2003; 119:18-23.
Schürks M, Zee RY, Buring JE, Kurth T. Polymorphisms in the renin-angiotensin system and migraine in women. Headache 2009; 49:292-9.
Schuster I. Cytochromes P450 are essential players in the vitamin D signaling system. Biochim Biophys Acta 2011; 1814:186-99.
Schutgens RB, Wanders RJ, Nijenhuis A et al. Genetic diseases caused by peroxisomal dysfunction. New findings in clinical and biochemical studies. Enzyme 1987; 38:161-76.
Schuurman M, van Waardenburg D, Da Costa J, Niemarkt H, Leroy P. Severe hemolysis and methemoglobinemia following fava beans ingestion in glucose-6-phosphatase dehydrogenase deficiency: case report and literature review. Eur J Pediatr 2009; 168:779-82.
Schuyer M, Berns EM. Is TP53 dysfunction required for BRCA1-associated carcinogenesis? Molec Cell Endocr 1999; 155:143-52.
Schuyler CA, Ta NN, Li Y, Lopes-Virella MF, Huang Y. Insulin treatment attenuates diabetes-increased atherosclerotic intimal lesions and matrix metalloproteinase-9 expression in Apolipoprotein E-deficient mice. J Endocrinol 2011; 210:37-46.
Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J. Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem 2003; 46:1716-25.
Schwab M, Klotz U. Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Clin Pharmacokinet 2001; 40:723-51.
Schwab M, Klotz U, Hofmann U et al. Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data. Clin Pharmacol Ther 2005; 78:627-34.
Schwab SG, Knapp M, Mondabon S et al. Support for association of schizophrenia with genetic variation in the 6p22. 3 gene, dysbindin, in sib-pair families with linkage and in an additional sample of triad families. Am J Hum Genet 2003; 72:185-90.
Schwabedissen HE, Kroemer HK. In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2). Handb Exp Pharmacol 2011:325-71.
Schwarcz R, Okuno E, White R, Bird E, Whetsell W Jr. 3-Hydroxyanthranilate oxygenase activity is increased in the brains of Huntington disease victims. Proc Nat Acad Sci USA 1988; 85:4079-81.
Schwartz GL, Turner ST, Chapman AB, Boerwinkle E. Interacting effects of gender and genotype on blood pressure response to hydrochlorothiazide. Kidney Int 2002; 62:1718-23.
Schwartz GL, Turner ST. Pharmacogenetics of antihypertensive drug responses. Am J Pharmacogenomics 2004; 4:151-60.
Schwartz JB. Race but not age affects erythromycin breath test results in older hypertensive men. J Clin Pharmacol 2001; 41:324-9.
Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet 2003; 42:107-21.
Schwartz JI, Liu F, Stroh M et al. Influence of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the pharmacokinetics and pharmacodynamics of warfarin. Am J Ther 2009; 16:215-23.
Schwartz JI, Stroh M, Gao B et al. Effects of laropiprant, a selective prostaglandin D(2) receptor 1 antagonist, on the pharmacokinetics of rosiglitazone. Cardiovasc Ther 2009; 27:239-45.
Schwartz SM, Siscovick DS, Malinow MR et al. Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene. Circulation 1997; 96:412-7.
Schwarz PE, Govindarajalu S, Towers W et al. Haplotypes in the promoter region of the ADIPOQ gene are associated with increased diabetes risk in a German Caucasian population. Horm Metab Res 2006; 38:447-51.
Schwarz UI, Johnston PE, Bailey DG, Kim RB, Mayo G, Milstone A. Impact of citrus soft drinks relative to grapefruit juice on ciclosporin disposition. Br J Clin Pharmacol 2006; 62:485-91.
Schwarz UI, Ritchie MD, Bradford Y et al. Genetic determinants of response to warfarin during initial anticoagulation. New Eng J Med 2008; 358:999-1008.
Schwarzmeier JD, Hubmann R, Düchler M, Jäger U, Shehata M. Regulation of CD23 expression by Notch2 in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2005; 46:157-65.
Sealls W, Penque BA, Elmendorf JS. Evidence that chromium modulates cellular cholesterol homeostasis and ABCA1 functionality impaired by hyperinsulinemia. Arterioscler Thromb Vasc Biol 2011; 31:1139-40.
Sears MR, Lötvall J. Past, present and future-beta2-adrenoceptor agonists in asthma management. Respir Med 2005; 99:152-70.
Seaton MJ, Follansbee MH, Bond JA. Oxidation of 1,2-epoxy-3-butene to 1,2:3,4-diepoxybutane by cDNA-expressed human cytochromes P450 2E1 and 3A4 and human, mouse and rat liver microsomes. Carcinogenesis 1995; 16:2287-93.
Sebastian BM, Roychowdhury S, Tang H et al. Identification of a CYP2E1/Bid/C1q-dependent axis mediating inflammation in adipose tissue after chronic ethanol feeding to mice. J Biol Chem 2011; 286:35989-97.
Sebastiani V, Ricci F, Rubio-Viqueira B et al. Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. Clin Cancer Res 2006; 12:2492-7.
Seden K, Dickinson L, Khoo S, Back D. Grapefruit-drug interactions. Drugs 2010; 70:2373-407.
See S, Stirling AL. Candesartan cilexetil: an angiotensin II-receptor blocker. Am J Health Syst Pharm 2000; 57:739-46.
Seedhouse CH, Grundy M, White P et al. Sequential influences of leukemia-specific and genetic factors on p-glycoprotein expression in blasts from 817 patients entered into the National Cancer Research Network acute myeloid leukemia 14 and 15 trials. Clin Cancer Res 2007; 13:7059-66.
Seegmiller JE, Watanabe T, Shreier MH, Waldmann TA. Immunological aspects of purine metabolism. Adv Exp Med Biol 1977; 76:412-33.
Seeland S, Treiber A, Hafner M, Huwyler J. On-line identification of P-glycoprotein substrates by monitoring of extracellular acidification and respiration rates in living cells. Biochim Biophys Acta 2011; 1808:1827-31.
Seeringer A, Brockmöller J, Bauer S, Kirchheiner J. Enantiospecific pharmacokinetics of metoprolol in CYP2D6 ultra-rapid metabolizers and correlation with exercise-induced heart rate. Eur J Clin Pharmacol 2008; 64:883-8.
Seeringer A, Kirchheiner J. Pharmacogenetics-guided dose modifications of antidepressants. Clin Lab Med 2008; 28:619-26.
Segawa M. Hereditary progressive dystonia with marked diurnal fluctuation. Brain Dev 2000; 22 Suppl 1:65-80.
Segman R, Neeman T, Heresco-Levy U et al. Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 1999; 4:247-53.
Segura M, Farré M, Pichini S et al. Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe. Clin Pharmacokinet 2005; 44:649-60.
Ségurel L, Lafosse S, Heyer E, Vitalis R. Frequency of the AGT Pro11Leu polymorphism in humans: Does diet matter? Ann Hum Genet 2010; 74:57-64.
Sehnert AJ, Daniels SE, Elashoff M et al. Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. J Am Coll Cardiol 2008; 52:644-51.
Sehrt D, Meineke I, Tzvetkov M, Gültepe S, Brockmöller J. Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics. Pharmacogenomics 2011; 12:783-95.
Seidegård J, Ekström G et al. The role of human glutathione transferases and epoxide hydrolases in the metabolism of xenobiotics. Environ Health Perspect 1997; 105 Suppl 4:791-9.
Seidner GA, Ye Y, Faraday MM, Alvord WG, Fortini ME. Modeling clinically heterogeneous presenilin mutations with transgenic Drosophila. Curr Biol 2006; 16:1026-33.
Seifert M, Tilgen W, Reichrath J. Expression of 25-hydroxyvitamin D-1alpha-hydroxylase (1alphaOHase, CYP27B1) splice variants in HaCaT keratinocytes and other skin cells: modulation by culture conditions and UV-B treatment in vitro. Anticancer Res 2009; 29:3659-67.
Seifi M, Fallah S, Firoozrai M. Influence of genetic polymorphism in matrix metalloproteinase-3 on extent of coronary atherosclerosis and risk of coronary artery stenosis. Arch Med Res 2009; 40:600-4.
Seigel GM. Differentiation potential of human retinoblastoma cells. Curr Pharm Biotechnol 2011; 12:213-6.
Seip RL, Duconge J, Ruaño G. Implementing genotype-guided antithrombotic therapy. Future Cardiol 2010; 6:409-24.
Seip RL, Zoeller RF, Angelopoulos TJ et al. Interactive effects of APOE haplotype, sex, and exercise on postheparin plasma lipase activities. J Appl Physiol 2011; 110:1021-8.
Seitz HK, Stickel F. Acetaldehyde as an underestimated risk factor for cancer development: role of genetics in ethanol metabolism. Genes Nutr 20; 5:121-8.
Seki N, Muramatsu M, Sugano S et al. Cloning, expression analysis, and chromosomal localization of HIP1R, an isolog of huntingtin interactin protein (HIP1). J Hum Genet 1998; 43:268-271.
Sekiguchi N, Higashida A, Kato M et al. Prediction of drug-drug interactions based on time-dependent inhibition from high throughput screening of cytochrome P450 3A4 inhibition. Drug Metab Pharmacokinet 2009; 24:500-10.
Sekine I, Yamamoto N, Nishio K, Saijo N. Emerging ethnic differences in lung cancer therapy. Br J Cancer 2008; 99:1757-62.
Sekine S, Ogawa R, Mcmanus MT, Kanai Y, Hebrok M. Dicer is required for proper liver zonation. J Pathol 2009; 219:365-72.
Sekine S, Ogawa R, Ojima H, Kanai Y. Expression of SLCO1B3 is associated with intratumoral cholestasis and CTNNB1 mutations in hepatocellular carcinoma. Cancer Sci 2011; 102:1742-7.
Sekine Y, Demosky SJ, Stonik JA et al. High-density lipoprotein induces proliferation and migration of human prostate androgen-independent cancer cells by an ABCA1-dependent mechanism. Mol Cancer Res 2010; 8:1284-94.
Sekino K, Kubota T, Okada Y et al. Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects. Eur J Clin Pharmacol 2003; 59:589-92.
Sekuri C, Cam FS, Ercan E et al. Renin-angiotensin system gene polymorphisms and premature coronary heart disease. J Renin Angiotensin Aldosterone Syst 2005; 6:38-42.
Selkoe D. Alzheimer’s disease: mechanistic understanding predicts novel therapies. Ann Intern Med 2004; 140:627-38.
Selkoe D, Kopan R. Notch and presenilin: Regulated intramembrane proteolysis links development and degeneration. Annu Rev Neurosci 2003; 26:565-97.
Selzer RR, Rosenblatt DS, Laxova R, Hogan K. Adverse effect of nitrous oxide in a child with 5,10-methylenetetrahydrofolate reductase deficiency. N Engl J Med 2003; 349:45-50.
Sellebjerg F, Kristiansen TB, Wittenhagen P et al. Chemokine receptor CCR5 in interferon-treated multiple sclerosis. Acta Neurol Scand 2007; 115:413-8.
Sellin Jeffries MK, Abbott KI, Cowman T, Kolok AS. Occurrence and endocrine effects of agrichemicals in a small Nebraska, USA, watershed. Environ Toxicol Chem 2011; 30:2253-60.
Seminari E, Castagna A, Lazzarin A. Etravirine for the treatment of HIV infection. Expert Rev Anti Infect Ther 2008; 6:427-33.
Semiz S, Dujic T, Ostanek B et al. Analysis of CYP2C9*2, CYP2C19*2, and CYP2D6*4 polymorphisms in patients with type 2 diabetes mellitus. Bosn J Basic Med Sci 2010; 10:287-91.
Sen-Chowdhry S, Syrris P, McKenna WJ. Role of genetic analysis in the management of patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol 2007; 50:1813-21.
Senda C, Kishimoto W, Sakai K, Nagakura A, Igarashi T. Identification of human cytochrome P450 isoforms involved in the metabolism of brotizolam. Xenobiotica 1997; 27:913-22.
Senda C, Yamaura Y, Kobayashi K et al. Influence of the CYP2D6*10 allele on the metabolism of mexiletine by human liver microsomes. Br J Clin Pharmacol 2001; 52:100-3.
Seneca N, Zoghbi SS, Shetty HU et al. Effects of ketoconazole on the biodistribution and metabolism of [11C]loperamide and [11C]N-desmethyl-loperamide in wild-type and P-gp knockout mice. Nucl Med Biol 2010; 37:335-45.
Seneca S, Verhelst H, de Meirleir L et al. A new mitochondrial point mutation in the transfer RNA(Leu) gene in a patient with a clinical phenotype resembling Kearns-Sayre syndrome. Arch Neurol 2001; 58:1113-8.
Senekeo-Effenberger K, Chen S, Brace-Sinnokrak E et al. Expression of the human UGT1 locus in transgenic mice by 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid (WY-14643) and implications on drug metabolism through peroxisome proliferator-activated receptor alpha activation. Drug Metab Dispos 2007; 35:419-27.
Senggunprai L, Kukongviriyapan U, Jetsrisuparb A, Kukongviriyapan V. Drug metabolizing enzyme CYP1A2 status in pediatric patients with hemoglobin E-beta thalassemia. J Med Assoc Thai 2009; 92:1675-80.
Sengupta S, Mantha AK, Mitra S, Bhakat KK. Human AP endonuclease (APE1/Ref-1) and its acetylation regulate YB-1-p300 recruitment and RNA polymerase II loading in the drug-induced activation of multidrug resistance gene MDR1. Oncogene 2011; 30:482-93.
Sensken S, Waclawczyk S, Knaupp AS et al. In vitro differentiation of human cord blood-derived unrestricted somatic stem cells towards an endodermal pathway. Cytotherapy 2007; 9:362-78.
Seo KA, Bae SK, Choi YK, Choi CS, Liu KH, Shin JG. Metabolism of 1’- and 4-hydroxymidazolam by glucuronide conjugation is largely mediated by UDP-glucuronosyltransferases 1A4, 2B4, and 2B7. Drug Metab Dispos 2010; 38:2007-13.
Seo SB, Hur JG, Kim MJ et al. TRAIL sensitize MDR cells to MDR-related drugs by down-regulation of P-glycoprotein through inhibition of DNA-PKcs/Akt/GSK-3beta pathway and activation of caspases. Mol Cancer 2010; 9:199.
Seo T, Ishitsu T, Oniki K, Abe T, Shuto T, Nakagawa K. ABCC2 haplotype is not associated with drug-resistant epilepsy. J Pharm Pharmacol 2008; 60:631-5.
Seo T, Ishitsu T, Ueda N et al. ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients. Pharmacogenomics 2006; 7:551-61.
Seo T, Pahwa P, McDuffie HH et al. Association between cytochrome P450 3A5 polymorphism and the lung function in Saskatchewan grain workers. Pharmacogenet Genomics 2008; 18:487-93.
Seo Y, Yang SR, Jee MK et al. Human umbilical cord blood-derived mesenchymal stem cells protect against neuronal cell death and ameliorate motor deficits in Niemann Pick Type C1 mice. Cell Transplant 2011; 20:1033-47.
Seppen J, Bosma PJ, Goldhoorn BG et al. Discrimination between Crigler-Najjar type I and II by expression of mutant bilirubin uridine diphosphate-glucuronosyltransferase. J Clin Invest 1994; 94:2385-91.
Seppen J, Steenken E, Lindhout D, Bosma PJ, Elferink RP. A mutation which disrupts the hydrophobic core of the signal peptide of bilirubin UDP-glucuronosyltransferase, an endoplasmic reticulum membrane protein, causes Crigler-Najjar type II. FEBS Lett 1996; 390:294-8.
Sequist LV, Martins RG, Spigel D et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008; 26:2442-9.
Sérée E, Villard PH, Hevér A et al. Modulation of MDR1 and CYP3A expression by dexamethasone: evidence for an inverse regulation in adrenals. Biochem Biophys Res Commun 1998; 252:392-5.
Serels SR, Appell RA. Tolterodine: a new antimuscarinic agent for the treatment of the overactive bladder. Expert Opin Investig Drugs 1999; 8:1073-8.
Seremak-Mrozikiewicz A, Drews K, Mrozikiewicz PM et al. Correlation of vitamin D receptor gene (VDR) polymorphism with osteoporotic changes in Polish postmenopausal women. Neuro Endocrinol Lett 2009; 30:540-6.
Sereš M, Ditte P, Breier A, Sulová Z. Effect of thapsigargin on P-glycoprotein-negative and P-glycoprotein-positive L1210 mouse leukaemia cells. Gen Physiol Biophys 2010; 29:396-401.
Sergent T, Dupont I, Jassogne C et al. CYP1A1 induction and CYP3A4 inhibition by the fungicide imazalil in the human intestinal Caco-2 cells-comparison with other conazole pesticides. Toxicol Lett 2009; 184:159-68.
Sergent T, Dupont I, van der Heiden E et al. CYP1A1 and CYP3A4 modulation by dietary flavonoids in human intestinal Caco-2 cells. Toxicol Lett 2009; 191:216-22.
Sergentanis TN, Economopoulos KP. GSTT1 and GSTP1 polymorphisms and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 2010; 121:195-202.
Sergentanis TN, Economopoulos KP, Choussein S, Vlahos NF. Cytochrome P450 1A1 gene polymorphisms and endometrial cancer risk: a meta-analysis. Int J Gynecol Cancer 2011; 21:323-31.
Seripa D, Bizzarro A, Panza F et al. The APOE gene locus in frontotemporal dementia and primary progressive aphasia. Arch Neurol 2011; 68:622-8.
Seripa D, Bizzarro A, Pilotto A et al. Role of cytochrome P4502D6 functional polymorphisms in the efficacy of donepezil in patients with Alzheimer’s disease. Pharmacogenet Genomics 2011; 21:225-30.
Serova M, Astorgues-Xerri L, Bieche I et al. Epithelial-to-mesenchymal transition and oncogenic Ras expression in resistance to the protein kinase Cbeta inhibitor enzastaurin in colon cancer cells. Mol Cancer Ther 2010; 9:1308-17.
Serralta A, Donato MT, Orbis F, Castell JV, Mir J, Gómez-Lechón MJ. Functionality of cultured human hepatocytes from elective samples, cadaveric grafts and hepatectomies. Toxicol In Vitro 2003; 17:769-74.
Serrano D, Lazzeroni M, Zambon CF et al. Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian tamoxifen prevention trial. Pharmacogenomics J 2011; 11:100-7.
Serrano J, Goebel SU, Peghini PL, Lubensky IA, Gibril F, Jensen RT. Alterations in the p16INK4a/CDKN2A tumor suppressor gene in gastrinomas. J Clin Endocrinol Metab 2000; 85:4146-56.
Serrato M, Marian AJ. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest 1995; 96:3005-8.
Serretti A, Drago A, de Ronchi D. HTR2A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. Curr Med Chem 2007; 14:2053-69.
Sertel S, Fu Y, Zu Y et al. Molecular docking and pharmacogenomics of Vinca alkaloids and their monomeric precursors, vindoline and catharanthine. Biochem Pharmacol 2011; 81:723-35.
Seruga B, Amir E. Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis. Breast Cancer Res Treat 2010; 122:609-17.
Servedio V, d’Apolito M, Maiorano N et al. Spectrum of UGT1A1 mutations in Crigler-Najjar (CN) syndrome patients: identification of twelve novel alleles and genotype-phenotype correlation. Hum Mutat 2005; 25:325.
Serý O, Prikryl R, Castulík L, St’astný F. A118G polymorphism of OPRM1 gene is associated with schizophrenia. J Mol Neurosci 2010; 41:219-22.
Sesardic D, Boobis AR, Edwards RJ, Davies DS. A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Brit J Clin Pharm 1988; 26:363-72.
Sesink AL, Arts IC, de Boer VC et al. Breast cancer resistance protein (Bcrp1/Abcg2) limits net intestinal uptake of quercetin in rats by facilitating apical efflux of glucuronides. Mol Pharmacol 2005; 67:1999-2006.
Sestan N, Artavanis-Tsakonas S, Rakic P. Contact-dependent inhibition of cortical neurite growth mediated by Notch signaling. Science 1999; 286:741-6.
Sesti F, Abbott GW, Wei J et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci USA 2000; 97:10613-8.
Sesti G, Laratta E, Cardellini M et al. The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5’-triphosphate-sensitive potassium channel subunit Kir6. 2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. J Clin Endocrinol Metab 2006; 91:2334-9.
Sethi SK, Waterham HR, Sharma S, Sharma A, Hari P, Bagga A. Primary hyperoxaluria type 1 with a novel mutation. Indian J Pediatr 2009; 76:215-7.
Sethupathy P, Borel C, Gagnebin M et al. Human microRNA-155 on chromosome 21 differentially interacts with its polymorphic target in the AGTR1 3-prime untranslated region: a mechanism for functional single-nucleotide polymorphisms related to phenotypes. Am J Hum Genet 2007; 81:405-13.
Seto-Young D, Avtanski D, Parikh G et al. Rosiglitazone and pioglitazone inhibit estrogen synthesis in human granulosa cells by interfering with androgen binding to aromatase. Horm Metab Res 2011; 3:250-6.
Settin A, Abdel-Hady H, El-Baz R, Saber I. Gene polymorphisms of TNF-alpha(-308), IL-10(-1082), IL-6(-174), and IL-1Ra(VNTR) related to susceptibility and severity of rheumatic heart disease. Pediatr Cardiol 2007; 5:363-71.
Sève P, Mackey JR, Isaac S et al. cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer. Lung Cancer 2005; 49:363-70.
Sève P, Reiman T, Isaac S et al. Protein abundance of class III beta-tubulin but not Delta2-alpha-tubulin or tau is related to paclitaxel response in carcinomas of unknown primary site. Anticancer Res 2008; 28:1161-7.
Severino G, Chillotti C, de Lisa R, del Zompo M, Ardau R. Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors. Ann Pharmacother 2005; 39:162-4.
Sevilla-Mantilla C, Ortega L, Agúndez JA, Fernández-Gutiérrez B, Ladero JM, Díaz-Rubio M. Leflunomide-induced acute hepatitis. Dig Liver Dis 2004; 36:82-4.
Sevior DK, Hokkanen J, Tolonen A et al. Rapid screening of commercially available herbal products for the inhibition of major human hepatic cytochrome P450 enzymes using the N-in-one cocktail. Xenobiotica 2010; 40:245-54.
Sevov M, Elfineh L, Cavelier LB. Resveratrol regulates the expression of LXR-alpha in human macrophages. Biochem Biophys Res Commun 2006; 348:1047-54.
Sevoz C, Benoit E, Buronfosse T. Thioesterification of 2-arylpropionic acids by recombinant acyl-coenzyme A synthetases (ACS1 and ACS2). Drug Metab Dispos 2000; 28:398-402.
Seyberth HW, Schlingmann KP. Bartter- and Gitelman-like syndromes: salt-losing tubulopathies with loop or DCT defects. Pediatr Nephrol 2011; 26:1789-802.
Seznec H, Simon D, Bouton C et al. Friedreich ataxia: the oxidative stress paradox. Hum Mol Genet 2005; 14:463-74.
Sgambato A, Camerini A, Collecchi P et al. Cyclin E correlates with manganese superoxide dismutase expression and predicts survival in early breast cancer patients receiving adjuvant epirubicin-based chemotherapy. Cancer Sci 2009; 100:1026-33.
Sgroi DC, Haber DA, Ryan PD, Ma XJ, Erlander MG. RE: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004; 6:445.
Shaat N, Karlsson E, Lernmark A et al. Common variants in MODY genes increase the risk of gestational diabetes mellitus. Diabetologia 2006; 49:1545-51.
Shabalina SA, Zaykin DV, Gris P et al. Expansion of the human mu-opioid receptor gene architecture: novel functional variants. Hum Mol Genet 2009; 18:1037-51.
Shacham S, Heal DJ, Cheetham SC et al. PRX-07034, a potent and selective 5-HT6 receptor antagonist, reduces food intake and body weight in dietary-induced obese (DIO) rats. Abstract Viewer/Itinerary Planner, Program No. 62. 10. Society for Neuroscience,Washington, DC. 2006.
Shader RI, Granda BW, von Moltke LL, Giancarlo GM, Greenblatt DJ. Inhibition of human cytochrome P450 isoforms in vitro by zafirlukast. Biopharm Drug Dispos 1999; 20:385-8.
Shadle CR, Lee Y, Majumdar AK et al. Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. J Clin Pharmacol 2004; 44:215-23.
Shadli RM, Pieter MS, Yaacob MJ, Rashid FA. APOE genotype and neuropsychological outcome in mild-to-moderate traumatic brain injury: A pilot study. Brain Inj 2011; 25:596-603.
Shafeghati Y, Momenin N, Esfahani T, Reyniers E, Wuyts W. Vitamin D-dependent rickets type II: report of a novel mutation in the vitamin D receptor gene. Arch Iran Med 2008; 11:330-4.
Shafran A, Ifergan I, Bram E et al. ABCG2 harboring the Gly482 mutation confers high-level resistance to various hydrophilic antifolates. Cancer Res 2005; 65:8414-22.
Shah AK, Tioleco NM, Nolan K et al. Rare NRXN1 promoter variants in patients with schizophrenia. Neurosci Lett 2010; 475:80-4.
Shah K, Qureshi SU, Johnson M, Parikh N, Schulz PE, Kunik ME. Does use of antihypertensive drugs affect the incidence or progression of dementia? A systematic review. Am J Geriatr Pharmacother 2009; 7:250-61.
Shah MA, Kortmansky J, Motwani M et al. A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. Clin Cancer Res 2005; 11:3836-45.
Shah PK, Yano J, Reyes O et al. High-dose recombinant apolipoprotein A-I(Milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E-deficient mice: potential implications for acute plaque stabilization. Circulation 2001; 103:3047-50.
Shah S, Islam MN, Dakshanamurthy S et al. The molecular basis of vitamin D receptor and beta-catenin crossregulation. Molec Cell 2006; 21:799-809.
Shahin MH, Khalifa SI, Gong Y et al. Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients. Pharmacogenet Genomics 2011; 21:130-5.
Shahinian A, Pfeffer K, Lee KP et al. Differential T cell costimulatory requirements in CD28-deficient mice. Science 1993; 261:609-612.
Shahzadi A, Javed I, Aslam B et al. Therapeutic effects of ciprofloxacin on the pharmacokinetics of carbamazepine in healthy adult male volunteers. Pak J Pharm Sci 2011; 24:63-8.
Shai SY, Sukhanov S, Higashi Y, Vaughn C, Rosen CJ, Delafontaine P. Low circulating insulin-like growth factor I increases atherosclerosis in ApoE-deficient mice. Am J Physiol Heart Circ Physiol 2011; 300:1898-906.
Shaik IH, Mehvar R. Effects of normothermic hepatic ischemia-reperfusion injury on the in vivo, isolated perfused liver, and microsomal disposition of chlorzoxazone, a cytochrome P450 2E1 probe, in rats. J Pharm Sci 2011; 100:5281-8292.
Shaikh AR, Broclawik E, Tsuboi H et al. Oxidation mechanism in the metabolism of (S)-N-[1-(3-morpholin-4-ylphenyl)ethyl]-3-phenylacrylamide on oxyferryl active site in CYP3A4 Cytochrome: DFT modeling. J Mol Model 2007; 13:851-60.
Shaker O, Zahra A, Sayed A et al. Role of ICAM-1 and E-selectin gene polymorphisms in pathogenesis of PAOD in Egyptian patients. Vasc Health Risk Manag 2010; 6:9-15.
Shakeri-Nejad K, Stahlmann R. Drug interactions during therapy with three major groups of antimicrobial agents. Expert Opin Pharmacother 2006; 7:639-51.
Shakhtshneider EV, Ragino YI, Chernjavski AM, Kulikov IV, Ivanova MV, Voevoda MI. Apolipoprotein E gene polymorphism in men with coronary atherosclerosis in Siberia. Bull Exp Biol Med 2011; 150:355-8.
Shams ME, Arneth B, Hiemke C et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther 2006; 31:493-502.
Shan D, Fang Y, Ye Y, Liu J. EGCG reducing the susceptibility to cholesterol gallstone formation through the regulation of inflammation. Biomed Pharmacother 2008; 62:677-83.
Shan L, Makita N, Xing Y et al. SCN5A variants in Japanese patients with left ventricular noncompaction and arrhythmia. Mol Genet Metab 2008; 4:468-574.
Shang Q, Saumoy M, Holst JJ, Salen G, Xu G. Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1. Am J Physiol Gastrointest Liver Physiol 2010; 298:419-24.
Shankar S, Nall D, Tang SN et al. Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition. PLoS One 2011. doi:10. 1371/journal. pone. 0016530.
Shannon JR, Flattem NL, Jordan J et al. Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency. N Engl J Med 2000; 342:541-9.
Shao H, Ren XM, Liu NF et al. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers. J Clin Pharm Ther 2010; 35:351-60.
Shao J, Stapleton PL, Lin YS, Gallagher EP. Cytochrome p450 and glutathione s-transferase mRNA expression in human fetal liver hematopoietic stem cells. Drug Metab Dispos 2007; 35:168-75.
Shao K, Huang R, Li J et al. Angiopep-2 modified PE-PEG based polymeric micelles for amphotericin B delivery targeted to the brain. J Control Release 2010; 147:118-26.
Shapiro GI. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin Cancer Res 2004; 10:4270-5.
Sharma A, Hamelin BA. Classic histamine H1 receptor antagonists: a critical review of their metabolic and pharmacokinetic fate from a bird’s eye view. Curr Drug Metab 2003; 4:105-29.
Sharma A, Pibarot P, Pilote S et al. Modulation of metoprolol pharmacokinetics and hemodynamics by diphenhydramine coadministration during exercise testing in healthy premenopausal women. J Pharmacol Exp Ther 2005; 313:1172-81.
Sharma G, Mirza S, Parshad R et al. CpG hypomethylation of MDR1 gene in tumor and serum of invasive ductal breast carcinoma patients. Clin Biochem 2010; 43:373-9.
Sharma M, Manoharlal R, Shukla S et al. Curcumin modulates efflux mediated by yeast ABC multidrug transporters and is synergistic with antifungals. Antimicrob Agents Chemother 2009; 53:3256-65.
Sharma R, Ahuja M, Panda N, Khullar M. Polymorphisms in CYP2A13 and UGT1A7 genes and head and neck cancer susceptibility in North Indians. Oral Dis 2010; 16:760-8.
Sharma R, Ahuja M, Panda NK, Khullar M. Interactions among genetic variants in tobacco metabolizing genes and smoking are associated with head and neck cancer susceptibility in North Indians. DNA Cell Biol 2011; 30:611-6.
Sharma S, Das M, Kumar A et al. Interaction of genes from influx-metabolism-efflux pathway and their influence on methotrexate efficacy in rheumatoid arthritis patients among Indians. Pharmacogenet Genomics 2008; 18:1041-9.
Sharma S, Das M, Kumar A et al. Purine biosynthetic pathway genes and methotrexate response in rheumatoid arthritis patients among north Indians. Pharmacogenet Genomics 2009; 19:823-8.
Sharma S, Ellis EC, Dorko K et al. Metabolism of 17alpha-hydroxyprogesterone caproate, an agent for preventing preterm birth, by fetal hepatocytes. Drug Metab Dispos 2010; 38:723-7.
Sharma S, Ou J, Strom S, Mattison D, Caritis S, Venkataramanan R. Identification of enzymes involved in the metabolism of 17alpha-hydroxyprogesterone caproate: an effective agent for prevention of preterm birth. Drug Metab Dispos 2008; 36:1896-902.
Sharma S, Rana SV. Melatonin inhibits benzene-induced lipid peroxidation in rat liver. Arh Hig Rada Toksikol 2010; 61:11-8.
Sharp CF, Gardiner SJ, Jensen BP et al. CYP2D6 genotype and its relationship with metoprolol dose, concentrations and effect in patients with systolic heart failure. Pharmacogenomics J 2009; 9:175-84.
Sharples EJ, Varagunam M, Sinnott PJ, McCloskey DJ, Raftery MJ, Yaqoob MM. The effect of proinflammatory cytokine gene and angiotensin-converting enzyme polymorphisms on erythropoietin requirements in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 2006; 26:64-8.
Shatalova EG, Klein-Szanto AJ, Devarajan K, Cukierman E, Clapper ML. Estrogen and cytochrome P450 1B1 contribute to both early- and late-stage head and neck carcinogenesis. Cancer Prev Res 2011; 4:107-15.
Shaukat A, Benekli M, Vladutiu GD, Slack JL, Wetzler M, Baer MR. Simvastatin-fluconazole causing rhabdomyolysis. Ann Pharmacother 2003; 37:1032-5.
Shawahna R, Uchida Y, Declèves X et al. Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels. Mol Pharm 2011; 8:1332-41.
Shayeganpour A, El-Kadi AO, Brocks DR. Determination of the enzyme(s) involved in the metabolism of amiodarone in liver and intestine of rat: the contribution of cytochrome P450 3A isoforms. Drug Metab Dispos 2006; 34:43-50.
Shchekotikhin AE, Glazunova VA, Dezhenkova LG et al. The first series of 4,11-bis[(2-aminoethyl)amino]anthra[2,3-b]furan-5,10-diones: Synthesis and anti-proliferative characteristics. Eur J Med Chem 2011; 46:423-8.
Shchepotina EG, Vavilin VA, Goreva OB, Lyakhovich VV. Some mutations of exon-7 in cytochrome P450 gene 3A4 and their effect on 6beta-hydroxylation of cortisol. Bull Exp Biol Med 2006; 141:701-3.
Shearman AM, Cooper JA, Kotwinski PJ et al. Estrogen receptor alpha gene variation is associated with risk of myocardial infarction in more than seven thousand men from five cohorts. Circ Res 2006; 98:590-2.
Sheehan AL, Carrell S, Johnson B, Stanic B, Banfi B, Miller FJ Jr. Role for Nox1 NADPH oxidase in atherosclerosis. Atherosclerosis 2011; 216:321-6.
Sheehan K, Lowe N, Kirley A et al. Tryptophan hydroxylase 2 (TPH2) gene variants associated with ADHD. Mol Psychiatry 2005; 10:944-9.
Shelepova T, Nafziger AN, Victory J et al. Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktail. J Clin Pharmacol 2005; 45:1413-21.
Shelton MJ, Hewitt RG, Adams J, Della-Coletta A, Cox S, Morse GD. Pharmacokinetics of ritonavir and delavirdine in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2003; 47:1694-9.
Shelton PS, Barnett FL, Krick SE. Hyperventilation associated with quetiapine. Ann Pharmacother 2000; 34:335-7.
Shelton RC. The combination of olanzapine and fluoxetine in mood disorders. Expert Opin Pharmacother 2003; 4:1175-83.
Shen C, Bai Y, Wang S et al. Expression profile of PIN, AUX/LAX and PGP auxin transporter gene families in Sorghum bicolor under phytohormone and abiotic stress. FEBS J 2010; 277:2954-69.
Shen DD, Kunze KL, Thummel KE. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv Drug Deliv Rev 1997; 27:99-127.
Shen G, Liang A, Zhao Y et al. Interaction between four herb compounds and a western drug by CYP3A4 enzyme metabolism in vitro. Zhongguo Zhong Yao Za Zhi 2009; 34:1705-11.
Shen H, He MM, Liu H et al. Comparative metabolic capabilities and inhibitory profiles of CYP2D6. 1, CYP2D6. 10, and CYP2D6. 17. Drug Metab Dispos 2007; 35:1292-300.
Shen H, Lee FY, Gan J. Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther 2011; 337:423-32.
Shen H, Newmann AS, Hu Z et al. Methylenetetrahydrofolate reductase polymorphisms/haplotypes and risk of gastric cancer: a case-control analysis in China. Oncol Rep 2005; 13:355-60.
Shen H, Xu W, Chen Q, Wu Z, Tang H, Wang F. Tetrandrine prevents acquired drug resistance of K562 cells through inhibition of mdr1 gene transcription. J Cancer Res Clin Oncol 2010; 136:659-65.
Shen H, Xu W, Luo W et al. Upregulation of mdr1 gene is related to activation of the MAPK/ERK signal transduction pathway and YB-1 nuclear translocation in B-cell lymphoma. Exp Hematol 2011; 39:558-69.
Shen H, Yuan Y, Hu HG et al. Clinical significance of K-ras and BRAF mutations in Chinese colorectal cancer patients. World J Gastroenterol 2011; 17:809-16.
Shen HW, Jiang XL, Winter JC, Yu AM. Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions. Curr Drug Metab 2010; 11:659-66.
Shen HW, Jiang XL, Yu AM. Nonlinear pharmacokinetics of 5-methoxy-N,N-dimethyltryptamine in mice. Drug Metab Dispos 2011; 39:1227-34.
Shen J, Gammon MD, Wu HC et al. Multiple genetic variants in telomere pathway genes and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2010; 19:219-28.
Shen J, Terry MB, Gammon MD et al. MGMT genotype modulates the associations between cigarette smoking, dietary antioxidants and breast cancer risk. Carcinogenesis 2005; 26:2131-7.
Shen L, Ahmad S, Park S et al. In vitro metabolism, permeability, and efflux of bazedoxifene in humans. Drug Metab Dispos 2010; 38:1471-9.
Shen L, Fitzloff JF, Cook CS. Differential enantioselectivity and product-dependent activation and inhibition in metabolism of verapamil by human CYP3As. Drug Metab Dispos 2004; 32:186-96.
Shen L, Wang DQ, Tso P, Jandacek RJ, Woods SC, Liu M. Apolipoprotein E reduces food intake via PI3K/Akt signaling pathway in the hypothalamus. Physiol Behav 2011; 105:124-8.
Shen M, Vermeulen R, Rajaraman P et al. Polymorphisms in innate immunity genes and lung cancer risk in Xuanwei, China. Environ Mol Mutagen 2009; 50:285-90.
Shen S, Callaghan D, Juzwik C, Xiong H, Huang P, Zhang W. ABCG2 reduces ROS-mediated toxicity and inflammation: a potential role in Alzheimer’s disease. J Neurochem 2010; 114:1590-604.
Shen S, Marchick MR, Davis MR, Doss GA, Pohl LR. Metabolic activation of diclofenac by human cytochrome P450 3A4: role of 5-hydroxydiclofenac. Chem Res Toxicol 1999; 12:214-22.
Shen S, Zhang W. ABC transporters and drug efflux at the blood-brain barrier. Rev Neurosci 2010; 21:29-53.
Shen WW. Cytochrome P450 monooxygenases and interactions of psychotropic drugs: a five-year update. Int J Psychiatry Med 1995; 25:277-90.
Shen Y, Lu Y, Yin X, Zhu G, Zhu J. KRAS and BRAF mutations in prostate carcinomas of Chinese patients. Cancer Genet Cytogenet 2010; 198:35-9.
Shen Y, Xia M, Zhang J et al. IRF-1 and p65 mediate upregulation of constitutive HLA-A antigen expression by hepatocellular carcinoma cells. Mol Immunol 2009; 46:2045-53.
Shen YC, Chen SF, Chen CH et al. Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients. J Psychiatr Res 2009; 43:600-6.
Shen Z, Saloniemi T, Rönnblad A, Järvensivu P, Pakarinen P, Poutanen M. Sex steroid-dependent and -independent action of hydroxysteroid (17beta) Dehydrogenase 2: evidence from transgenic female mice. Endocrinology 2009; 150:4941-9.
Sheng L, Tan W, Hu JP, Chen H, Li Y. Effect of CYP3A and P-glycoprotein on the absorption of buagafuran in rat intestinal lumen. Yao Xue Xue Bao 2010; 45:43-8.
Sheng YC, Wang K, He YC, Yang J, Zheng QS. Effect of CYP2C19 genotypes on the pharmacokinetic/pharmacodynamic relationship of rabeprazole after a single oral dose in healthy Chinese volunteers. Eur J Clin Pharmacol 2010; 66:1165-9.
Sherman JG, Paul AJ, Firkins LD. Evaluation of the safety of spinosad and milbemycin 5-oxime orally administered to Collies with the MDR1 gene mutation. Am J Vet Res 2010; 71:115-9.
Sherr CJ, Roberts JM. Living with or without cyclins and cyclin-dependent kinases. Genes Dev 2004; 18:2699-711.
Sherva R, Ford CE, Eckfeldt JH, Davis BR, Boerwinkle E, Arnett DK. Pharmacogenetic effect of the stromelysin (MMP3) polymorphism on stroke risk in relation to antihypertensive treatment: the genetics of hypertension associated treatment study. Stroke 2011; 42:330-5.
Shet MS, McPhaul M, Fisher CW, Stallings NR, Estabrook RW. Metabolism of the antiandrogenic drug (Flutamide) by human CYP1A2. Drug Metab Dispos 1997; 25:1298-303.
Shete S, Hosking FJ, Robertson LB et al. Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet 2009; 41:899-904.
Sheu BS, Cheng HC, Yeh YC, Chang WL. CYP2C19 Genotypes determine the efficacy of on-demand therapy of pantoprazole for reflux esophagitis as Los-Angeles Grade C & D. J Gastroenterol Hepatol 2011. doi:10. 1111/j. 1440-1746. 2011. 06848. x.
Sheu MT, Liou YB, Kao YH, Lin YK, Ho HO. A quantitative structure-activity relationship for the modulation effects of flavonoids on p-glycoprotein-mediated transport. Chem Pharm Bull 2010; 58:1187-94.
Shi C, Tian R, Wang M et al. CD44+ CD133+ population exhibits cancer stem cell-like characteristics in human gallbladder carcinoma. Cancer Biol Ther 2010; 10:1182-90.
Shi CJ, Wang F, Ren MF et al. Up-regulation of ABCB1/P-glycoprotein by escaping promoter hypermethylation indicates poor prognosis in hematologic malignancy patients with and without bone marrow transplantation. Leuk Res 2011; 35:73-9.
Shi HY, Yan J, Zhu WH et al. Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism. Eur J Clin Pharmacol 2010; 66:1131-6.
Shi J, Chapel S, Montay G et al. Effect of ketoconazole on the pharmacokinetics and safety of telithromycin and clarithromycin in older subjects with renal impairment. Int J Clin Pharmacol Ther 2005; 43:123-33.
Shi J, Gershon ES, Liu C. Genetic associations with schizophrenia: meta-analyses of 12 candidate genes. Schizophr Res 2008; 104:96-107.
Shi J, Misso NL, Duffy DL et al. Cyclooxygenase-1 gene polymorphisms in patients with different asthma phenotypes and atopy. Eur Respir J 2005; 26:249-56.
Shi J, Montay G, Bhargava VO. Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. Clin Pharmacokinet 2005; 44:915-34.
Shi J, Montay G, Leroy B, Bhargava VO. Effects of itraconazole or grapefruit juice on the pharmacokinetics of telithromycin. Pharmacotherapy 2005; 25:42-51.
Shi J, Yoshino O, Osuga Y et al. Bone morphogenetic protein-2 (BMP-2) increases gene expression of FSH receptor and aromatase and decreases gene expression of LH receptor and StAR in human granulosa cells. Am J Reprod Immunol 2011; 65:421-7.
Shi J, Zhang X, Ma Z, Zhang M, Sun F. Characterization of aromatase binding agents from the dichloromethane extract of Corydalis yanhusuo using ultrafiltration and liquid chromatography tandem mass spectrometry. Molecules 2010; 15:3556-66.
Shi JY, Shi ZZ, Zhang SJ et al. Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients. Pharmacogenetics 2004; 14:759-68.
Shi P, Liu W, Zhou ZT, He QB, Jiang WW. Podoplanin and ABCG2: malignant transformation risk markers for oral lichen planus. Cancer Epidemiol Biomarkers Prev 2010; 19:844-9.
Shi QY, Lin YG, Zhou X, Lin YQ, Yan S. Expression of FXR mRNA, PPAR alpha mRNA and bile acid metabolism related genes in intrahepatic cholestasis of pregnant rats. Zhonghua Gan Zang Bing Za Zhi 2010; 18:927-30.
Shi R, Li J, Cao X, Zhu X, Lu X. Exploration of the binding of proton pump inhibitors to human P450 2C9 based on docking and molecular dynamics simulation. J Mol Model 2011; 17:1941-51.
Shi S, Klotz U. Clinical use and pharmacological properties of selective COX-2 inhibitors. Eur J Clin Pharmacol 2008; 64:233-52.
Shi X, Dick RA, Ford KA, Casida JE. Enzymes and inhibitors in neonicotinoid insecticide metabolism. J Agric Food Chem 2009; 57:4861-6.
Shi XB, Ma AH, Xia L, Kung HJ, de Vere White RW. Functional analysis of 44 mutant androgen receptors from human prostate cancer. Cancer Res 2002; 62:1496-502.
Shi Y, Li C, O’Connor SP et al. Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577. Bioorg Med Chem Lett 2009; 19:6882-9.
Shi Y, Wang H, Su Z et al. Differentiation imbalance of Th1/Th17 in peripheral blood mononuclear cells might contribute to pathogenesis of Hashimoto’s thyroiditis. Scand J Immunol 2010; 72:250-5.
Shi Y, Xiang P, Li L, Shen M. Analysis of 50 SNPs in CYP2D6, CYP2C19, CYP2C9, CYP3A4 and CYP1A2 by MALDI-TOF mass spectrometry in Chinese Han population. Forensic Sci Int 2011; 207:183-7.
Shi YP, Nahlen BL, Kariuki S et al. Fcgamma receptor IIa (CD32) polymorphism is associated with protection of infants against high-density Plasmodium falciparum infection. VII. Asembo Bay Cohort Project. J Infect Dis 2001; 184:107-11.
Shi Z, Chen Y, Dong H, Amos-Kroohs RM, Nebert DW. Generation of a ‘humanized’ hCYP1A1_1A2_Cyp1a1/1a2(-/-)_Ahrd mouse line harboring the poor-affinity aryl hydrocarbon receptor. Biochem Biophys Res Commun 2008; 376:775-80.
Shi Z, Johnstone D, Talseth-Palmer BA et al. Haemochromatosis HFE gene polymorphisms as potential modifiers of hereditary nonpolyposis colorectal cancer risk and onset age. Int J Cancer 2009; 125:78-83.
Shi Z, Peng XX, Kim IW et al. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res 2007; 67:11012-20.
Shi Z, Tiwari AK, Shukla S et al. Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol 2009; 77:781-93.
Shi Z, Tiwari AK, Shukla S et al. Sildenafil reverses ABCB1-and ABCG2-mediated chemotherapeutic drug resistance. Cancer Res 2011; 71:3029-41.
Shi ZZ, Habib GM, Rhead WJ et al. Mutations in the glutathione synthetase gene cause 5-oxoprolinuria. Nat Genet 1996; 14:361-5.
Shibahara N, Masunaga Y, Iwano S, Yamazaki H, Kiyotani K, Kamataki T. Human cytochrome P450 1A1 is a novel target gene of liver X receptor α. Drug Metab Pharmacokinet 2011. doi:10. 2133/dmpk. DMPK-11-RG-030.
Shibata H, Shibata A, Ninomiya H, Tashiro N, Fukumaki Y. Association study of polymorphisms in the GluR6 kainate receptor gene (GRIK2) with schizophrenia. Psychiatry Res 2002; 113:59-67.
Shibata H, Takano H, Ito M et al. Alpha-catenin is essential in intestinal adenoma formation. Proc Natl Acad Sci USA 2007; 104:18199-204.
Shibata N, Hayakawa T, Takada K, Hoshino N, Minouchi T, Yamaji A. Simultaneous determination of glucocorticoids in plasma or urine by high-performance liquid chromatography with precolumn fluorimetric derivatization by 9-anthroyl nitrile. J Chromatogr B Biomed Sci Appl 1998; 706:191-9.
Shibata R, Sato K, Pimentel DR et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 2005; 11:1096-103.
Shibata S, Hayakawa K, Egashira Y, Sanada H. Hypocholesterolemic mechanism of Chlorella: Chlorella and its indigestible fraction enhance hepatic cholesterol catabolism through up-regulation of cholesterol 7alpha-hydroxylase in rats. Biosci Biotechnol Biochem 2007; 71:916-25.
Shibata Y, Takahashi H, Chiba M, Ishii Y. A novel approach to the prediction of drug-drug interactions in humans based on the serum incubation method. Drug Metab Pharmacokinet 2008; 23:328-39.
Shibayama T, Sugiyama D, Kamiyama E, Tokui T, Hirota T, Ikeda T. Characterization of CS-023 (RO4908463), a novel parenteral carbapenem antibiotic, and meropenem as substrates of human renal transporters. Drug Metab Pharmacokinet 2007; 22:41-7.
Shibuya A, Ikuta T, Hsu LC, Yoshida A. Genotypes of alcohol metabolizing enzymes in Japanese with alcoholic liver diseases: a strong association of the usual Caucasian type aldehyde dehydrogenase allele (ALDH2) with the disease. Am J Hum Genet 1988; 43:201.
Shibuya S, Higuchi J, Shin RW et al. Protective prion protein polymorphisms against sporadic Creutzfeldt-Jakob disease. Lancet 1998; 351:419.
Shieh JP, Chu CC, Wang JJ, Lin MT. Epinephrine, phenylephrine, and methoxamine induce infiltrative anesthesia via alpha1-adrenoceptors in rats. Acta Pharmacol Sin 2009; 30:1227-36.
Shieh MJ, Hsu CY, Huang LY, Chen HY, Huang FH, Lai PS. Reversal of doxorubicin-resistance by multifunctional nanoparticles in MCF-7/ADR cells. J Control Release 2011; 152:418-25.
Shield AJ, Murray TP, Cappello JY, Coggan M, Board PG. Polymorphisms in the human glutathione transferase Kappa (GSTK1) promoter alter gene expression. Genomics 2010; 95:299-305.
Shiga K, Fukuyama R, Kimura S, Nakajima K, Fushiki S. Mutation of the sterol 27-hydroxylase gene (CYP27) results in truncation of mRNA expressed in leucocytes in a Japanese family with cerebrotendinous xanthomatosis. J Neurol Neurosurg Psychiatry 1999; 67:675-7.
Shih DQ, Bussen M, Sehayek E et al. Hepatocyte nuclear factor-1alpha is an essential regulator of bile acid and plasma cholesterol metabolism. Nat Genet 2001; 27:375-82.
Shih PH, Wu CH, Yeh CT, Yen GC. Protective effects of anthocyanins against amyloid β-peptide-induced damage in neuro-2A cells. J Agric Food Chem 2011; 59:1683-9.
Shiizaki K, Ohsako S, Kawanishi M, Yagi T. Omeprazole alleviates benzo[a]pyrene cytotoxicity by inhibition of CYP1A1 activity in human and mouse hepatoma cells. Basic Clin Pharmacol Toxicol 2008; 103:468-75.
Shikata E, Ieiri I, Ishiguro S et al. Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood 2004; 103:2630-5.
Shilliday FB, Walker DP, Gu C et al. Multiple species metabolism of PHA-568487, a selective alpha 7 nicotinic acetylcholine receptor agonist. Drug Metab Lett 2010; 4:162-72.
Shim HJ, Yun JY, Hwang JE et al. BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin. Cancer Sci 2010; 101:1247-54.
Shim J, Handberg A, Ostergren C, Falk E, Bentzon JF. Genetic susceptibility of the arterial wall is an important determinant of atherosclerosis in C57BL/6 and FVB/N mouse strains. Arterioscler Thromb Vasc Biol 2011; 31:1814-20.
Shim JY, Kim MH, Kim HD, Ahn JY, Yun YS, Song JY. Protective action of the immunomodulator ginsan against carbon tetrachloride-induced liver injury via control of oxidative stress and the inflammatory response. Toxicol Appl Pharmacol 2010; 242:318-25.
Shimada H, Eto M, Ohtaguro M et al. Differential mechanisms for the inhibition of human cytochrome P450 1A2 by apigenin and genistein. J Biochem Mol Toxicol 2010; 24:230-4.
Shimada N, Iwasaki M, Kasuga Y et al. Genetic polymorphisms in estrogen metabolism and breast cancer risk in case-control studies in Japanese, Japanese Brazilians and non-Japanese Brazilians. J Hum Genet 2009; 54:209-15.
Shimada T, Mimura M, Inoue K et al. Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans. Arch Toxicol 1997; 71:401-8.
Shimada T, Tanaka K, Takenaka S et al. Reverse type I binding spectra of human cytochrome P450 1B1 induced by flavonoid, stilbene, pyrene, naphthalene, phenanthrene, and biphenyl derivatives that inhibit catalytic activity: a structure-function relationship study. Chem Res Toxicol 2009; 22:1325-33.
Shimada T, Tsumura F, Yamazaki H, Guengerich FP, Inoue K. Characterization of (+/-)-bufuralol hydroxylation activities in liver microsomes of Japanese and Caucasian subjects genotyped for CYP2D6. Pharmacogenetics 2001; 11:143-56.
Shimada T, Tsumura F, Yamazaki H. Prediction of human liver microsomal oxidations of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes. Drug Metab Dispos 1999; 27:1274-80.
Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharm Exp Ther 1994; 270:414-23.
Shimakura J, Tani N, Mizuno Y, Komuro S, Kanamaru H. In vitro drug-drug interactions with perospirone and concomitantly administered drugs in human liver microsomes. Eur J Drug Metab Pharmacokinet 2003; 28:67-72.
Shimamoto J, Ieiri I, Urae A et al. Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9*3 allele. Eur J Clin Pharmacol 2000; 56:65-8.
Shimamoto K, Dewa Y, Ishii Y et al. Indole-3-carbinol enhances oxidative stress responses resulting in the induction of preneoplastic liver cell lesions in partially hepatectomized rats initiated with diethylnitrosamine. Toxicology 2011; 283:109-17.
Shimamoto K, Dewa Y, Kemmochi S et al. Relationship between CYP1A induction by indole-3-carbinol or flutamide and liver tumor-promoting potential in rats. Arch Toxicol 2011; 85:1159-66.
Shimazu S, Inui H, Ohkawa H. Phytomonitoring and phytoremediation of agrochemicals and related compounds based on recombinant cytochrome P450s and aryl hydrocarbon receptors (AhRs) J Agric Food Chem 2011; 59:2870-5.
Shimizu M, Uno T, Yasui-Furukori N, Sugawara K, Tateishi T. Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. Eur J Clin Pharmacol 2006; 62:597-603.
Shimizu T, Akimoto K, Yoshimura T et al. Autoinduction of MKC-963 [(R)-1-(1-cyclohexylethylamino)-4-phenylphthalazine] metabolism in healthy volunteers and its retrospective evaluation using primary human hepatocytes and cDNA-expressed enzymes. Drug Metab Dispos 2006; 34:950-4.
Shimizu W, Moss AJ, Wilde AA et al. Genotype-phenotype aspects of type 2 long QT syndrome. J Am Coll Cardiol 2009; 54:2052-62.
Shimizu Y, Mita S, Takeuchi T, Notsu T, Mizuguchi K, Kyo S. Dienogest, a synthetic progestin, inhibits prostaglandin E2 production and aromatase expression by human endometrial epithelial cells in a spheroid culture system. Steroids 2011; 76:60-7.
Shimizu Y, Nakatsuru Y, Ichinose M et al. Benzo[a]pyrene carcinogenicity is lost in mice lacking the aryl hydrocarbon receptor. Proc Nat Acad Sci USA 2000; 97:779-82.
Shimoda H, Tanaka J, Kikuchi M et al. Effect of polyphenol-rich extract from Walnut on diet-induced hypertriglyceridemia in mice via enhancement of fatty acid oxidation in the Liver. J Agric Food Chem 2009; 57:1786-1792.
Shimoda K, Morita S, Hirokane G, Yokono A, Someya T, Takahashi S. Metabolism of desipramine in Japanese psychiatric patients: the impact of CYP2D6 genotype on the hydroxylation of desipramine. Pharmacol Toxicol 2000; 86:245-9.
Shimoda K, Someya T, Yokono A et al. The impact of CYP2C19 and CYP2D6 genotypes on metabolism of amitriptyline in Japanese psychiatric patients. J Clin Psychopharmacol 2002; 22:371-8.
Shimohama S. Apoptosis in Alzheimer’s disease – an update. Apoptosis 2000; 5:9-16.
Shimomura K, de Nanclares GP, Foutinou C, Caimari M, Castaño L, Ashcroft FM. The first clinical case of a mutation at residue K185 of Kir6. 2 (KCNJ11): a major ATP-binding residue. Diabet Med 2010; 27:225-9.
Shimura H, Miura-Shimura Y, Kosik KS. Binding of tau to heat shock protein 27 leads to decreased concentration of hyperphosphorylated tau and enhanced cell survival. J Biol Chem 2004; 279:17957-62.
Shimura H, Schwartz D, Gygi SP, Kosik KS. CHIP-Hsc70 complex ubiquitination phosphorylated tau and enhaces cell survival. J Biol Chem 2004; 279:4869-76.
Shin A, Shrubsole MJ, Rice JM et al. Meat intake, heterocyclic amine exposure, and metabolizing enzyme polymorphisms in relation to colorectal polyp risk. Cancer Epidemiol Biomarkers Prev 2008; 17:320-9.
Shin DJ, Osborne TF. Peroxisome proliferator-activated receptor-gamma coactivator-1alpha activation of CYP7A1 during food restriction and diabetes is still inhibited by small heterodimer partner. J Biol Chem 2008; 283:15089-96.
Shin DJ, Osborne TF. FGF15/FGFR4 integrates growth factor signaling with hepatic bile acid metabolism and insulin action. J Biol Chem 2009; 284:11110-20.
Shin DJ, Plateroti M, Samarut J, Osborne TF. Two uniquely arranged thyroid hormone response elements in the far upstream 5’ flanking region confer direct thyroid hormone regulation to the murine cholesterol 7alpha hydroxylase gene. Nucleic Acids Res 2006; 34:3853-61.
Shin EK, Lee SH, Cho SH et al. Association between colony-stimulating factor 1 receptor gene polymorphisms and asthma risk. Hum Genet 2010; 128:293-302.
Shin HC, Kim HR, Cho HJ et al. Comparative gene expression of intestinal metabolizing enzymes. Biopharm Drug Dispos 2009; 30:411-21.
Shin HD, Park BL, Kim LH et al. Interleukin 10 haplotype associated with increased risk of hepatocellular carcinoma. Hum Mol Genet 2003; 12:901-6.
Shin HD, Park BL, Shin HJ et al. Association of KCNQ1 polymorphisms with the gestational diabetes mellitus in Korean women. J Clin Endocrinol Metab 2010; 95:445-9.
Shin HD, Winkler C, Stephens JC et al. Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc Natl Acad Sci USA 2000; 97:14467-72.
Shin HJ, Lee CH, Lee SS, Song IS, Shin JG. Identification of genetic polymorphisms of human OAT1 and OAT2 genes and their relationship to hOAT2 expression in human liver. Clin Chim Acta 2010; 411:99-105.
Shin HS, Slattery JT. CYP3A4-mediated oxidation of lisofylline to lisofylline 4,5-diol in human liver microsomes. J Pharm Sci 1998; 87:390-3.
Shin J, Johnson JA. Pharmacogenetics of beta-blockers. Pharmacotherapy 2007; 27:874-87.
Shin J, Johnson JA. Beta-blocker pharmacogenetics in heart failure. Heart Fail Rev 2010; 15:187-96.
Shin JG, Kane K, Flockhart DA. Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol. Br J Clin Pharmacol 2001; 51:45-52.
Shin JG, Park JY, Kim MJ et al. Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin. Drug Metab Dispos 2002; 30:1102-7.
Shin JG, Soukhova N, Flockhart DA. Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos 1999; 27:1078-84.
Shin KH, Chung YJ, Kim BH et al. Effect of ketoconazole on the pharmacokinetics of udenafil in healthy Korean subjects. Br J Clin Pharmacol 2010; 69:307-10.
Shin KH, Kim BH, Kim TE et al. The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: an open-label, one-sequence, three-period, three-treatment crossover study. Clin Ther 2009; 31:3009-20.
Shin SC, Choi JS, Li X. Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats. Int J Pharm 2006; 313:144-9.
Shinderman M, Maxwell S, Brawand-Amey M, Golay KP, Baumann P, Eap CB. Cytochrome P4503A4 metabolic activity, methadone blood concentrations, and methadone doses. Drug Alcohol Depend 2003; 69:205-11.
Shingaki T, Hidalgo IJ, Furubayashi T et al. Nasal delivery of P-gp substrates to the brain through nose-brain pathway. Drug Metab Pharmacokinet 2011; 26:248-55.
Shinkyo R, Guengerich FP. Cytochrome P450 7A1 cholesterol 7alpha-hydroxylation: individual reaction steps in the catalytic cycle and rate-limiting ferric iron reduction. J Biol Chem 2011; 286:4632-43.
Shintani M, Ieiri I, Inoue K et al. Genetic polymorphisms and functional characterization of the 5’-flanking region of the human CYP2C9 gene: in vitro and in vivo studies. Clin Pharmacol Ther 2001; 70:175-82.
Shiotani A, Nishi R, Yamanaka Y et al. Renin-angiotensin system associated with risk of upper GI mucosal injury induced by low dose aspirin: renin angiotensin system genes’ polymorphism. Dig Dis Sci 2011; 56:465-71.
Shiotani A, Sakakibara T, Nomura M et al. Aspirin-induced peptic ulcer and genetic polymorphisms. J Gastroenterol Hepatol 2010; 25 Suppl 1:31-4.
Shiraga T, Kaneko H, Iwasaki K, Tozuka Z, Suzuki A, Hata T. Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes. Xenobiotica 1999; 29:217-29.
Shiraga T, Tozuka Z, Ishimura R, Kawamura A, Kagayama A. Identification of cytochrome P450 enzymes involved in the metabolism of FK228, a potent histone deacetylase inhibitor, in human liver microsomes. Biol Pharm Bull 2005; 28:124-9.
Shirakawa T, Sakai K, Kitagawa Y, Hori A, Hirose G. A novel murine myotonia congenita without molecular defects in the ClC-1 and the SCN4A. Neurology 2002; 59:1091-4.
Shiran MR, Lennard MS, Iqbal MZ et al. Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment. Br J Clin Pharmacol 2009; 67:29-37.
Shirasaka Y, Kawasaki M, Sakane T et al. Induction of human P-glycoprotein in Caco-2 cells: development of a highly sensitive assay system for P-glycoprotein-mediated drug transport. Drug Metab Pharmacokinet 2006; 21:414-23.
Shirasaka Y, Suzuki K, Nakanishi T, Tamai I. Differential effect of grapefruit juice on intestinal absorption of statins due to inhibition of organic anion transporting polypeptide and/or P-glycoprotein. J Pharm Sci 2011; 100:3843-53.
Shirasaka Y, Suzuki K, Shichiri M, Nakanishi T, Tamai I. Intestinal absorption of HMG-CoA reductase inhibitor pitavastatin mediated by organic anion transporting polypeptide and P-glycoprotein/multidrug resistance 1. Drug Metab Pharmacokinet 2010; 26:171-9.
Shirolkar SC, Fiuzat M, Becker RC. Dronedarone and vitamin K antagonists: a review of drug-drug interactions. Am Heart J 2010; 160:577-82.
Shirouchi B, Nagao K, Furuya K et al. Effect of dietary phosphatidylinositol on cholesterol metabolism in Zucker (fa/fa) rats. J Oleo Sci 2009; 58:111-5.
Shitara K, Matsuo K, Ito S et al. Effects of genetic polymorphisms in the ABCB1 gene on clinical outcomes in patients with gastric cancer treated by second-line chemotherapy. Asian Pac J Cancer Prev 2010; 11:447-52.
Shitara K, Muro K, Ito S et al. Folate intake along with genetic polymorphisms in methylenetetrahydrofolate reductase and thymidylate synthase in patients with advanced gastric cancer. Cancer Epidemiol Biomarkers Prev 2010; 19:1311-9.
Shitara Y, Hirano M, Sato H, Sugiyama Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 2004; 311:228-36.
Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006; 112:71-105.
Shivanna B, Jiang W, Wang L, Couroucli X, Moorthy B. Omeprazole attenuates hyperoxic lung injury in mice via aryl hydrocarbon receptor activation, and is associated with increased expression of cytochrome P4501A enzymes. J Pharmacol Exp Ther 2011; 339:106-14.
Shivaswamy V, Ochsner L, Maroni D et al. Tacrolimus and sirolimus induce reproductive abnormalities in female rats. Transplantation 2011; 91:1333-9.
Shiwaku K, Nogi A, Anuurad E et al. Difficulty in losing weight by behavioral intervention for women with Trp64Arg polymorphism of the beta3-adrenergic receptor gene. Int J Obes Relat Metab Disord 2003; 27:1028-36.
Shoaf SE, Elizari MV, Wang Z et al. Tolvaptan administration does not affect steady state amiodarone concentrations in patients with cardiac arrhythmias. J Cardiovasc Pharmacol Ther 2005; 10:165-71.
Shoaf SE, Ohzone Y, Ninomiya SI et al. In vitro P-glycoprotein interactions and steady-state pharmacokinetic interactions between tolvaptan and digoxin in healthy subjects. J Clin Pharmacol 2011; 51:761-9.
Shobha JC, Muppidi MR. Interaction between voriconazole and glimepiride. J Postgrad Med 2010; 56:44-5.
Shoffner JM, Brown MD, Torroni A et al. Mitochondrial DNA variants observed in Alzheimer disease and Parkinson disease patients. Genomics 1993; 17:171-84.
Shoffner JM, Fernhoff PM, Krawiecki NS et al. Subacute necrotizing encephalopathy: oxidative phosphorylation defects and the ATPase 6 point mutation. Neurology 1992; 42:2168-74.
Shoffner JM, Lott MT, Lezza AM, Seibel P, Ballinger SW, Wallace DC. Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a mitochondrial DNA tRNA(Lys) mutation. Cell 1990; 61:931-7.
Shoji Y, Takahashi M, Kitamura T et al. Downregulation of prostaglandin E receptor subtype EP3 during colon cancer development. Gut 2004; 53:1151-8.
Shon JH, Yoon YR, Kim KA et al. Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans. Pharmacogenetics 2002; 12:111-9.
Shon JH, Yoon YR, Kim MJ et al. Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. Br J Clin Pharmacol 2005; 59:552-63.
Shon SM, Park JH, Nahrendorf M et al. Exercise attenuates matrix metalloproteinase activity in preexisting atherosclerotic plaque. Atherosclerosis 2011; 216:67-73.
Shord SS, Cavallari LH, Gao W et al. The pharmacokinetics of codeine and its metabolites in Blacks with sickle cell disease. Eur J Clin Pharmacol 2009; 65:651-8.
Shou M, Dai R, Cui D, Korzekwa KR, Baillie TA, Rushmore TH. A kinetic model for the metabolic interaction of two substrates at the active site of cytochrome P450 3A4. J Biol Chem 2001; 276:2256-62.
Shou M, Grogan J, Mancewicz JA et al. Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 1994; 33:6450-5.
Shou M, Hayashi M, Pan Y et al. Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction. Drug Metab Dispos 2008; 36:2355-70.
Shou M, Lin Y, Lu P et al. Enzyme kinetics of cytochrome P450-mediated reactions. Curr Drug Metab 2001; 2:17-36.
Shou M, Lu T, Krausz KW et al. Use of inhibitory monoclonal antibodies to assess the contribution of cytochromes P450 to human drug metabolism. Eur J Pharmacol 2000; 394:199-209.
Shou M, Mei Q, Ettore MW Jr, Dai R, Baillie TA, Rushmore TH. Sigmoidal kinetic model for two co-operative substrate-binding sites in a cytochrome P450 3A4 active site: an example of the metabolism of diazepam and its derivatives. Biochem J 1999; 340:845-53.
Shrestha K, Hughes JD, Lee YP, Parsons R. The prevalence of co-administration of clopidogrel and proton pump inhibitors. Qual Prim Care 2011; 19:35-42.
Shrestha UK, Karimi O, Crusius JB et al. Distribution of peroxisome proliferator-activated receptor-gamma polymorphisms in Chinese and Dutch patients with inflammatory bowel disease. Inflamm Bowel Dis 2010; 16:312-9.
Shridas P, Bailey WM, Gizard F et al. Group X secretory phospholipase A2 negatively regulates ABCA1 and ABCG1 expression and cholesterol efflux in macrophages. Arterioscler Thromb Vasc Biol 2010; 30:2014-21.
Shrif NE, Won HH, Lee ST et al. Evaluation of the effects of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patients. Eur J Clin Pharmacol 2011; 67:1119-30.
Shrikhande GV, Scali ST, da Silva CG et al. O-glycosylation regulates ubiquitination and degradation of the anti-inflammatory protein A20 to accelerate atherosclerosis in diabetic ApoE-null mice. PLoS One 2010. doi:10. 1371/journal. pone. 0014240.
Shu Y, Cheng ZN, Liu ZQ et al. Interindividual variations in levels and activities of cytochrome P-450 in liver microsomes of Chinese subjects. Acta Pharmacol Sin 2001; 22:283-8.
Shu Y, Leabman MK, Feng B et al. PharmGKB update: III. Genetic variants of SLC22A1, solute carrier family 22 (organic cation transporter), member 1. Pharmacol Rev 2004; 56:161.
Shu Y, Wang LS, Xiao WM, Wang W, Huang SL, Zhou HH. Probing CYP2C19 and CYP3A4 activities in Chinese liver microsomes by quantification of 5-hydroxyomeprazole and omeprazole sulphone. Acta Pharmacol Sin 2000; 21:753-8.
Shu Y, Wang LS, Xu ZH et al. 5-Hydroxylation of omeprazole by human liver microsomal fractions from Chinese populations related to CYP2C19 gene dose and individual ethnicity. J Pharmacol Exp Ther 2000; 295:844-51.
Shukla A, Hillegass JM, MacPherson MB et al. Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin. Mol Cancer 2010; 9:314.
Shukla S, Robey RW, Bates SE, Ambudkar SV. The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2. Biochemistry 2006; 45:8940-51.
Shukla S, Robey RW, Bates SE, Ambudkar SV. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos 2009; 37:359-65.
Shulman K, Cohen I, Barnett-Griness O et al. Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients. Cancer 2011; 117:3156-62.
Shulman RW, Ozdemir V. Psychotropic medications and cytochrome P450 2D6: pharmacokinetic considerations in the elderly. Can J Psychiatry 1997; 42 Suppl 1:4-9.
Shumaker SA, Legault C, Rapp SR et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA 2003; 289:2651-62.
Shurin SB, Nabel EG. Pharmacogenetics-ready for prime time? New Eng J Med 2007; 358:1061-3.
Shvartsman I, Dvir T, Harel-Adar T, Cohen S. Perfusion cell seeding and cultivation induce the assembly of thick and functional hepatocellular tissue-like construct. Tissue Eng Part A 2009; 15:751-60.
Si D, Guo Y, Zhang Y, Yang L, Zhou H, Zhong D. Identification of a novel variant CYP2C9 allele in Chinese. Pharmacogenetics 2004; 14:465-9.
Si K, Lindquist S, Kandel ER. A neuronal isoform of the aplysia CPEB has prion-like properties. Cell 2003; 115:879-91.
Sia AT, Sng BL, Lim EC, Law H, Tan EC. The influence of ATP-binding cassette sub-family B member -1 (ABCB1) genetic polymorphisms on acute and chronic pain after intrathecal morphine for caesarean section: a prospective cohort study. Int J Obstet Anesth 2010; 19:254-60.
Siam A, Brancale A, Simons C. Comparative modeling of 25-hydroxycholesterol-7α-hydroxylase (CYP7B1): ligand binding and analysis of hereditary spastic paraplegia type 5 CYP7B1 mutations. J Mol Model 2011. doi:10. 1007/s00894-011-1084-6.
Siani A, Russo P, Paolo Cappuccio F et al. Combination of renin-angiotensin system polymorphisms is associated with altered renal sodium handling and hypertension. Hypertension 2004; 43:598-602.
Sibbald M, Yan AT, Huang W et al. Association between smoking, outcomes, and early clopidogrel use in patients with acute coronary syndrome: insights from the Global Registry of Acute Coronary Events. Am Heart J 2010; 160:855-61.
Sibbing D, Koch W, Gebhard D et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 2010; 121:512-8.
Sibbing D, Koch W, Massberg S et al. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Eur Heart J 2011; 32:1605-13.
Sibbing D, von Beckerath O, Schömig A, Kastrati A, von Beckerath N. P2Y1 gene A1622G dimorphism is not associated with adenosine diphosphate-induced platelet activation and aggregation after administration of a single high dose of clopidogrel. J Thromb Haemost 2006; 4:912-4.
Sica DA. Interaction of grapefruit juice and calcium channel blockers. Am J Hypertens 2006; 19:768-73.
Sica DA, Gehr TW, Ghosh S. Clinical pharmacokinetics of losartan. Clin Pharmacokinet 2005; 44:797-814.
Sicouri S, Antzelevitch C. Sudden cardiac death secondary to antidepressant and antipsychotic drugs. Expert Opin Drug Saf 2008; 7:181-94.
Siddiqui A, Kerb R, Weale ME et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. New Eng J Med 2003; 348:1442-8.
Sidjanin DJ, McCarty CA, Patchett R, Smith E, Wilke RA. Pharmacogenetics of ophthalmic topical beta-blockers. Per Med 2008; 5:377-85.
Siedlinski M, Cho MH, Bakke P et al. Genome-wide association study of smoking behaviours in patients with COPD. Thorax 2011; 66:894-902.
Siegel-Lakhai WS, Zandvliet AS, Huitema AD et al. A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours. Br J Cancer 2008; 98:1320-6.
Siegerink B, Rosendaal FR, Algra A. Genetic variation in fibrinogen; its relationship to fibrinogen levels and the risk of myocardial infarction and ischemic stroke. J Thromb Haemost 2009; 7:385-90.
Siegle I, Fritz P, Eckhardt K, Zanger UM, Eichelbaum M. Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogenetics 2001; 11:237-45.
Siest G, Ferrari L, Accaoui MJ, Batt AM, Visvikis S. Pharmacogenomics of drugs affecting the cardiovascular system. Clin Chem Lab Med 2003; 41:590-9.
Siest G, Jeannesson E, Marteau JB et al. Transcription factor and drug-metabolizing enzyme gene expression in lymphocytes from healthy human subjects. Drug Metab Dispos 2008; 36:182-9.
Siest G, Jeannesson E, Visvikis-Siest S. Enzymes and pharmacogenetics of cardiovascular drugs. Clin Chim Acta 2007; 381:26-31.
Siest G, Pillot T, Regis-Bailly A et al. Apolipoprotein E: An important gene and protein to follow in laboratory medicine. Clinical Chemistry 1995; 41:1060-86.
Siezen CL, Tijhuis MJ, Kram NR et al. Protective effect of nonsteroidal anti-inflammatory drugs on colorectal adenomas is modified by a polymorphism in peroxisome proliferator-activated receptor delta. Pharmacogenet Genomics 2006; 16:43-50.
Siffert W, Rosskopf D, Siffert G et al. Association of a human G-protein beta3 subunit variant with hypertension. Nat Genet 1998; 18:45-8.
Siffert W. G protein polymorphisms in hypertension, atherosclerosis, and diabetes. Annu Rev Med 2005; 56:17-28.
Sigmond J, Bergman AM, Leon LG, Loves WJ, Hoebe EK, Peters GJ. Staurosporine increases toxicity of gemcitabine in non-small cell lung cancer cells: role of protein kinase C, deoxycytidine kinase and ribonucleotide reductase. Anticancer Drugs 2010; 21:591-9.
Sigmund JC, Vogler C, Huynh KD, de Quervain DJ, Papassotiropoulos A. Fine-mapping at the HTR2A locus reveals multiple episodic memory-related variants. Biol Psychol 2008; 79:239-42.
Signorelli SS, Barresi V, Musso N et al. Polymorphisms of steroid 5-alpha-reductase type I (SRD5A1) gene are associated to peripheral arterial disease. J Endocrinol Invest 2008; 31:1092-7.
Sigurdson AJ, Bhatti P, Chang SC et al. Polymorphisms in estrogen biosynthesis and metabolism-related genes, ionizing radiation exposure, and risk of breast cancer among US radiologic technologists. Breast Cancer Res Treat 2009; 118:177-84.
Sikander A, Rana SV, Sharma SK et al. Association of alpha 2A adrenergic receptor gene (ADRAlpha2A) polymorphism with irritable bowel syndrome, microscopic and ulcerative colitis. Clin Chim Acta 2010; 411:59-63.
Silberberg G, Darvasi A, Pinkas-Kramarski R, Navon R. The involvement of ErbB4 with schizophrenia: association and expression studies. Am J Med Genet B Neuropsychiatr Genet 2006; 141:142-8.
Silberberg G, Levit A, Collier D et al. Stargazin involvement with bipolar disorder and response to lithium treatment. Pharmacogenet Genomics 2008; 18:403-12.
Silberstein SD, McCrory DC. Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache 2003; 43:144-66.
Siller M, Anzenbacher P, Anzenbacherov E, Dole Al K, Strnad M. In vitro interaction of a novel neutrophil growth factor with human liver microsomal cytochromes P450 and the contribution of UDP-glucuronosyltransferases to its metabolism. Xenobiotica 2011; 41:934-44.
Silva AK, Yi H, Hayes SH, Seigel GM, Hackam AS. Lithium chloride regulates the proliferation of stem-like cells in retinoblastoma cell lines: a potential role for the canonical Wnt signaling pathway. Mol Vis 2010; 16:36-45.
Silva Mdo C, Gaspar J, Duarte Silva I, Faber A, Rueff J. GSTM1, GSTT1, and GSTP1 genotypes and the genotoxicity of hydroquinone in human lymphocytes. Environ Mol Mutagen 2004; 43:258-64.
Silva Neto B, Koff WJ, Biolchi V et al. Polymorphic CAG and GGC repeat lengths in the androgen receptor gene and prostate cancer risk: analysis of a Brazilian population. Cancer Invest 2008; 26:74-80.
Silverberg GD, Messier AA, Miller MC et al. Amyloid efflux transporter expression at the blood-brain barrier declines in normal aging. J Neuropathol Exp Neurol 2010; 69:1034-43.
Silverman GL, Quin K, Moore RC et al. Doppel is an N-glycosylated, glycosylphosphatidylinositol-anchored protein: expression in testis and ectopic production in the brain of Prnp(0/0) mice predisposed to Purkinje cell loss. J Biol Chem 2000; 275:26834-41.
Silvestri G, Santorelli FM, Shanske S et al. A new mtDNA mutation in the tRNA(Leu(UUR)) gene associated with maternally inherited cardiomyopathy. Hum Mutat 1994; 3:37-43.
Silvestri L, Sonzogni L, de Silvestri A et al. CYP enzyme polymorphisms and susceptibility to HCV-related chronic liver disease and liver cancer. Int J Cancer 2003; 104:310-7.
Siller M, Anzenbacher P, Anzenbacherova E, Dolezal K, Popa I, Strnad M. Interactions of olomoucine II with human liver microsomal cytochromes P450. Drug Metab Dispos 2009; 37:1198-202.
Siller M, Anzenbacher P, Anzenbacherová E, Doležal K, Strnad M. In vitro interaction of a novel neutrophil growth factor with human liver microsomal cytochromes P450 and the contribution of UDP-glucuronosyltransferases to its metabolism. Xenobiotica 2011; 41:934-44
Siller-Matula JM, Lang I, Christ G, Jilma B. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 2008; 52:1557-63.
Sills G, Brodie M. Pharmacokinetics and drug interactions with zonisamide. Epilepsia 2007; 48:435-41.
Sim HM, Loh KY, Yeo WK, Lee CY, Go ML. Aurones as modulators of ABCG2 and ABCB1: synthesis and structure-activity relationships. ChemMedChem 2011; 6:713-24.
Sim SC, Edwards RJ, Boobis AR, Ingelman-Sundberg M. CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele. Pharmacogenet Genomics 2005; 15:625-31.
Sim SC, Nordin L, Andersson TM et al. Association between CYP2C19 polymorphism and depressive symptoms. Am J Med Genet B Neuropsychiatr Genet 2010; 153:1160-6.
Sim SC, Risinger C, Dahl ML et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006; 79:103-13.
Simard C, Michaud V, Gibbs B, Massé R, Lessard E, Turgeon J. Identification of the cytochrome P450 enzymes involved in the metabolism of domperidone. Xenobiotica 2004; 34:1013-23.
Simard C, O’Hara GE, Prévost J, Guilbaud R, Masseé R, Turgeon J. Study of the drug-drug interaction between simvastatin and cisapride in man. Eur J Clin Pharmacol 2001; 57:229-34.
Simard JM, Woo SK, Norenberg MD et al. Brief suppression of Abcc8 prevents autodestruction of spinal cord after trauma. Sci Transl Med 2010; 2:28ra29.
Simarro Doorten AY, Bull S, van der Doelen MA, Fink-Gremmels J. Metabolism-mediated cytotoxicity of ochratoxin A. Toxicol In Vitro 2004; 18:271-7.
Simarro Doorten Y, Nijmeijer S, de Nijs-Tjon L, Fink-Gremmels J. Metabolism-mediated Ochratoxin A genotoxicity in the single-cell gel electrophoresis (Comet) assay. Food Chem Toxicol 2006; 44:261-70.
Simeonova PP, Luster MI. Arsenic and atherosclerosis. Toxicol Appl Pharmacol 2004; 198:444-9.
Simha V, Garg A. Phenotypic heterogeneity in body fat distribution in patients with congenital generalized lipodystrophy caused by mutations in the AGPAT2 or seipin genes. J Clin Endocrinol Metab 2003; 88:5433-7.
Simmons CR, Zou F, Younkin SG, Estus S. Rheumatoid arthritis-associated polymorphisms are not protective against Alzheimer’s disease. Mol Neurodegener 2011; 6:33.
Simon C, Stieger B, Kullak-Ublick GA et al. Intestinal expression of cytochrome P450 enzymes and ABC transporters and carbamazepine and phenytoin disposition. Acta Neurol Scand 2007; 115:232-42.
Simon HU, Malhotra B. The pharmacokinetic profile of fesoterodine: similarities and differences to tolterodine. Swiss Med Wkly 2009; 139:146-51.
Simon JA, Lin F, Hulley SB et al. Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study. Am J Cardiol 2006; 97:843-50.
Simon KC, Munger KL, Yang X, Ascherio A. Polymorphisms in vitamin D metabolism related genes and risk of multiple sclerosis. Mult Scler 2010; 16:133-8.
Simon M, Franke D, Ludwig M et al. Association of a polymorphism of the ACVRL1 gene with sporadic arteriovenous malformations of the central nervous system. J Neurosurg 2006; 104:945-9.
Simon T, Becquemont L, Mary-Krause M et al. Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity. Clin Pharmacol Ther 2000; 67:432-7.
Simon T, Bhatt DL, Bergougnan L et al. Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects. Clin Pharmacol Ther 2011; 90:287-95.
Simon T, Steg PG, Gilard M et al. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry. Circulation 2011; 123:474-82.
Simon T, Verstuyft C, Mary-Krause M et al Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360:363-75.
Simons FE, Silver NA, Gu X, Simons KJ. Skin concentrations of H1-receptor antagonists. J Allergy Clin Immunol 2001; 107:526-30.
Simón-Sánchez J, Schulte C, Bras JM et al. Genome-wide association study reveals genetic risk underlying Parkinson’s disease. Nat Genet 2009; 41:1308-12.
Simonsen U. Interactions between drugs for erectile dysfunction and drugs for cardiovascular disease. Int J Impot Res 2002; 14:178-88.
Simonson SG, Martin PD, Warwick MJ, Mitchell PD, Schneck DW. The effect of rosuvastatin on oestrogen & progestin pharmacokinetics in healthy women taking an oral contraceptive. Br J Clin Pharmacol 2004; 57:279-86.
Simpkins JW, Swenberg JS, Weiss N et al. Atrazine and breast cancer: A framework assessment of the toxicological and epidemiological evidence. Toxicol Sci 2011; 123:441-59.
Simpson JE, Ince PG, Shaw PJ et al. Microarray analysis of the astrocyte transcriptome in the aging brain: relationship to Alzheimer’s pathology and APOE genotype. Neurobiol Aging 2011; 32:1795-807.
Simpson S, Johnston A. The prevalence and patterns of care if Huntington’s chorea in Grampian. Brit J Psychiat 1989; 155:799-804.
Sims EJ, Jackson CM, Lipworth BJ. Add-on therapy with montelukast or formoterol in patients with the glycine-16 beta2-receptor genotype. Br J Clin Pharmacol 2003; 56:104-11.
Sims EJ, Lipworth BJ. Concomitant occasional use of salbutamol influences bronchoprotective responsiveness afforded by formoterol in patients with the glycine-16 genotype. Eur J Clin Pharmacol 2004; 59:791-5.
Simsek M, Cetin Z, Bilgen T, Taskin O, Luleci G, Keser I. Effects of hormone replacement therapy on bone mineral density in Turkish patients with or without COL1A1 Sp1 binding site polymorphism. J Obstet Gynaecol Res 2008; 34:73-7.
Sinclair JF, Szakacs JG, Wood SG et al. Short-term treatment with alcohols causes hepatic steatosis and enhances acetaminophen hepatotoxicity in Cyp2e1(-/-) mice. Toxicol Appl Pharmacol 2000; 168:114-22.
Sinclair PR, Gorman N, Tsyrlov IB, Fuhr U, Walton HS, Sinclair JF. Uroporphyrinogen oxidation catalyzed by human cytochromes P450. Drug Metab Dispos 1998; 26:1019-25.
Sindrup SH, Brøsen K, Gram LF et al. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992; 51:278-87.
Sindrup SH, Brøsen K. The pharmacogenetics of codeine hypoalgesia. Pharmacogenetics 1995; 5:335-46.
Sindrup SH, Poulsen L, Brøsen K, Arendt-Nielsen L, Gram LF. Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers? Pain 1993; 53:335-9.
Singaraja R, Hadano S, Metzler M et al. HIP14, a novel ankyrin domain-containing protein, links huntingtin to intracellular trafficking and endocytosis. Hum Molec Genet 2002; 11:2815-28.
Singaraja RR, Bocher V, James ER et al. Human ABCA1 BAC transgenic mice show increased high density lipoprotein cholesterol and ApoAI-dependent efflux stimulated by an internal promoter containing liver X receptor response elements in intron 1. J Biol Chem 2001; 276:33969-79.
Singer JB, Holdaas H, Jardine AG et al. Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients. J Lipid Res 2007; 48:2072-8.
Singer JB, Shou Y, Giles F et al. UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia. Leukemia 2007; 21:2311-5.
Singh B, Banerjee S, Bera NK, Nayak CR, Chaudhuri TK. Analysis of the role of human leukocyte antigen class-I genes to understand the etiopathology of schizophrenia. Indian J Psychiatry 2008; 50:166-70.
Singh BN. Effects of food on clinical pharmacokinetics. Clin Pharmacokinet 1999; 37:213-55.
Singh H, Sachan R, Jain M, Mittal B. CCR5-Delta32 polymorphism and susceptibility to cervical cancer: association with early stage of cervical cancer. Oncol Res 2008; 17:87-91.
Singh K, Chaturvedi R, Barry DP et al. The apolipoprotein E-mimetic peptide COG112 inhibits NF-kappaB signaling, proinflammatory cytokine expression, and disease activity in murine models of colitis. J Biol Chem 2011; 286:3839-50.
Singh K, Singh SK, Raman R. MTHFR A1298C polymorphism and idiopathic male infertility. J Postgrad Med 2010; 56:267-9.
Singh KK, Hughes MD, Chen J et al. Associations of chemokine receptor polymorphisms With HIV-1 mother-to-child transmission in sub-Saharan Africa: possible modulation of genetic effects by antiretrovirals. J Acquir Immune Defic Syndr 2008; 49:259-65.
Singh M, Khan AJ, Shah PP, Shukla R, Khanna VK, Parmar D. Polymorphism in environment responsive genes and association with Parkinson disease. Mol Cell Biochem 2008; 312:131-8.
Singh M, Khanna VK, Shukla R, Parmar D. Association of polymorphism in cytochrome P450 2D6 and N-acetyltransferase-2 with Parkinson’s disease. Dis Markers 2010; 28:87-93.
Singh M, Thapa B, Arora R. Clopidogrel pharmacogenetics and its clinical implications. Am J Ther 2010; 17:66-73.
Singh MN, Stringfellow HF, Walsh MJ et al. Quantifiable mRNA transcripts for tamoxifen-metabolising enzymes in human endometrium. Toxicology 2008; 249:85-90.
Singh MS, Francis PA, Michael M. Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes. Breast 2011; 20:111-8.
Singh NA, Pappas C, Dahle EJ et al. A role of SCN9A in human epilepsies, as a cause of febrile seizures and as a potential modifier of Dravet syndrome. PLoS Genet 2009. doi:10. 1371/journal. pgen. 1000649.
Singh O, Sandanaraj E, Subramanian K, Lee LH, Chowbay B. Influence of CYP4F2 rs2108622 (V433M) on warfarin dose requirement in Asian patients. Drug Metab Pharmacokinet 2011; 26:130-6.
Singh P, Kaur J, Bhardwaj A. Synthesis of highly functionalized barbituric acids and study of their interactions with p-glycoprotein and Mg2+-potential candidates for multi drug resistance modulation. Eur J Med Chem 2010; 45:1256-62.
Singh PB, Ragavan N, Ashton KM et al. Quantified gene expression levels for phase I/II metabolizing enzyme and estrogen receptor levels in benign prostate from cohorts designated as high-risk (UK) versus low-risk (India) for adenocarcinoma at this organ site: a preliminary study. Asian J Androl 2010; 12:203-14.
Singh R, Deepa SR, Madhavi S et al. Male infertility: no evidence of involvement of androgen receptor gene among Indian men. J Androl 2006; 27:102-5.
Singh R, Kaul R, Kaul A, Khan K. A comparative review of HLA associations with hepatitis B and C viral infections across global populations. World J Gastroenterol 2007; 13:1770-87.
Singh R, Srivastava A, Kapoor R, K Sharma R, D Mittal R. Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India. Naunyn Schmiedebergs Arch Pharmacol 2009; 380:169-77.
Singh R, Srivastava A, Kapoor R, Mittal RD. Do drug transporter (ABCB1) SNPs influence cyclosporine and tacrolimus dose requirements and renal allograft outcome in the posttransplantation period? J Clin Pharmacol 2011; 51:603-15.
Singh R, Wang Y, Schattenberg JM, Xiang Y, Czaja MJ. Chronic oxidative stress sensitizes hepatocytes to death from 4-hydroxynonenal by JNK/c-Jun overactivation. Am J Physiol Gastrointest Liver Physiol 2009; 297:907-17.
Singh S, Kumar V, Vashisht K et al. Role of genetic polymorphisms of CYP1A1, CYP3A5, CYP2C9, CYP2D6 and PON1 in the modulation of DNA damage in workers occupationally exposed to organophosphate pesticides. Toxicol Appl Pharmacol 2011. doi:10. 1016/j. taap. 2011. 08. 021.
Singh S, Sherkhane PD, Kale SP, Eapen S. Expression of a human cytochrome P4502E1 in Nicotiana tabacum enhances tolerance and remediation of γ-hexachlorocyclohexane. N Biotechnol 2011; 28:423-9.
Singh S, Singh K, Gupta SP et al. Effect of caffeine on the expression of cytochrome P450 1A2, adenosine A2A receptor and dopamine transporter in control and 1-methyl 4-phenyl 1, 2, 3, 6-tetrahydropyridine treated mouse striatum. Brain Res 2009; 1283:115-26.
Singh S, Thakur MK. Gonadal steroids do not affect apolipoprotein E expression in aging mouse cerebral cortex. Cell Mol Neurobiol 2011; 31:401-5.
Singh SB, Shen LQ, Walker MJ, Sheridan RP. A model for predicting likely sites of CYP3A4-mediated metabolism on drug-like molecules. J Med Chem 2003; 46:1330-6.
Singh V, Parmar D, Singh MP. Do single nucleotide polymorphisms in xenobiotic metabolizing genes determine breast cancer susceptibility and treatment outcomes? Cancer Invest 2008; 26:769-83.
Singh V, Upadhyay G, Rastogi N, Singh K, Singh MP. Polymorphism of xenobiotic-metabolizing genes and breast cancer susceptibility in North Indian women. Genet Test Mol Biomarkers 2011; 15:343-9.
Singh YN. Potential for interaction of kava and St. John’s wort with drugs. J Ethnopharmacol 2005; 100:108-13.
Singh YP, Singh RA. Insilico studies of organosulfur-functional active compounds in garlic. Biofactors 2010; 36:297-311.
Singhal NK, Srivastava G, Patel DK, Jain SK, Singh MP. Melatonin or silymarin reduces maneb- and paraquat-induced Parkinson’s disease phenotype in the mouse. J Pineal Res 2011; 50:97-109.
Sinha S, Prasad KN, Jain D, Nyati KK, Pradhan S, Agrawal S. Immunoglobulin IgG Fc-receptor polymorphisms and HLA class II molecules in Guillain-Barré syndrome. Acta Neurol Scand 2010; 122:21-6.
Sinha-Hikim I, Sinha-Hikim AP, Shen R et al. A novel cystine based antioxidant attenuates oxidative stress and hepatic steatosis in diet-induced obese mice. Exp Mol Pathol 2011; 91:419-28.
Sinici I, Güven EO, Serefoğlu E, Hayran M. T-786C polymorphism in promoter of eNOS gene as genetic risk factor in patients with erectile dysfunction in Turkish population. Urology 2010; 75:955-60.
Sinici I, Kalyoncu U, Karahan S, Kiraz S, Atalar E. Endothelial nitric oxide gene polymorphism and risk of systemic sclerosis: predisposition effect of T-786C promoter and protective effect of 27 bp repeats in Intron 4. Clin Exp Rheumatol 2010; 28:169-75.
Sinilnikova OM, Ginolhac SM, Magnard C et al. Acetyl-CoA carboxylase alpha gene and breast cancer susceptibility. Carcinogenesis 2004; 25:2417-24.
Sinilnikova OM, McKay JD, Tavtigian SV et al. Haplotype-based analysis of common variation in the acetyl-coA carboxylase alpha gene and breast cancer risk: a case-control study nested within the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev 2007; 16:409-15.
Sinner MF, Pfeufer A, Akyol M et al. The non-synonymous coding IKr-channel variant KCNH2-K897T is associated with atrial fibrillation: results from a systematic candidate gene-based analysis of KCNH2 (HERG). Eur Heart J 2008; 29:907-14.
Sinués B, Vicente J, Fanlo A et al. CYP3A5*3 and CYP3A4*1B allele distribution and genotype combinations: differences between Spaniards and Central Americans. Ther Drug Monit 2007; 29:412-6.
Sinués B, Vicente J, Fanlo A et al. CYP3A5 3, CYP3A4 1B and MDR1 C3435T genotype distributions in Ecuadorians. Dis Markers 2008; 24:325-31.
Sinz M, Kim S, Zhu Z et al. Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions. Curr Drug Metab 2006; 7:375-88.
Sipeky C, Csongei V, Jaromi L et al. Genetic variability and haplotype profile of MDR1 (ABCB1) gene in Roma and Hungarian population samples with a review of the literature. Drug Metab Pharmacokinet 2010; 26:206-15.
Siqueira DR, Romitti M, da Rocha AP et al. The RET polymorphic allele S836S is associated with early metastatic disease in patients with hereditary or sporadic medullary thyroid carcinoma. Endocr Relat Cancer 2010; 17:953-63.
Sirulnik LA, Stone RM. Acute promyelocytic leukemia: current strategies for the treatment of newly diagnosed disease. Clin Adv Hematol Oncol 2005; 3:391-7, 429.
Sissung TM, Danesi R, Kirkland CT et al. Estrogen receptor α and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy. J Clin Endocrinol Metab 2011; 96:368-72.
Sissung TM, Gardner ER, Piekarz RL et al. Impact of ABCB1 allelic variants on QTc interval prolongation. Clin Cancer Res 2011; 17:937-46.
Sissung TM, Mross K, Steinberg SM et al. Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur J Cancer 2006; 42:2893-6.
Sissung TM, Price DK, Sparreboom A, Figg WD. Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention. Mol Cancer Res 2006; 4:135-50.
Sistonen J, Fuselli S, Palo JU, Chauhan N, Padh H, Sajantila A. Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. Pharmacogenet Genomics 2009; 19:170-9.
Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics 2007; 17:93-101.
Sittler A, Lurz R, Lueder G et al. Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington’s disease. Hum Mol Genet 2001; 10:1307-15.
Sivakumar PM, Prabhu Seenivasan S, Kumar V, Doble M. Novel 1,3,5-triphenyl-2-pyrazolines as anti-infective agents. Bioorg Med Chem Lett 2010; 20:3169-72.
Sivapackiam J, Harpstrite SE, Prior JL, Gu H, Rath NP, Sharma V. Synthesis, molecular structure, and validation of metalloprobes for assessment of MDR1 P-glycoprotein-mediated functional transport. Dalton Trans 2010; 39:5842-50.
Sivertsson L, Ek M, Darnell M, Edebert I, Ingelman-Sundberg M, Neve EP. CYP3A4 catalytic activity is induced in confluent Huh7 hepatoma cells. Drug Metab Dispos 2010; 66:555-61.
Sivils JC, Gonzalez I, Bain LJ. Mice lacking Mrp1 have reduced testicular steroid hormone levels and alterations in steroid biosynthetic enzymes. Gen Comp Endocrinol 2010; 167:51-9.
Sivonová M, Waczulíková I, Dobrota D et al. Polymorphisms of glutathione-S-transferase M1, T1, P1 and the risk of prostate cancer: a case-control study. J Exp Clin Cancer Res 2009; 28:32.
Sjöblom T, Jones S, Wood LD et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314:268-74.
Sjogren M, Englund E. Negative neurofilament light and tau immunostainig in frontotemporal dementia. Dement Geriart Cogn Disord 2004; 17:346-9.
Sjögren M, Hesse C, Basun H et al. Tacrine and rate of progression in Alzheimer’s disease –relation to ApoE allele genotype. J Neural Transm 2001; 108:451-8.
Skaanild MT, Friis C. Cytochrome P450 sex differences in minipigs and conventional pigs. Pharmacol Toxicol 1999; 85:174-80.
Skaanild MT, Friis C. Characterization of the P450 system in Göttingen minipigs. Pharmacol Toxicol 1997; 80 Suppl 2:28-33.
Skarke C, Reus M, Schmidt R et al. The cyclooxygenase 2 genetic variant -765G>C does not modulate the effects of celecoxib on prostaglandin E2 production. Clin Pharmacol Ther 2006; 80:621-32.
Skarke C, Schuss P, Kirchhof A, Doehring A, Geisslinger G, Lötsch J. Pyrosequencing of polymorphisms in the COX-2 gene (PTGS2) with reported clinical relevance. Pharmacogenomics 2007; 8:1643-60.
Skazik C, Wenzel J, Marquardt Y et al. P-glycoprotein (ABCB1) expression in human skin is mainly restricted to dermal components. Exp Dermatol 2011; 20:450-2.
Skerjanec A, Wang J, Maren K, Rojkjaer L. Investigation of the pharmacokinetic interactions of deferasirox, a once-daily oral iron chelator, with midazolam, rifampin, and repaglinide in healthy volunteers. J Clin Pharmacol 2010; 50:205-13.
Skibola CF, Bracci PM, Nieters A et al. Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium. Am J Epidemiol 2010; 171:267-76.
Skibola CF, Smith MT, Hubbard A et al. Polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and risk of adult acute lymphocytic leukemia. Blood 2002; 99:3786-91.
Skinner MA, Safford SD, Reeves JG, Jackson ME, Freemerman AJ. Renal aplasia in humans is associated with RET mutations. Am J Hum Genet 2008; 82:344-51.
Skinner MH, Kuan HY, Pan A et al. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther 2003; 73:170-7.
Skipper L, Wilkes K, Toft M et al. Linkage disequilibrium and association of MAPT H1 in Parkinson disease. Am J Hum Genet 2004; 75:669-77.
Skjelbo E, Brøsen K. Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 1992; 34:256-61.
Skjelbred CF, Svendsen M, Haugan V et al. Influence of DNA repair gene polymorphisms of hOGG1, XRCC1, XRCC3, ERCC2 and the folate metabolism gene MTHFR on chromosomal aberration frequencies. Mutat Res 2006; 602:151-62.
Sklan EH, Berson A, Birikh KR et al. Acetylcholinesterase modulates stress-induced motor responses through catalytic and noncatalytic properties. Biol Psychiatry 2006; 60:741-51.
Skogh E, Sjödin I, Josefsson M, Dahl ML. High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug. J Clin Psychopharmacol 2011; 31:4-9.
Skolness SY, Durhan EJ, Garcia-Reyero N et al. Effects of a short-term exposure to the fungicide prochloraz on endocrine function and gene expression in female fathead minnows (Pimephales promelas). Aquat Toxicol 2011; 103:170-8.
Skoog I, Kalaria RN, Breteler MM. Vascular factors and Alzheimer disease. Alzheimer Dis Assoc Disord 1999; 13:106-14.
Skoog I, Olesen PJ, Blennow K, Palmertz B, Johnson SC, Bigler ED. Head size may modify the impact of white matter lesions on dementia. Neurobiol Aging 2011. doi:10. 1016/j. neurobiolaging. 2011. 01. 011.
Skopalík J, Anzenbacher P, Otyepka M. Flexibility of human cytochromes P450: molecular dynamics reveals differences between CYPs 3A4, 2C9, and 2A6, which correlate with their substrate preferences. J Phys Chem B 2008; 112:8165-73.
Skrętkowicz J, Baranska M, Rychlik-Sych M. Genetic polymorphisms of CYP2D6 oxidation in patients with systemic sclerosis. Eur J Clin Pharmacol 2009; 65:971-6.
Skrygan M, Bartholomé B, Bonafé L, Blau N, Bartholomé K. A splice mutation in the GTP cyclohydrolase I gene causes dopa-responsive dystonia by exon skipping. J Inherit Metab Dis 2001; 24:345-51.
Skrzyszowska M, Smorag Z, Słomski R et al. Generation of transgenic rabbits by the novel technique of chimeric somatic cell cloning. Biol Reprod 2006; 74:1114-20.
Skupinska K, Misiewicz-Krzeminska I, Stypulkowski R, Lubelska K, Kasprzycka-Guttman T. Sulforaphane and its analogues inhibit CYP1A1 and CYP1A2 activity induced by benzo[a]pyrene. J Biochem Mol Toxicol 2009; 23:18-28.
Sládek NE. Aldehyde dehydrogenase-mediated cellular relative insensitivity to the oxazaphosphorines. Curr Pharm Des 1999; 5:607-25.
Slain D, Pakyz A, Israel DS, Monroe S, Polk RE. Variability in activity of hepatic CYP3A4 in patients infected with HIV. Pharmacotherapy 2000; 20:898-907.
Slama R, Gräbsch C, Lepeule J et al. Maternal fine particulate matter exposure, polymorphism in xenobiotic-metabolizing genes and offspring birth weight. Reprod Toxicol 2010; 30:600-12.
Slätis K, Gåfvels M, Kannisto K et al. Abolished synthesis of cholic acid reduces atherosclerotic development in apolipoprotein E knockout mice. J Lipid Res 2010; 51:3289-98.
Slatter JG, Templeton IE, Castle JC et al. Compendium of gene expression profiles comprising a baseline model of the human liver drug metabolism transcriptome. Xenobiotica 2006; 36:938-62.
Slattery ML, Herrick JS, Lundgreen A, Fitzpatrick FA, Curtin K, Wolff RK. Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1. Carcinogenesis 2010; 31:1604-11.
Slattery ML, Lundgreen A, Herrick JS et al. Variation in the CYP19A1 gene and risk of colon and rectal cancer. Cancer Causes Control 2011; 22:955-63.
Slattery ML, Lundgreen A, Herrick JS et al. Genetic variation in bone morphogenetic protein (BMP) and colon and rectal cancer. Int J Cancer 2011. doi:10. 1002/ijc. 26047.
Slaugenhaupt SA, Roca AL, Liebert CB, Altherr MR, Gusella JF, Reppert SM. Mapping of the gene for the Mel1a-melatonin receptor to human chromosome 4 (MTNR1A) and mouse chromosome 8 (Mtnr1a). Genomics 1995; 27:355-7.
Slaviero KA, Clarke SJ, McLachlan AJ, Blair EY, Rivory LP. Population pharmacokinetics of weekly docetaxel in patients with advanced cancer. Br J Clin Pharmacol 2004; 57:44-53.
Slingerland AS, Bruining GJ. From gene to disease; neonatal diabetes mellitus and the KCNJ11 gene. Ned Tijdschr Geneeskd 2005; 149:2732-6.
Sliwinski T, Sitarek P, Stetkiewicz T, Sobczuk A, Blasiak J. Polymorphism of the ERalpha and CYP1B1 genes in endometrial cancer in a Polish subpopulation. J Obstet Gynaecol Res 2010; 36:311-7.
Slof-Op ‘t Landt MC, Meulenbelt I, Bartels M et al. Association study in eating disorders: TPH2 associates with anorexia nervosa and self-induced vomiting. Genes Brain Behav 2011; 10:236-43.
Slooter AJC, Breteler MB, Ott A, van Broeckhoven C, van Duijn CM. APOE genotyping in differential diagnosis of Alzheimer’s disease. Lancet 1996; 348:334.
Slot AJ, Wise DD, Deeley RG, Monks TJ, Cole SP. Modulation of human multidrug resistance protein (MRP) 1 (ABCC1) and MRP2 (ABCC2) transport activities by endogenous and exogenous glutathione-conjugated catechol metabolites. Drug Metab Dispos 2008; 36:552-60.
Slot KA, Kastelijn J, Bachelot A, Kelly PA, Binart N, Teerds KJ. Reduced recruitment and survival of primordial and growing follicles in GH receptor-deficient mice. Reproduction 2006; 131:525-32.
Slowik A, Turaj W, Dziedzic T et al. DD genotype of ACE gene is a risk factor for intracerebral hemorrhage. Neurology 2004; 63:359-61.
Smach MA, Charfeddine B, Lammouchi T et al. Analysis of association between bleomycin hydrolase and apolipoprotein E polymorphism in Alzheimer’s disease. Neurol Sci 2010; 31:687-91.
Smach MA, Charfeddine B, Othman LB et al. -1154G/A and -2578C/A polymorphisms of the vascular endothelial growth factor gene in Tunisian Alzheimer patients in relation to beta-amyloid (1-42) and total tau protein. Neurosci Lett 2010; 472:139-42.
Small D. FLT3 mutations: biology and treatment. Hematology Am Soc Hematol Educ Program 2006:178-84.
Small D. Targeting FLT3 for the treatment of leukemia. Semin Hematol 2008; 45:17-21.
Small DH, Gasperini R, Vincent AJ, Hung AC, Foa L. The role of Abeta-induced calcium dysregulation in the pathogenesis of Alzheimer’s disease. J Alzheimers Dis 2009; 16:225-33.
Small DS, Farid NA, Payne CD et al. Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel. Clin Pharmacokinet 2010; 49:777-98.
Small KM, Brown KM, Seman CA, Theiss CT, Liggett SB. Complex haplotypes derived from noncoding polymorphisms of the intronless alpha2A-adrenergic gene diversify receptor expression. Proc Natl Acad Sci USA 2006; 103:5472-7.
Small KM, Brown KM, Theiss CT, Seman CA, Weiss ST, Liggett SB. An Ile to Met polymorphism in the catalytic domain of adenylyl cyclase type 9 confers reduced beta2-adrenergic receptor stimulation. Pharmacogenetics 2003; 13:535-41.
Small KM, McGraw DW, Liggett SB. Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu Rev Pharmacol Toxicol 2003; 43:381-411.
Small KM, Mialet-Perez J, Seman CA, Theiss CT, Brown KM, Liggett SB. Polymorphisms of cardiac presynaptic alpha2C adrenergic receptors: Diverse intragenic variability with haplotype-specific functional effects. Proc Natl Acad Sci USA 2004; 101:13020-5.
Small KM, Wagoner LE, Levin AM, Kardia SLR, Liggett SB. Synergistic polymorphisms of beta-1- and alpha-2C-adrenergic receptors and the risk of congestive heart failure. New Eng J Med 2002; 347:1135-42.
Smelt AH. Triglycerides and gallstone formation. Clin Chim Acta 2010; 411:1625-31.
Smet C, Sambo AV, Wieruszeski JM et al. The peptidyl prolyl cis/trans-isomerase Pin1 recognizes the phospho-Thr212-Pro213 site on Tau. Biochemistry 2004; 43:2032-40.
Smeti I, Savary E, Capelle V, Hugnot JP, Uziel A, Zine A. Expression of candidate markers for stem/progenitor cells in the inner ears of developing and adult GFAP and nestin promoter-GFP transgenic mice. Gene Expr Patterns 2011; 11:22-32.
Smeyne M, Boyd J, Raviie Shepherd K et al. GSTpi expression mediates dopaminergic neuron sensitivity in experimental parkinsonism. Proc Natl Acad Sci USA 2007; 104:1977-82.
Smirnova I, Hamblin MT, McBride C, Beutler B, Di Rienzo A. Excess of rare amino acid polymorphisms in the Toll-like receptor 4 in humans. Genetics 2001; 158:1657-64.
Smit P, van Schaik RH, van der Werf M et al. A common polymorphism in the CYP3A7 gene is associated with a nearly 50% reduction in serum dehydroepiandrosterone sulfate levels. J Clin Endocrinol Metab 2005; 90:5313-6.
Smith A, Moran A, Boyd MC et al. Phenocopies in BRCA1 and BRCA2 families; evidence for modifier genes and implications for screening. J Med Genet 2007; 44:10-5.
Smith AG, Lim W, Pearen M, Muscat GE, Sturm RA. Regulation of NR4A nuclear receptor expression by oncogenic BRAF in melanoma cells. Pigment Cell Melanoma Res 2011; 24:551-63.
Smith C, Stamm SC, Riggs JE et al. Ethanol-mediated CYP1A1/2 induction in rat skeletal muscle tissue. Exp Mol Pathol 2000; 69:223-32.
Smith CA, Harrison DJ. Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema. Lancet 1997; 350:630-3.
Smith D, Sadagopan N, Zientek M, Reddy A, Cohen L. Analytical approaches to determine cytochrome P450 inhibitory potential of new chemical entities in drug discovery. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 850:455-63.
Smith DA. Design of drugs through a consideration of drug metabolism and pharmacokinetics. Eur J Drug Metab Pharmacokinet 1994; 19:193-9.
Smith DA. Induction and drug development. Eur J Pharm Sci 2000; 11:185-9.
Smith DA, Koch KM, Arya N, Bowen CJ, Herendeen JM, Beelen A. Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects. Br J Clin Pharmacol 2009; 67:421-6.
Smith EE, Salat DH, Jeng J et al. Correlations between MRI white matter lesion location and executive function and episodic memory. Neurology 2011; 76:1492-9.
Smith EP, Specker B, Bachrach BE et al. Impact on bone of an estrogen receptor-alpha gene loss of function mutation. J Clin Endocrinol Metab 2008; 93:3088-96.
Smith G, Bounds R, Wolf H, Steele RJ, Carey FA, Wolf CR. Activating K-Ras mutations outwith ‘hotspot’ codons in sporadic colorectal tumours – implications for personalised cancer medicine. Br J Cancer 2010; 102:693-703.
Smith G, Haverkamp LJ, Case S, Appel V, Appel SH. Apolipoprotein E e4 in bulbar-onset motor neuron disease. Lancet 1996; 348:334-48.
Smith G, Ibbotson SH, Comrie MM et al. Regulation of cutaneous drug-metabolizing enzymes and cytoprotective gene expression by topical drugs in human skin in vivo. Br J Dermatol 2006; 155:275-81.
Smith HE, Jones JP 3rd, Kalhorn TF et al. Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease. Pharmacogenet Genomics 2008; 18:943-53.
Smith HS. Opioid metabolism. Mayo Clin Proc 2009; 84:613-24.
Smith JC, Curry SC. Prolonged toxicity after amitriptyline overdose in a patient deficient in CYP2D6 activity. J Med Toxicol 2011; 7:220-3.
Smith M, Duester G, Bilanchone V, Carlock L, Hatfield W. Derivation of probes for molecular genetic analysis of human class I alcohol dehydrogenase (ADH), a polymorphic gene family on chromosome 4. Am J Hum Genet 1984; 36:153.
Smith M, Duester G, Carlock L, Wasmuth J. Assignment of ADH1, ADH2 and ADH3 genes (class I ADH) to human chromosome 4q21-4q25, through use of DNA probes. Cytogenet Cell Genet 1985; 40:748.
Smith MA, Marinaki AM, Arenas M et al. Novel pharmacogenetic markers for treatment outcome in azathioprine-treated inflammatory bowel disease. Aliment Pharmacol Ther 2009; 30:375-84.
Smith MT. Benzene, NQO1, and genetic susceptibility to cancer. Proc Natl Acad Sci USA 1999; 96:7624-6.
Smith NF, Baker SD, Gonzalez FJ, Harris JW, Figg WD, Sparreboom A. Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100. Br J Cancer 2008; 98:1630-2.
Smith NF, Figg WD, Sparreboom A. Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination. Expert Opin Drug Metab Toxicol 2005; 1:429-45.
Smith NF, Figg WD, Sparreboom A. Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol In Vitro 2006; 20:163-75.
Smith NF, Mani S, Schuetz EG et al. Induction of CYP3A4 by vinblastine: Role of the nuclear receptor NR1I2. Ann Pharmacother 2010; 44:1709-17.
Smith PJ, Furon E, Wiltshire M et al. ABCG2-associated resistance to Hoechst 33342 and topotecan in a murine cell model with constitutive expression of side population characteristics. Cytometry A 2009; 75:924-33.
Smith R, Healy E, Siddiqui S et al. Melanocortin 1 receptor variants in an Irish population. J Invest Dermatol 1998; 111:119-22.
Smith RC, Segman RH, Golcer-Dubner T, Pavlov V, Lerer B. Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia. Pharmacogenomics J 2008; 8:228-36.
Smith RM, Alachkar H, Papp AC et al. Nicotinic α5 receptor subunit mRNA expression is associated with distant 5’ upstream polymorphisms. Eur J Hum Genet 2011; 19:76-83.
Smith S, Su D, Rigault de la Longrais IA et al. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. J Clin Oncol 2007; 25:5172-9.
Smith SM, Judge HM, Peters G, Storey RF. Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention. Platelets 2004; 15:465-74.
Smith TJ. Mechanisms of carcinogenesis inhibition by isothiocyanates. Expert Opin Investig Drugs 2001; 10:2167-74.
Smith TJ, Crecelius EA, Reading JC. Airborne arsenic exposure and excretion of methylated arsenic compounds. Environ Health Perspect 1977; 19:89-93.
Smitherman PK, Townsend AJ, Kute TE, Morrow CS. Role of multidrug resistance protein 2 (MRP2, ABCC2) in alkylating agent detoxification: MRP2 potentiates glutathione S-transferase A1-1-mediated resistance to chlorambucil cytotoxicity. J Pharmacol Exp Ther 2004; 308:260-7.
Smith-Sørensen B, Lind GE, Skotheim RI et al. Frequent promoter hypermethylation of the O6-Methylguanine-DNA Methyltransferase (MGMT) gene in testicular cancer. Oncogene 2002; 21:8878-84.
Smollich M, Götte M, Fischgräbe J et al. ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole. Breast Cancer Res Treat 2010; 123:345-57.
Smyth JF, Aamdal S, Awada A et al. Phase II study of E7070 in patients with metastatic melanoma. Ann Oncol 2005; 16:158-61.
Snell R, MacMillan J, Cheadle J et al. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington’s disease. Nat Genet 1993; 4:393-7.
Snider NT, Kornilov AM, Kent UM, Hollenberg PF. Anandamide metabolism by human liver and kidney microsomal cytochrome p450 enzymes to form hydroxyeicosatetraenoic and epoxyeicosatrienoic acid ethanolamides. J Pharmacol Exp Ther 2007; 321:590-7.
Snider NT, Walker VJ, Hollenberg PF. Oxidation of the endogenous cannabinoid arachidonoyl ethanolamide by the Cytochrome P450 Monooxygenases: Physiological and pharmacological implications. Pharmacol Rev 2010; 62:136-54.
Snoeck E, van Peer A, Sack M et al. Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychopharmacology 1995; 122:223-9.
Snoussi K, Mahfoudh W, Bouaouina N et al. Combined effects of IL-8 and CXCR2 gene polymorphisms on breast cancer susceptibility and aggressiveness. BMC Cancer 2010; 10:283.
Snozek CL, O’Kane DJ, Algeciras-Schimnich A. Pharmacogenetics of solid tumors: directed therapy in breast, lung, and colorectal cancer: a paper from the 2008 William Beaumont Hospital symposium on molecular pathology. J Mol Diagn 2009; 11:381-9.
Snyder EM, Beck KC, Dietz Nmet al. Arg16Gly polymorphism of the beta2-adrenergic receptor is associated with differences in cardiovascular function at rest and during exercise in humans. J Physiol 2006; 571:121-30.
Snyder EM, Johnson BD. Beta2-adrenergic receptor genotype and survival after acute coronary syndrome. JAMA 2006; 295:756-7.
Snyder EM, Turner ST, Johnson BD. Beta2-adrenergic receptor genotype and pulmonary function in patients with heart failure. Chest 2006; 130:1527-34.
Snyderwine EG, Turesky RJ, Turteltaub KW et al. Metabolism of food-derived heterocyclic amines in nonhuman primates. Mutat Res 1997; 376:203-10.
Soars MG, Gelboin HV, Krausz KW, Riley RJ. A comparison of relative abundance, activity factor and inhibitory monoclonal antibody approaches in the characterization of human CYP enzymology. Br J Clin Pharmacol 2003; 55:175-81.
Soars MG, Grime K, Riley RJ. Comparative analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5. Xenobiotica 2006; 36:287-99.
Soars MG, Petullo DM, Eckstein JA, Kasper SC, Wrighton SA. An assessment of udp-glucuronosyltransferase induction using primary human hepatocytes. Drug Metab Dispos 2004; 32:140-8.
Sobell JL, Lind TJ, Sigurdson DC et al. The D5 dopamine receptor gene in schizophrenia: identification of a nonsense change and multiple missense changes but lack of association with disease. Hum Mol Genet 1995; 4:507-14.
Sobolewski C, Cerella C, Dicato M, Ghibelli L, Diederich M. The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies. Int J Cell Biol 2010. doi:10. 1155/2010/215158.
Sobrido MJ, Abu-Khalil A, Weintraub et al. Posible association of the tau H1/H1 genotype with primary progressive aphasia. Neurology 2003; 60:862-4.
Sobrido MJ, Miller BL, Havlioglu N et al. Novel tau polymorphisms, tau haplotypes, and splicing in familial and sporadic frototemporal dementia. Arch Neurol 2003; 60:698-702.
Sobti RC, Berhane N, Mahedi SA et al. Polymorphisms of IL-6 174 G/C, IL-10 -592 C/A and risk of HIV/AIDS among North Indian population. Mol Cell Biochem 2010; 337:145-52.
Söderbergh A, Rorsman F, Halonen M et al. Autoantibodies against aromatic L-amino acid decarboxylase identifies a subgroup of patients with Addison’s disease. J Clin Endocrinol Metab 2000; 85:460-3.
Söderström T, Wadelius M, Andersson SO et al. 5alpha-reductase 2 polymorphisms as risk factors in prostate cancer. Pharmacogenetics 2002; 12:307-12.
Sodhi MS, Arranz MJ, Curtis D et al. Association between clozapine response and allelic variation in the 5-HT2C receptor gene. Neuroreport 1995; 7:169-72.
Sofowora G, Dishy V, Xie HG et al. In-vivo effects of Glu298Asp endothelial nitric oxide synthase polymorphism. Pharmacogenetics 2001; 11:809-14.
Sofowora GG, Dishy V, Muszkat M et al. A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade. Clin Pharmacol Ther 2003; 73:366-71.
Soga Y, Nishimura F, Ohtsuka Y et al. CYP2C polymorphisms, phenytoin metabolism and gingival overgrowth in epileptic subjects. Life Sci 2004; 74:827-34.
Sohda S, Arinami T, Hamada H, Yamada N, Hamaguchi H, Kubo T. Methylenetetrahydrofolate reductase polymorphism and pre-eclampsia. J Med Genet 1997; 34:525-6.
Sohi G, Marchand K, Revesz A, Arany E, Hardy DB. Maternal protein restriction elevates cholesterol in adult rat offspring due to repressive changes in histone modifications at the cholesterol 7alpha-hydroxylase promoter. Mol Endocrinol 2011; 25:785-98.
Sohl CD, Guengerich FP. Kinetic analysis of the three-step steroid aromatase reaction of human cytochrome P450 19A1. J Biol Chem 2010; 285:17734-43.
Sohn DR, Kwon JT, Kim HK, Ishizaki T. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4’-hydroxylation phenotype status. Clin Pharmacol Ther 1997; 61:574-82.
Soininen HS, Riekkinen PJ Sr. Apolipoprotein E, memory and Alzheimer’s disease. Trends Neurosci 1996; 19:224-8.
Solai LK, Mulsant BH, Pollock BG et al. Effect of sertraline on plasma nortriptyline levels in depressed elderly. J Clin Psychiatry 1997; 58:440-3.
Solai LK, Pollock BG, Mulsant BH et al. Effect of nortriptyline and paroxetine on CYP2D6 activity in depressed elderly patients. J Clin Psychopharmacol 2002; 22:481-6.
Solano A, Roig M, Vives-Bauza C et al. Bilateral striatal necrosis associated with a novel mutation in the mitochondrial ND6 gene. Ann Neurol 2003; 54:527-30.
Soldevila M, Calafell F, Andrés AM et al. Prion susceptibility and protective allele exhibits marked geographic differences. Hum Mutant 2003; 22:104-5.
Solon EG, Balani SK, Luo G et al. Interaction of ritonavir on tissue distribution of a [(14)c]L-valinamide, a potent human immunodeficiency virus-1 protease inhibitor, in rats using quantitative whole-body autoradiography. Drug Metab Dispos 2002; 30:1164-9.
Solovieva S, Kämäräinen OP, Hirvonen A et al. Association between interleukin 1 gene cluster polymorphisms and bilateral distal interphalangeal osteoarthritis. J Rheumatol 2009; 36:1977-86.
Solus JF, Arietta BJ, Harris JR et al. Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics 2004; 5:895-931.
Somer M, Kallio J, Pesonen U, Pyykkö K, Huupponen R, Scheinin M. Influence of hydroxychloroquine on the bioavailability of oral metoprolol. Br J Clin Pharmacol 2000; 49:549-54.
Somers GI, Harris AJ, Bayliss MK, Houston JB. The metabolism of the 5HT3 antagonists ondansetron, alosetron and GR87442 I: a comparison of in vitro and in vivo metabolism and in vitro enzyme kinetics in rat, dog and human hepatocytes, microsomes and recombinant human enzymes. Xenobiotica 2007; 37:832-54.
Somers GI, Lindsay N, Lowdon BM et al. A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes. Drug Metab Dispos 2007; 35:1797-805.
Someya T, Shimoda K, Suzuki Y et al. Effect of CYP2D6 genotypes on the metabolism of haloperidol in a Japanese psychiatric population. Neuropsychopharmacology 2003; 28:1501-5.
Sommer A, Blanton SH, Weymouth K et al. Smoking, the xenobiotic pathway, and clubfoot. Birth Defects Res A Clin Mol Teratol 2011; 91:20-8.
Sommer B, Keinänen K, Verdoorn TA et al. Flip and flop: a cell-specific functional switch in glutamate-operated channels of the CNS. Science 1990; 249:1580-5.
Somogyi AA, Barratt DT, Coller JK. Pharmacogenetics of opioids. Clin Pharmacol Ther 2007; 81:429-44.
Somogyi AA, Menelaou A, Fullston SV. CYP3A4 mediates dextropropoxyphene N-demethylation to nordextropropoxyphene: human in vitro and in vivo studies and lack of CYP2D6 involvement. Xenobiotica 2004; 34:875-87.
Somparn N, Kukongviriyapan U, Tassaneeyakul W, Jetsrisuparb A, Kukongviriyapan V. Modification of CYP2E1 and CYP3A4 activities in haemoglobin E-beta thalassemia patients. Eur J Clin Pharmacol 2007; 63:43-50.
Son DS, Terranova PF, Roby KF. Interaction of adenosine 3’,5’-cyclic monophosphate and tumor necrosis factor-alpha on serum amyloid A3 expression in mouse granulosa cells: dependence on CCAAT-enhancing binding protein-beta isoform. Endocrinology 2010; 151:3407-19.
Sone M, Osamura RY. Leptin and the pituitary. Pituitary 2001; 4:15-23.
Sonesson A, Buur Rasmussen B. In vitro studies investigating the interactions between degarelix, a decapeptide gonadotropin-releasing hormone blocker, and cytochrome P450. Basic Clin Pharmacol Toxicol 2011; 109:195-202.
Song D, Bandsma RH, Xiao C et al. Acute cannabinoid receptor type 1 (CB1R) modulation influences insulin sensitivity by an effect outside the central nervous system in mice. Diabetologia 2011; 54:1181-9.
Song DH, Jhung K, Song J, Cheon KA. The 1287 G/A polymorphism of the norepinephrine transporter gene (NET) is involved in commission errors in Korean children with attention deficit hyperactivity disorder. Behav Brain Funct 2011; 7:12.
Song G, Liu J, Zhao Z et al. Simvastatin reduces atherogenesis and promotes the expression of hepatic genes associated with reverse cholesterol transport in apoE-knockout mice fed high-fat diet. Lipids Health Dis 2011; 10:8.
Song H, Jia L, Zuo X, Jia J. Association between haplotype -88G/25G in A2M with Alzheimer’s disease. Neurosci Lett 2010; 479:143-5.
Song IS, Choi MK, Jin QR, Shim WS, Shim CK. Increased affinity to canalicular P-gp via formation of lipophilic ion-pair complexes with endogenous bile salts is associated with mw threshold in hepatobiliary excretion of quaternary ammonium compounds. Pharm Res 2010; 27:823-31.
Song J, da Costa KA, Fischer LM et al. Polymorphism of the PEMT gene and susceptibility to nonalcoholic fatty liver disease (NAFLD). FASEB J 2005; 19:1266-71.
Song J, Parker L, Hormozi L, Tanouye MA. DNA topoisomerase I inhibitors ameliorate seizure-like behaviors and paralysis in a Drosophila model of epilepsy. Neuroscience 2008; 156:722-8.
Song J, Sakatsume M, Narita I et al. Peroxisome proliferator-activated receptor gamma C161T polymorphisms and survival of Japanese patients with immunoglobulin A nephropathy. Clin Genet 2003; 64:398-403.
Song J, Song DH, Jhung K, Cheon KA. Norepinephrine transporter gene (SLC6A2) is involved with methylphenidate response in Korean children with attention deficit hyperactivity disorder. Int Clin Psychopharmacol 2011; 26:107-13.
Song KH, Chiang JY. Glucagon and cAMP inhibit cholesterol 7alpha-hydroxylase (CYP7A1) gene expression in human hepatocytes: discordant regulation of bile acid synthesis and gluconeogenesis. Hepatology 2006; 43:117-25.
Song KH, Li T, Owsley E, Chiang JY. A putative role of micro RNA in regulation of cholesterol 7alpha-hydroxylase expression in human hepatocytes. J Lipid Res 2010; 51:2223-33.
Song KH, Li T, Owsley E, Strom S, Chiang JY. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression. Hepatology 2009; 49:297-305.
Song SB, Jin HS, Hong KW et al. Association between renin-angiotensin-aldosterone system-related genes and blood pressure in a Korean population. Blood Press 2011; 20:204-10.
Song SZ, Choi YH, Jin GY, Li GZ, Yan GH. Protective effect of cornuside against carbon tetrachloride-induced acute hepatic injury. Biosci Biotechnol Biochem 2011; 75:656-61.
Song WY, Ji HY, Baek NI, Jeong TS, Lee HS. In vitro metabolism of jaceosidin and characterization of cytochrome P450 and UDP-glucuronosyltransferase enzymes in human liver microsomes. Arch Pharm Res 2010; 33:1985-96.
Song X, Li Y, Liu J, Mukundan M, Yan B. Simultaneous substitution of phenylalanine-305 and aspartate-318 of rat pregnane X receptor with the corresponding human residues abolishes the ability to transactivate the CYP3A23 promoter. J Pharmacol Exp Ther 2005; 312:571-82.
Song X, Siriwardhana N, Rathore K, Lin D, Wang HC. Grape seed proanthocyanidin suppression of breast cell carcinogenesis induced by chronic exposure to combined 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and benzo[a]pyrene. Mol Carcinog 2010; 49:450-63.
Song X, Xie M, Zhang H, Li Y, Sachdeva K, Yan B. The pregnane X receptor binds to response elements in a genomic context-dependent manner, and PXR activator rifampicin selectively alters the binding among target genes. Drug Metab Dispos 2004; 32:35-42.
Songpatanasilp T, Chailurkit LO, Chantprasertyothin S, Ongphiphadhanakul B, Taechakraichana N. Effect of GGCX gene polymorphism on the responses of serum undercarboxylated osteocalcin and bone turnover markers after treatment with vitamin K2 (menatetrenone) among postmenopausal Thai women. J Bone Miner Metab 2011; 29:606-14.
Sonnichsen DS, Liu Q, Schuetz EG, Schuetz JD, Pappo A, Relling MV. Variability in human cytochrome P450 paclitaxel metabolism. J Pharmacol Exp Ther 1995; 275:566-75.
Sonnier M, Cresteil T. Delayed ontogenesis of CYP1A2 in the human liver. Eur J Biochem 1998; 251:893-8.
Sonoda T, Suzuki H, Mori M et al. Polymorphisms in estrogen related genes may modify the protective effect of isoflavones against prostate cancer risk in Japanese men. Eur J Cancer Prev 2010; 19:131-7.
Sontag TJ, Parker RS. Influence of major structural features of tocopherols and tocotrienols on their omega-oxidation by tocopherol-omega-hydroxylase. J Lipid Res 2007; 48:1090-8.
Soo GW, Law JH, Kan E et al. Differential effects of ketoconazole and primaquine on the pharmacokinetics and tissue distribution of imatinib in mice. Anticancer Drugs 2010; 21:695-703.
Soo RA, Wang LZ, Ng SS et al. Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients. Lung Cancer 2009; 63:121-7.
Sood R, Sholl L, Isermann B, Zogg M, Coughlin SR, Weiler H. Maternal Par4 and platelets contribute to defective placenta formation in mouse embryos lacking thrombomodulin. Blood 2008; 112:585-91.
Sookoian S, Castaño G, Gianotti TF, Gemma C, Pirola CJ. Polymorphisms of MRP2 (ABCC2) are associated with susceptibility to nonalcoholic fatty liver disease. J Nutr Biochem 2009; 20:765-70.
Sookoian S, Castaño GO, Burgueño AL, Gianotti TF, Rosselli MS, Pirola CJ. The nuclear receptor PXR gene variants are associated with liver injury in nonalcoholic fatty liver disease. Pharmacogenet Genomics 2010; 20:1-8.
Sookoian S, García SI, Porto PI, Dieuzeide G, González CD, Pirola CJ. Peroxisome proliferator-activated receptor gamma and its coactivator-1 alpha may be associated with features of the metabolic syndrome in adolescents. J Mol Endocrinol 2005; 35:373-80.
Sookoian S, Gemma C, Pirola CJ. Influence of hepatocyte nuclear factor 4alpha (HNF4alpha) gene variants on the risk of type 2 diabetes: a meta-analysis in 49,577 individuals. Mol Genet Metab 2010; 99:80-9.
Soranzo N, Cavalleri GL, Weale ME et al. Identifying candidate causal variants responsible for altered activity of the ABCB1 multidrug resistance gene. Genome Res 2004; 14:1333-44.
Soria JM, Fontcuberta J, Borrell M, Estivill X, Sala N. Protein C deficiency: identification of a novel two-base pair insertion and two point mutations in exon 7 of the protein C gene in Spanish families. Hum Mutat 1992; 1:428-31.
Soriano A, Vicente J, Carcas C et al. Differences between Spaniards and Ecuadorians in CYP2A6 allele frequencies: comparison with other populations. Fundam Clin Pharmacol 2011; 25:627-32.
Sorich MJ, Vitry A, Ward MB, Horowitz JD, McKinnon RA. Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. J Thromb Haemost 2010; 8:1678-84.
Soroka CJ, Mennone A, Hagey LR, Ballatori N, Boyer JL. Mouse organic solute transporter alpha deficiency enhances renal excretion of bile acids and attenuates cholestasis. Hepatology 2010; 51:181-90.
Sosa-Macías M, Dorado P, Alanis-Bañuelos RE, Llerena A, Lares-Asseff I. Influence of CYP2D6 deletion, multiplication, -1584C→G, 31G→A and 2988G→a gene polymorphisms on dextromethorphan metabolism among Mexican tepehuanos and mestizos. Pharmacology 2010; 86:30-6.
Sotaniemi EA, Lumme P, Arvela P, Rautio A. Age and CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in man. Therapie 1996; 51:363-6.
Sotaniemi EA, Rautio A, Bäckstrom M, Arvela P, Pelkonen O. CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients. Br J Clin Pharmacol 1995; 39:71-6.
Sotoodehnia N, Li G, Johnson CO et al. Genetic variation in angiotensin-converting enzyme-related pathways associated with sudden cardiac arrest risk. Heart Rhythm 2009; 6:1306-14.
Sotoodehnia N, Siscovick DS, Vatta M et al. Beta2-adrenergic receptor genetic variants and risk of sudden cardiac death. Circulation 2006; 113:1842-8.
Soto-Sánchez J, Santos-Juanes J, Coto-Segura P et al. Genetic variation at the CCR5/CCR2 gene cluster and risk of psoriasis and psoriatic arthritis. Cytokine 2010; 50:114-6.
Sotos-Prieto M, Guillén M, Guillem-Sáiz P, Portolés O, Corella D. The rs1466113 polymorphism in the somatostatin receptor 2 gene is associated with obesity and food intake in a Mediterranean population. Ann Nutr Metab 2010; 57:124-31.
Sotsuka T, Sasaki Y, Hirai S, Yamagishi F, Ueno K. Association of isoniazid-metabolizing enzyme genotypes and isoniazid-induced hepatotoxicity in tuberculosis patients. In Vivo 2011; 25:803-12.
Soubeyrand S, Pope L, Haché RJ. Topoisomerase IIalpha-dependent induction of a persistent DNA damage response in response to transient etoposide exposure. Mol Oncol 2010; 4:38-51.
Soucek P, Sarmanová J, Kristensen VN, Apltauerová M, Gut I. Genetic polymorphisms of biotransformation enzymes in patients with Hodgkin’s and non-Hodgkin’s lymphomas. Int Arch Occup Environ Health 2002; 75 Suppl:86-92.
Soucek P, Susova S, Mohelnikova-Duchonova B et al. Polymorphisms in metabolizing enzymes and the risk of head and neck squamous cell carcinoma in the Slavic population of the central Europe. Neoplasma 2010; 57:415-21.
Soucek P, Zuber R, Anzenbacherová E, Anzenbacher P, Guengerich FP. Minipig cytochrome P450 3A, 2A and 2C enzymes have similar properties to human analogs. BMC Pharmacol 2001; 1:11
Soufir N, Avril MF, Chompret A et al. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum Mol Genet 1998; 7:209-16.
Souiden Y, Mahdouani M, Chaieb K, Elkamel R, Mahdouani K. Polymorphisms of glutathione-S-transferase M1 and T1 and prostate cancer risk in a Tunisian population. Cancer Epidemiol 2010; 34:598-603.
Souidi M, Scanff P, Grison S, Gourmelon P, Aigueperse J. Effects of ionizing radiation on the activity of the major hepatic enzymes implicated in bile acid biosynthesis in the rat. C R Biol 2007; 330:861-70.
Souidi M, Tissandie E, Grandcolas L et al. Chronic contamination with 137cesium in rat: effect on liver cholesterol metabolism. Int J Toxicol 2006; 25:493-7.
Soundararajan CC, Adhin A, Tripathi M, Prasad HK, Jain S, Vivekanandhan S. Association of CYP2D6 100 C > T and 2850 C > T polymorphisms with generalized tonic clonic seizures among Indians. J Neural Transm 2006; 113:1873-6.
Soundravally R, Hoti SL. Polymorphisms of the TAP 1 and 2 gene may influence clinical outcome of primary dengue viral infection. Scand J Immunol 2008; 67:618-25.
Soupene E, Kuypers FA. Multiple erythroid isoforms of human long-chain acyl-CoA synthetases are produced by switch of the fatty acid gate domains. BMC Mol Biol 2006; 7:21.
Southren AL, Dominguez MO, Gordon GG et al. Nuclear translocation of the cytoplasmic glucocorticoid receptor in the iris-ciliary body and adjacent corneoscleral tissue of the rabbit following topical administration of various glucocorticoids. A rapid screening method for glucocorticoid activity. Invest Ophthalmol Vis Sci 1983; 24:147-52.
Southwell AL, Ko J, Patterson PH. Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington’s disease. J Neurosci 2009; 29:13589-602.
Souto JC, Blanco-Vaca F, Soria JM et al. A genomewide exploration suggests a new candidate gene at chromosome 11q23 as the major determinant of plasma homocysteine levels: results from the GAIT project. Am J Hum Genet 2005; 76:925-33.
Souza DG, Lomez ESL, Pinho V et al. Role of bradykinin B(2) and B(1) receptors in the local, remote, and systemic inflammatory responses that follow intestinal ischemia and reperfusion injury. J Immunol 2004; 172:2542-8.
Souza RP, de Luca V, Meltzer HY, Lieberman JA, Kennedy JL. Influence of serotonin 3A and 3B receptor genes on clozapine treatment response in schizophrenia. Pharmacogenet Genomics 2010; 20:274-6.
Souza RP, Meltzer HY, Lieberman JA, Le Foll B, Kennedy JL. Influence of neurexin 1 (NRXN1) polymorphisms in clozapine response. Hum Psychopharmacol 2010; 25:582-5.
Souza RP, Romano-Silva MA, Lieberman JA, Meltzer HY, Wong AH, Kennedy JL. Association study of GSK3 gene polymorphisms with schizophrenia and clozapine response. Psychopharmacology 2008; 200:177-86.
Soverini S, Colarossi S, Gnani A et al. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica 2007; 92:401-4.
Sowers MR, Jannausch ML, McConnell DS, Kardia SR, Randolph JF Jr. Endogenous estradiol and its association with estrogen receptor gene polymorphisms. Am J Med 2006; 119(9 Suppl 1):16-22.
Sowers MR, Randolph JF, Zheng H et al. Genetic polymorphisms and obesity influence estradiol decline during the menopause. Clin Endocrinol 2011; 74:618-23.
Sowers MR, Symons JP, Jannausch ML, Chu J, Kardia SR. Sex steroid hormone polymorphisms, high-density lipoprotein cholesterol, and apolipoprotein A-1 from the Study of Women’s Health Across the Nation (SWAN). Am J Med 2006; 119(9 Suppl 1):61-8.
Sowinski KM, Burlew BS. Impact of CYP2D6 poor metabolizer phenotype on propranolol pharmacokinetics and response. Pharmacotherapy 1997; 17:1305-10.
Sowinski KM, Lima JJ, Burlew BS, Massie JD, Johnson JA. Racial differences in propranolol enantiomer kinetics following simultaneous i. v. and oral administration. Br J Clin Pharmacol 1996; 42:339-46.
Soyama A, Kubo T, Miyajima A et al. Novel nonsynonymous single nucleotide polymorphisms in the CYP2D6 gene. Drug Metab Pharmacokinet 2004; 19:313-9.
Soyama A, Saito Y, Komamura K et al. Five novel single nucleotide polymorphisms in the CYP2C8 gene, one of which induces a frame-shift. Drug Metab Pharmacokinet 2002; 17:374-7.
Soyinka JO, Onyeji CO. Alteration of pharmacokinetics of proguanil in healthy volunteers following concurrent administration of efavirenz. Eur J Pharm Sci 2010; 39:213-8.
Spacey SD, Pastore M, McGillivray B et al. Fatal familial insominia: the first account in a family of Chinese descent. Arch Neurol 2004; 61:122-5.
Spagnolo P, Sato H, Marshall SE et al. Association between heat shock protein 70/Hom genetic polymorphisms and uveitis in patients with sarcoidosis. Invest Ophthalmol Vis Sci 2007; 48:3019-25.
Spagnuolo MS, Cigliano L, Maresca B, Pugliese CR, Abrescia P. Identification of plasma haptoglobin forms which loosely bind hemoglobin. Biol Chem 2011; 392:371-6.
Spagnuolo PA, Hu J, Hurren R et al. The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma. Blood 2010; 115:4824-33.
Spaldin V, Madden S, Pool WF, Woolf TF, Park BK. The effect of enzyme inhibition on the metabolism and activation of tacrine by human liver microsomes. Br J Clin Pharmacol 1994; 38:15-22.
Spanakis M, Vizirianakis IS, Mironidou-Tzouveleki M, Niopas I. A validated SIM GC/MS method for the simultaneous determination of dextromethorphan and its metabolites dextrorphan, 3-methoxymorphinan and 3-hydroxymorphinan in biological matrices and its application to in vitro CYP2D6 and CYP3A4 inhibition study. Biomed Chromatogr 2009; 23:1131-7.
Spangler ML, Saxena S. Warfarin and bosentan interaction in a patient with pulmonary hypertension secondary to bilateral pulmonary emboli. Clin Ther 2010; 32:53-6.
Sparfel L, Pinel-Marie ML, Boize M et al. Transcriptional signature of human macrophages exposed to the environmental contaminant benzo(a)pyrene. Toxicol Sci 2010; 114:247-59.
Sparkes RS, Simon M, Cohn VH et al. Assigment of the human and mouse prion protein genes to homologous chromosomes. Proc Nat Acad Sci USA 1986; 83:7358-62.
Sparreboom A, Gelderblom H, Marsh S et al. Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin Pharmacol Ther 2004; 76:38-44.
Sparreboom A, Marsh S, Mathijssen RH, Verweij J, McLeod HL. Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients. Invest New Drugs 2004; 22:285-9.
Sparreboom A, Nooter K. Does P-glycoprotein play a role in anticancer drug pharmacokinetics? Drug Resist Updat 2000; 3:357-63.
Sparrer HE, Santoso A, Szoka FC Jr et al. Evidence for the prion hypothesis: induction of the yeast [PSI+] factor by in vitro-converted Sup35 protein. Science 2000; 289:595-9.
Spasovski G, Beck BB, Blau N, Hoppe B, Tasic V. Late diagnosis of primary hyperoxaluria after failed kidney transplantation. Int Urol Nephrol 2010; 42:825-9.
Spee B, Carpino G, Schotanus BA et al. Characterisation of the liver progenitor cell niche in liver diseases: potential involvement of Wnt and Notch signalling. Gut 2010; 59:247-57.
Spence R, Mandagere A, Richards DB, Magee MH, Dufton C, Boinpally R. Potential for pharmacokinetic interactions between ambrisentan and cyclosporine. Clin Pharmacol Ther 2010; 88:513-20.
Spencer EA, Key TJ, Appleby PN et al. Prospective study of the association between grapefruit intake and risk of breast cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Causes Control 2009; 20:803-9.
Spengler G, Evaristo M, Handzlik J et al. Biological activity of hydantoin derivatives on P-glycoprotein (ABCB1) of mouse lymphoma cells. Anticancer Res 2010; 30:4867-71.
Sperling RI, Benincaso AI, Anderson RJ, Coblyn JS, Austen KF, Weinblatt ME. Acute and chronic suppression of leukotriene B4 synthesis ex vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate. Arthritis Rheum 1992; 35:376-84.
Spicer LJ, Schreiber NB, Lagaly DV, Aad PY, Douthit LB, Grado-Ahuir JA. Effect of resistin on granulosa and theca cell function in cattle. Anim Reprod Sci 2011; 124:19-27.
Spiecker M, Darius H, Hankeln T et al. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation 2004; 110:2132-6.
Spiegelman BM. Transcriptional control of energy homeostasis through the PGC1 coactivators. Novartis Found Symp 2007; 286:3-6.
Spielberg SP, Garrick MD, Corash LM et al. Biochemical heterogeneity in glutathione synthetase deficiency. J Clin Invest 1978; 61:1417-20.
Spigset O, Axelsson S, Norström A, Hägg S, Dahlqvist R. The major fluvoxamine metabolite in urine is formed by CYP2D6. Eur J Clin Pharmacol 2001; 57:653-8.
Spigset O, Hedenmalm K, Dahl ML, Wiholm BE, Dahlqvist R. Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors. Acta Psychiatr Scand 1997; 96:379-84.
Spigset O, Molden E. Cytochrome P-450 3A4-the most important arena for drug interactions in the body. Tidsskr Nor Laegeforen 2008; 128:2832-5.
Spillantini MG, Goedert M. Tau protein pathology in neurodegenerative diseases. Trends Neurosci 1998; 21:428-33.
Spillantini MG, Murrell JR, Goedert M et al. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Nat Acad Sci USA 1998; 95:7737-41.
Spillantini MG, Yoshida H, Rizzini C et al. A novel tau mutation (N296) in familial dementia with swollen achromatic neurons and corticobasal inclusion bodies. Ann Neurol 2000; 48:939-43.
Spina E, Arena D, Scordo MG, Fazio A, Pisani F, Perucca E. Elevation of plasma carbamazepine concentrations by ketoconazole in patients with epilepsy. Ther Drug Monit 1997; 19:535-8.
Spina E, Avenoso A, Campo GM, Caputi AP, Perucca E. The effect of carbamazepine on the 2-hydroxylation of desipramine. Psychopharmacology 1995; 117:413-6.
Spina E, Avenoso A, Campo GM, Caputi AP, Perucca E. Phenobarbital induces the 2-hydroxylation of desipramine. Ther Drug Monit 1996; 18:60-4.
Spina E, Avenoso A, Campo GM, Scordo MG, Caputi AP, Perucca E. Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects. Br J Clin Pharmacol 1997; 43:315-8.
Spina E, Avenoso A, Facciolà G et al. Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia. Int Clin Psychopharmacol 1998; 13:141-5.
Spina E, Avenoso A, Facciolà G et al. Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate. Ther Drug Monit 2000; 22:481-5.
Spina E, Avenoso A, Salemi M et al. Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline. Pharmacopsychiatry 2000; 33:213-7.
Spina E, Avenoso A, Scordo MG et al. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. J Clin Psychopharmacol 2002; 22:419-23.
Spina E, Avenoso A, Scordo MG, Ancione M, Madia A, Levita A. No effect of reboxetine on plasma concentrations of clozapine, risperidone, and their active metabolites. Ther Drug Monit 2001; 23:675-8.
Spina E, D’Arrigo C, Migliardi G et al. Plasma risperidone concentrations during combined treatment with sertraline. Ther Drug Monit 2004; 26:386-90.
Spina E, D’Arrigo C, Migliardi G et al. Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. Ther Drug Monit 2006; 28:599-602.
Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 2007; 100:4-22.
Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. Clin Pharmacokinet 1996; 31:198-214.
Spina E, Pollicino AM, Avenoso A, Campo GM, Perucca E, Caputi AP. Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther Drug Monit 1993; 15:243-6.
Spina E, Santoro V, D’Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther 2008; 30:1206-27.
Spina E, Scordo MG. Clinically significant drug interactions with antidepressants in the elderly. Drugs Aging 2002; 19:299-320.
Spina E, Scordo MG, D’Arrigo C. Metabolic drug interactions with new psychotropic agents. Fundam Clin Pharmacol 2003; 17:517-38.
Spirin V, Schmidt S, Pertsemlidis A, Cooper RS, Cohen JC, Sunyaev SR. Common Single-Nucleotide Polymorphisms Act in Concert to Affect Plasma Levels of High-Density Lipoprotein Cholesterol. Am J Hum Genet 2007; 81:1298-303.
Spittaels K, van den Haute C, van Dorpe J et al. Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. Am J Pathol 1999; 155:2153-65.
Splawski I, Shen J, Timothy KW et al. Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation 2000; 102:1178-85.
Splawski I, Tristani-Firouzi M, Lehmann MH, Sanguinetti MC, Keating MT. Mutations in the hminK gene cause long QT syndrome and suppress IKs function. Nat Genet 1997; 17:338-40.
Spraggs CF, Pillai SG, Dow D et al. Pharmacogenetics and obesity: common gene variants influence weight loss response of the norepinephrine/dopamine transporter inhibitor GW320659 in obese subjects. Pharmacogenet Genomics 2005; 15:883-9.
Spreafico M, Lodigiani C, van Leeuwen Y et al. Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy. Pharmacogenomics 2008; 9:1237-50.
Spriet I, Meersseman W, de Hoon J, von Winckelmann S, Wilmer A, Willems L. Mini-series: II. clinical aspects. clinically relevant CYP450-mediated drug interactions in the ICU. Intensive Care Med 2009; 35:603-12.
Springer D, Staack RF, Paul LD, Kraemer T, Maurer HH. Identification of cytochrome P450 enzymes involved in the metabolism of 4’-methoxy-alpha-pyrrolidinopropiophenone (MOPPP), a designer drug, in human liver microsomes. Xenobiotica 2003; 33:989-98.
Springer W, Hoppe T, Schmidt E, Baumeister R. A Caenorhabditis elegans Parkin mutant with altered solubility couples alpha-synuclein aggregation to proteotoxic stress. Hum Mol Genet 2005; 14:3407-23.
Sproule BA, Hazra M, Pollock BG. Desvenlafaxine succinate for major depressive disorder. Drugs Today 2008; 44:475-87.
Sproule BA, Naranjo CA, Brenmer KE, Hassan PC. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clin Pharmacokinet 1997; 33:454-71.
Sprovieri SR, Sens YA, Martini Filho D. Association between polymorphisms of the renin-angiotensin system and more severe histological forms of lupus nephritis. Clin Nephrol 2005; 64:20-7.
Spurdle AB, Goodwin B, Hodgson E et al. The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. Pharmacogenetics 2002; 12:355-66.
Spurdle M, Marquart L, McGuffog L et al. Common genetic variation at BARD1 is not associated with Breast cancer risk in BRCA1 or BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 2011; 20:1032-8.
Spurlock G, Williams J, McGuffin P et al. European multicentre association study of schizophrenia: a study of the DRD2 ser311-to-cys and DRD3 ser9-to-gly polymorphisms. Am J Med Genet 1998; 81:24-8.
Sravani PV, Babu NK, Gopal KV et al. Determination of oxidative stress in vitiligo by measuring superoxide dismutase and catalase levels in vitiliginous and non-vitiliginous skin. Indian J Dermatol Venereol Leprol 2009; 75:268-71.
Sreelekha TT, Rajesh M, Anil Kumar V, Madhavan J, Balaram P. CYP1A1m2 polymorphisms regulate estrogen and interleukin-6 in lung cancer. Mol Med Report 2010; 3:971-6.
Sreerama L, Sládek NE. Primary breast tumor levels of suspected molecular determinants of cellular sensitivity to cyclophosphamide, ifosfamide, and certain other anticancer agents as predictors of paired metastatic tumor levels of these determinants. Rational individualization of cancer chemotherapeutic regimens. Cancer Chemother Pharmacol 2001; 47:255-62.
Sridar C, Kent UM, Noon K et al. Differential inhibition of cytochromes P450 3A4 and 3A5 by the newly synthesized coumarin derivatives 7-coumarin propargyl ether and 7-(4-trifluoromethyl)coumarin propargyl ether. Drug Metab Dispos 2008; 36:2234-43.
Sridar C, Kent UM, Notley LM, Gillam EM, Hollenberg PF. Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther 2002; 301:945-52.
Sridar C, Snider NT, Hollenberg PF. Anandamide oxidation by wild-type and polymorphically expressed CYP2B6 and CYP2D6. Drug Metab Dispos 2011; 39:782-8.
Sridevi P, Senthilkumaran B. Cloning and differential expression of FOXL2 during ovarian development and recrudescence of the catfish, Clarias gariepinus. Gen Comp Endocrinol 2011. doi:10. 1016/j. ygcen. 2011. 08. 015.
Srinivas NR. Is there a place for drug combination strategies using clinical pharmacology attributes?-review of current trends in research. Curr Clin Pharmacol 2009; 4:220-8.
Srinivas NR. Baicalin, an emerging multi-therapeutic agent: pharmacodynamics, pharmacokinetics, and considerations from drug development perspectives. Xenobiotica 2010; 40:357-67.
Srinivasan S, Hanes MA, Dickens T et al. A mouse model for hereditary hemorrhagic telangiectasia (HHT) type 2. Hum Mol Genet 2003; 12:473-82.
Srinivasan SR, Li S, Chen W, Boerwinkle E, Berenson GS. R219K polymorphism of the ABCA1 gene and its modulation of the variations in serum high-density lipoprotein cholesterol and triglycerides related to age and adiposity in white versus black young adults. The Bogalusa heart study. Metabolism 2003; 52:930-4.
Srinivasan V, Pandi-Perumal SR, Cardinali DP, Poeggeler B, Hardeland R. Melatonin in Alzheimer’s disease and other neurodegenerative disorders. Behav Brain Funct 2006; 2:15.
Srinivasan V, Pandi-Perumal SR, Trahkt I et al. Melatonin and melatonergic drugs on sleep: possible mechanisms of action. Int J Neurosci 2009; 119:821-46.
Srirangam P, Vidya SJ. Modulation of the p-glycoproein-mediated intestinal secretion of glibenclamide: in vitro and in vivo assessments. J Young Pharm 2010; 2:379-83.
Srivastava A, Choudhuri G, Mittal B. CYP7A1 (-204 A>C; rs3808607 and -469 T>C; rs3824260) promoter polymorphisms and risk of gallbladder cancer in North Indian population. Metabolism 2010; 59:767-73.
Srivastava A, Pandey SN, Choudhuri G, Mittal B. CCR5 Delta32 polymorphism: associated with gallbladder cancer susceptibility. Scand J Immunol 2008; 67:516-22.
Srivastava A, Poonkuzhali B, Shaji RV et al. Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood 2004; 104:1574-7.
Srivastava DP, Woolfrey KM, Liu F, Brandon NJ, Penzes P. Estrogen receptor ß activity modulates synaptic signaling and structure. J Neurosci 2010; 30:13454-60.
Srivastava K, Srivastava A, Kumar A, Mittal B. Gallbladder cancer predisposition: a multigenic approach to DNA-repair, apoptotic and inflammatory pathway genes. PLoS One 2011. doi:10. 1371/journal. pone. 0016449.
Srivastava K, Srivastava A, Sharma KL, Mittal B. Candidate gene studies in gallbladder cancer: A systematic review and meta-analysis. Mutat Res 2011; 728:67-79.
Srivastava P, Helms PJ, Stewart D, Main M, Russell G. Association of CCR5Delta32 with reduced risk of childhood but not adult asthma. Thorax 2003; 58:222-6.
Srivastava S, Sithu SD, Vladykovskaya E et al. Oral exposure to acrolein exacerbates atherosclerosis in apoE-null mice. Atherosclerosis 2011; 215:301-8.
Srivastava V, Deshpande SN, Nimgaonkar VL, Lerer B, Thelma B. Genetic correlates of olanzapine-induced weight gain in schizophrenia subjects from north India: role of metabolic pathway genes. Pharmacogenomics 2008; 9:1055-68.
St Clair D, Rennie M, Slorach E, Norrman J, Yates C, Carothers A. Apolipoprotein E epsilon-4 allele is a risk factor for familial and sporadic presenile Alzheimer’s disease in both homozygote and heterozygote carries. J Med Genet 1995; 32:642-4.
St Germaine CG, Bogaty P, Boyer L, Hanley J, Engert JC, Brophy JM. Genetic polymorphisms and the cardiovascular risk of non-steroidal anti-inflammatory drugs. Am J Cardiol 2010; 105:1740-5.
St John’s wort and depression: slight efficacy at best, many drug interactions. Prescrire Int 2004; 13:187-92.
Staack RF, Paul LD, Schmid D, Roider G, Rolf B. Proof of a 1-(3-chlorophenyl)piperazine (mCPP) intake: use as adulterant of cocaine resulting in drug-drug interactions? J Chromatogr B Analyt Technol Biomed Life Sci 2007; 855:127-33.
Staack RF, Paul LD, Springer D, Kraemer T, Maurer HH. Cytochrome P450 dependent metabolism of the new designer drug 1-(3-trifluoromethylphenyl)piperazine (TFMPP). In vivo studies in Wistar and Dark Agouti rats as well as in vitro studies in human liver microsomes. Biochem Pharmacol 2004; 67:235-44.
Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clin Pharmacokinet 2010; 49:141-75.
Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II. Clin Pharmacokinet 2010; 49:207-21.
Stadel R, Yang J, Nalwalk JW, Phillips JG, Hough LB. High-affinity binding of [3H]cimetidine to a heme-containing protein in rat brain. Drug Metab Dispos 2008; 36:614-21.
Staels B. A review of bile acid sequestrants: potential mechanism(s) for glucose-lowering effects in type 2 diabetes mellitus. Postgrad Med 2009; 121(3 Suppl 1):25-30.
Stallhofer J, Denk GU, Glas J et al. Analysis of IL2/IL21 gene variants in cholestatic liver diseases reveals an association with primary sclerosing cholangitis. Digestion 2011; 84:29-35.
Stamatos NM, Liang F, Nan X et al. Differential expression of endogenous sialidases of human monocytes during cellular differentiation into macrophages. FEBS J 2005; 272:2545-56.
Stamer K, Vogel R, Thies E, MadelkowE, Mandelkow EM. Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhaces oxidative stress. J Cell Biol 2002; 156:1051-63.
Stamer UM, Lee EH, Rauers NI et al. CYP2D6- and CYP3A-dependent enantioselective plasma concentrations of ondansetron in postanesthesia care. Anesth Analg 2011; 113:48-54.
Stamer UM, Lehnen K, Höthker F et al. Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain 2003; 105:231-8.
Stamer UM, Musshoff F, Kobilay M, Madea B, Hoeft A, Stuber F. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes. Clin Pharmacol Ther 2007; 82:41-7.
Stamer UM, Stüber F, Muders T, Musshoff F. Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication. Anesth Analg 2008; 107:926-9.
Stamer UM, Zhang L, Stüber F. Personalized therapy in pain management: where do we stand? Pharmacogenomics 2010; 11:843-64.
Stamp LK, Chapman PT, O’Donnell JL et al. Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate. Pharmacogenet Genomics 2010; 20:367-76.
Stanford BJ, Stanford SC. Postoperative delirium indicating an adverse drug interaction involving the selective serotonin reuptake inhibitor, paroxetine? J Psychopharmacol 1999; 13:313-7.
Stanford JL, Just JJ, Gibbs M et al. Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res 1997; 57:1194-8.
Stankovic S, Majkic-Singh N. Genetic aspects of ischemic stroke: coagulation, homocysteine, and lipoprotein metabolism as potential risk factors. Crit Rev Clin Lab Sci 2010; 47:72-123.
Stanley LA, Horsburgh BC, Ross J, Scheer N, Wolf CR. Drug transporters: gatekeepers controlling access of xenobiotics to the cellular interior. Drug Metab Rev 2009; 41:27-65.
Stanulla M, Dynybil C, Bartels DB et al. The NQO1 C609T polymorphism is associated with risk of secondary malignant neoplasms after treatment for childhood acute lymphoblastic leukemia: a matched-pair analysis from the ALL-BFM study group. Haematologica 2007; 92:1581-2.
Stanzione R, di Angelantonio E, Evangelista A et al. Beta2-adrenergic receptor gene polymorphisms and risk of ischemic stroke. Am J Hypertens 2007; 20:657-62.
Stapelbroek JM, van Erpecum KJ, Klomp LW, Houwen RH. Liver disease associated with canalicular transport defects: current and future therapies. J Hepatol 2010; 52:258-71.
Stapleton HM, Kelly SM, Pei R, Letcher RJ, Gunsch C. Metabolism of polybrominated diphenyl ethers (PBDEs) by human hepatocytes in vitro. Environ Health Perspect 2009; 117:197-202.
Stark K, Reinhard W, Grassl M et al. Common polymorphisms influencing serum uric acid levels contribute to susceptibility to gout, but not to coronary artery disease. PLoS One 2009. doi:10. 1371/journal. pone. 0007729.
Starlard-Davenport A, Lyn-Cook B, Radominska-Pandya A. Novel identification of UDP-glucuronosyltransferase 1A10 as an estrogen-regulated target gene. Steroids 2008; 73:139-47.
Starlard-Davenport A, Lyn-Cook B, Radominska-Pandya A. Identification of UDP-glucuronosyltransferase 1A10 in non-malignant and malignant human breast tissues. Steroids 2008; 73:611-20.
Starr JR, Chen C, Doody DR et al. Risk of testicular germ cell cancer in relation to variation in maternal and offspring cytochrome p450 genes involved in catechol estrogen metabolism. Cancer Epidemiol Biomarkers Prev 2005; 14:2183-90.
States JC, Srivastava S, Chen Y, Barchowsky A. Arsenic and cardiovascular disease. Toxicol Sci 2009; 107:312-23.
Stayoussef M, Benmansour J, Al-Irhayim AQ et al. Autoimmune type 1 diabetes genetic susceptibility encoded by human leukocyte antigen DRB1 and DQB1 genes in Tunisia. Clin Vaccine Immunol 2009; 16:1146-50.
Stayoussef M, Benmansour J, Al-Jenaidi FA et al. Influence of common and specific HLA-DRB1/DQB1 haplotypes on genetic susceptibilities of three distinct Arab populations to type 1 diabetes. Clin Vaccine Immunol 2009; 16:136-8.
Stayoussef M, Benmansour J, Al-Jenaidi FA et al. Identification of specific tumor necrosis factor-α-susceptible and -protective haplotypes associated with the risk of type 1 diabetes. Eur Cytokine Netw 2010; 21:285-91.
Stayrook KR, Rogers PM, Savkur RS et al. Regulation of human 3 alpha-hydroxysteroid dehydrogenase (AKR1C4) expression by the liver X receptor alpha. Mol Pharmacol 2008; 73:607-12.
Stearns RA, Chakravarty PK, Chen R, Chiu SH. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. Drug Metab Dispos 1995; 23:207-15.
Stearns V, Davidson NE, Flockhart DA. Pharmacogenetics in the treatment of breast cancer. Pharmacogenomics J 2004; 4:143-53.
Stearns V, Johnson MD, Rae JM et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003; 95:1758-64.
Stec DE, Roman RJ, Flasch A, Rieder MJ. Functional polymorphism in human CYP4F2 decreases 20-HETE production. Physiol Genomics 2007; 30:74-81.
Stedman C, Robertson G, Coulter S, Liddle C. Feed-forward regulation of bile acid detoxification by CYP3A4: studies in humanized transgenic mice. J Biol Chem 2004; 279:11336-43.
Stedman CA, Begg EJ, Kennedy MA, Roberts R, Wilkinson TJ. Cytochrome P450 2D6 genotype does not predict SSRI (fluoxetine or paroxetine) induced hyponatraemia. Hum Psychopharmacol 2002; 17:187-90.
Steeghs N, Gelderblom H, Wessels J et al. Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors. Invest New Drugs 2011; 29:137-43.
Steeghs N, Mathijssen RH, Wessels JA et al. Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib. Invest New Drugs 2011; 29:953-62.
Steen NE, Tesli M, Kähler AK et al. SRD5A2 is associated with increased cortisol metabolism in schizophrenia spectrum disorders. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34:1500-6.
Steen VM, Løvlie R, Osher Y, Belmaker RH, Berle JO, Gulbrandsen AK. The polymorphic inositol polyphosphate 1-phosphatase gene as a candidate for pharmacogenetic prediction of lithium-responsive manic-depressive illness. Pharmacogenetics 1998; 8:259-68.
Steen VM, Molven A, Aarskog NK, Gulbrandsen AK. Homologous unequal cross-over involving a 2. 8 kb direct repeat as a mechanism for the generation of allelic variants of human cytochrome P450 CYP2D6 gene. Hum Mol Genet 1995; 4:2251-7.
Steer EJ, Cross NC. Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor Beta. Acta Haematol 2002; 107:113-22.
Stefan N, Thamer C, Staiger H et al. Genetic variations in PPARD and PPARGC1A determine mitochondrial function and change in aerobic physical fitness and insulin sensitivity during lifestyle intervention. J Clin Endocrinol Metab 2007; 92:1827-33.
Stefanachi A, Favia AD, Nicolotti O et al. Design, synthesis, and biological evaluation of imidazolyl derivatives of 4,7-disubstituted coumarins as aromatase inhibitors selective over 17-α-hydroxylase/C17-20 lyase. J Med Chem 2011; 54:1613-25.
Stefanova E, Blennow K, Almkvist O, Hellström-Lindahl E, Nordberg A. Cerebral glucose metabolism, cerebrospinal fluid-beta-amyloid1-42 (CSF-Abeta42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients. Neurosci Lett 2003; 338:159-63.
Stefansson OA, Jonasson JG, Johannsson OT et al. Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes. Breast Cancer Res 2009; 11:47.
Steffens S, Veillard NR, Arnaud C et al. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 2005; 434:782-6.
Steffensen KD, Waldstrøm M, Brandslund I, Jakobsen A. The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer. Gynecol Oncol 2010; 117:109-16.
Stegbauer J, Potthoff SA, Quack I et al. Chronic treatment with angiotensin-(1-7) improves renal endothelial dysfunction in apolipoproteinE deficient mice. Br J Pharmacol 2011; 163:974-83.
Stegmann AP, Honders MW, Hagemeijer A, Hoebee B, Willemze R, Landegent JE. In vitro-induced resistance to the deoxycytidine analogues cytarabine (AraC) and 5-aza-2’-deoxycytidine (DAC) in a rat model for acute myeloid leukemia is mediated by mutations in the deoxycytidine kinase (dck) gene. Ann Hematol 1995; 71:41-7.
Stehle S, Kirchheiner J, Lazar A, Fuhr U. Pharmacogenetics of oral anticoagulants: a basis for dose individualization. Clin Pharmacokinet 2008; 47:565-94.
Steidl C, Telenius A, Shah SP et al. Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome. Blood 2010; 116:418-27.
Steimer W, Zöpf K, von Amelunxen S et al. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. Clin Chem 2004; 50:1623-33.
Steimer W, Zöpf K, von Amelunxen S et al. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin Chem 2005; 51:376-85.
Stein MA, McGough JJ. The pharmacogenomic era: promise for personalizing attention deficit hyperactivity disorder therapy. Child Adolesc Psychiatr Clin N Am 2008; 17:475-90, xi-xii.
Stein S, Lohmann C, Handschin C et al. ApoE-/- PGC-1α-/- mice display reduced IL-18 levels and do not develop enhanced atherosclerosis. PLoS One 2010. doi:10. 1371/journal. pone. 0013539.
Stein S, Matter CM. Protective roles of SIRT1 in atherosclerosis. Cell Cycle 2011; 10:640-7.
Steinacher L, Vandel P, Zullino DF, Eap CB, Brawand-Amey M, Baumann P. Carbamazepine augmentation in depressive patients non-responding to citalopram: a pharmacokinetic and clinical pilot study. Eur Neuropsychopharmacol 2002; 12:255-60.
Steinbach D, Wittig S, Cario G et al. The multidrug resistance-associated protein 3 (MRP3) is associated with a poor outcome in childhood ALL and may account for the worse prognosis in male patients and T-cell immunophenotype. Blood 2003; 102:4493-8.
Steinberger D, Trübenbach J, Zirn B, Leube B, Wildhardt G, Müller U. Utility of MLPA in deletion analysis of GCH1 in dopa-responsive dystonia. Neurogenetics 2007; 8:51-5.
Steiner H, Winkler E, Edbauer D et al. PEN-2 is an integral component of the gamma-secretase complex required for coordinated expression of presenilin and nicastrin. J Biol Chem 2002; 277:39062-5.
Steinke JW, Culp JA. Leukotriene synthesis inhibitors versus antagonists: the pros and cons. Curr Allergy Asthma Rep 2007; 7:126-33.
Steinkellner H, Rabot S, Freywald C et al. Effects of Cruciferous vegetables and their constituents on drug metabolizing enzymes involved in the bioactivation of DNA-reactive dietary carcinogens. Mutat Res 2001; 480-1:285-97.
Stejskalova L, Pavek P. The function of cytochrome P450 1A1 enzyme (CYP1A1) and aryl hydrocarbon receptor (AhR) in the placenta. Curr Pharm Biotechnol 2011; 12:715-30.
Stejskalova L, Vecerova L, Peréz LM et al. Aryl hydrocarbon receptor (AHR) and aryl hydrocarbon nuclear translocator (ARNT) expression in human and rat placentas and transcription activity in human trophoblast cultures. Toxicol Sci 2011; 123:26-36.
Stelmach I, Jerzynska J, Kuna P. A randomized, double-blind trial of the effect of treatment with montelukast on bronchial hyperresponsiveness and serum eosinophilic cationic protein (ECP), soluble interleukin 2 receptor (sIL-2R), IL-4, and soluble intercellular adhesion molecule 1 (sICAM-1) in children with asthma. J Allergy Clin Immunol 2002; 109:257-63.
Stempak D, Bukaveckas BL, Linder M, Koren G, Baruchel S. Cytochrome P450 2C9 genotype: impact on celecoxib safety and pharmacokinetics in a pediatric patient. Clin Pharmacol Ther 2005; 78:309-10.
Sten T, Finel M, Ask B, Rane A, Ekström L. Non-steroidal anti-inflammatory drugs interact with testosterone glucuronidation. Steroids 2009; 74:971-7.
Stephan PL, Jaquenoud Sirot E, Mueller B, Eap CB, Baumann P. Adverse drug reactions following nonresponse in a depressed patient with CYP2D6 deficiency and low CYP 3A4/5 activity. Pharmacopsychiatry 2006; 39:150-2.
Stephens HA. HLA and other gene associations with dengue disease severity. Curr Top Microbiol Immunol 2010; 338:99-114.
Stephenson J, Mufti GJ, Yoshida Y. Myelodysplastic syndromes: from morphology to molecular biology. Part II. The molecular genetics of myelodysplasia. Int J Hematol 1993; 57:99-112.
Stern RH, Smithers JA, Olson SC. Atorvastatin does not produce a clinically significant effect on the pharmacokinetics of terfenadine. J Clin Pharmacol 1998; 38:753-7.
Sternieri E, Coccia CP, Pinetti D, Ferrari A. Pharmacokinetics and interactions of headache medications, part I: introduction, pharmacokinetics, metabolism and acute treatments. Expert Opin Drug Metab Toxicol 2006; 2:961-79.
Sternieri E, Coccia CP, Pinetti D, Guerzoni S, Ferrari A. Pharmacokinetics and interactions of headache medications, part II: prophylactic treatments. Expert Opin Drug Metab Toxicol 2006; 2:981-1007.
Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. Ann Pharmacother 2008; 42:1290-7.
Stevens JC. New perspectives on the impact of cytochrome P450 3A expression for pediatric pharmacology. Drug Discov Today 2006; 11:440-5.
Stevens JC, Domanski TL, Harlow GR, White RB, Orton E, Halpert JR. Use of the steroid derivative RPR 106541 in combination with site-directed mutagenesis for enhanced cytochrome P-450 3A4 structure/function analysis. J Pharmacol Exp Ther 1999; 290:594-602.
Stevens JC, Hines RN, Gu C et al. Developmental expression of the major human hepatic CYP3A enzymes. J Pharmacol Exp Ther 2003; 307:573-82.
Stevens JC, Marsh SA, Zaya MJ et al. Developmental changes in human liver CYP2D6 expression. Drug Metab Dispos 2008; 36:1587-93.
Stevens VL, Bierut LJ, Talbot JT et al. Nicotinic receptor gene variants influence susceptibility to heavy smoking. Cancer Epidemiol Biomarkers Prev 2008; 17:3517-25.
Stevnsner T, Muftuoglu M, Aamann MD, Bohr VA. The role of Cockayne Syndrome group B (CSB) protein in base excision repair and aging. Mech Ageing Dev 2008; 129:441-8.
Stewart JD, Horvath R, Baruffini E et al. Polymerase γ gene POLG determines the risk of sodium valproate-induced liver toxicity. Hepatology 2010; 52:1791-6.
Stewart NA, Buch SC, Conrads TP, Branch RA. A UPLC-MS/MS assay of the “Pittsburgh cocktail”: six CYP probe-drug/metabolites from human plasma and urine using stable isotope dilution. Analyst 2011; 136:605-12.
Stiborová M, Bieler CA, Wiessler M, Frei E. The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts. Biochem Pharmacol 2001; 62:1675-84.
Stiborova M, Frei E, Arlt VM, Schmeiser HH. The role of biotransformation enzymes in the development of renal injury and urothelial cancer caused by aristolochic acid: urgent questions and difficult answers. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2009; 153:5-11.
Stiborová M, Martínek V, Rýdlová H, Hodek P, Frei E. Sudan I is a potential carcinogen for humans: evidence for its metabolic activation and detoxication by human recombinant cytochrome P450 1A1 and liver microsomes. Cancer Res 2002; 62:5678-84.
Stiborová M, Sejbal J, Borek-Dohalská L et al. The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine N2-oxide. Cancer Res 2004; 64:8374-80.
Stice E, Spoor S, Bohon C, Small DM. Relation between obesity and blunted striatal response to food is moderated by TaqIA A1 allele. Science 2008; 322:449-52.
Stickel F, Seitz HK. Alcoholic steatohepatitis. Best Pract Res Clin Gastroenterol 2010; 24:683-93.
Sticozzi C, Pecorelli A, Belmonte G, Valacchi G. Cigarette smoke affects ABCAl expression via liver X receptor nuclear translocation in human keratinocytes. Int J Mol Sci 2010; 11:3375-86.
Sticherling C, Schaer BA, Ammann P, Maeder M, Osswald S. Methadone-induced Torsade de pointes tachycardias. Swiss Med Wkly 2005; 135:282-5.
Stienstra Y, van der Werf TS, Oosterom E et al. Susceptibility to Buruli ulcer is associated with the SLC11A1 (NRAMP1) D543N polymorphism. Genes Immun 2006; 7:185-9.
Stingl JC, Esslinger C, Tost H et al. Genetic variation in CYP2D6 impacts neural activation during cognitive tasks in humans. Neuroimage 2011. doi:10. 1016/j. neuroimage. 2011. 07. 052.
Stingl JC, Parmar S, Huber-Wechselberger A et al. Impact of CYP2D6*4 genotype on progression free survival in tamoxifen breast cancer treatment. Curr Med Res Opin 2010; 26:2535-42.
Stocco G, Cheok MH, Crews KR et al. Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther 2009; 85:164-72.
Stocco G, Martelossi S, Barabino A et al. Glutathione-S-transferase genotypes and the adverse effects of azathioprine in young patients with inflammatory bowel disease. Inflamm Bowel Dis 2007; 13:57-64.
Stocco G, Martelossi S, Sartor F et al. Prevalence of methylenetetrahydrofolate reductase polymorphisms in young patients with inflammatory bowel disease. Dig Dis Sci 2006; 51:474-9.
Stock JL, Shinjo K, Burkhardt J et al. The prostaglandin E2 EP1 receptor mediates pain perception and regulates blood pressure. J Clin Invest 2001; 107:325-31.
Stoehlmacher J, Park DJ, Zhang W et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 2004; 91:344-54.
Stoffel M, Duncan SA. The maturity-onset diabetes of the young (MODY1) transcription factor HNF4alpha regulates expression of genes required for glucose transport and metabolism. Proc Natl Acad Sci USA 1997; 94:13209-14.
Stojanov S, Dejaco C, Lohse P et al. Clinical and functional characterisation of a novel TNFRSF1A c. 605T>A/V173D cleavage site mutation associated with tumour necrosis factor receptor-associated periodic fever syndrome (TRAPS), cardiovascular complications and excellent response to etanercept treatment. Ann Rheum Dis 2008; 67:1292-8.
Stolzenberg DS, Rissman EF. Oestrogen-independent, experience-induced maternal behaviour in female mice. J Neuroendocrinol 2011; 23:345-54.
Stoppoloni D, Salvatori L, Biroccio A et al. Aromatase inhibitor exemestane has antiproliferative effects on human mesothelioma cells. J Thorac Oncol 2011; 6:583-91.
Storch J, Xu Z. Niemann-Pick C2 (NPC2) and intracellular cholesterol trafficking. Biochim Biophys Acta 2009; 1791:671-8.
Storme T, Deroussent A, Mercier L et al. New ifosfamide analogs designed for lower associated neurotoxicity and nephrotoxicity with modified alkylating kinetics leading to enhanced in vitro anticancer activity. J Pharmacol Exp Ther 2009; 328:598-609.
Störmer E, Brockmöller J, Roots I, Schmider J. Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug perazine in vitro. Psychopharmacology 2000; 151:312-20.
Störmer E, von Moltke LL, Shader RI, Greenblatt DJ. Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab Dispos 2000; 28:1168-75.
Storr M, Emmerdinger D, Diegelmann J et al. The cannabinoid 1 receptor (CNR1) 1359 G/A polymorphism modulates susceptibility to ulcerative colitis and the phenotype in Crohn’s disease. PLoS One 2010. doi:10. 1371/journal. pone. 0009453.
Storvik M, Huuskonen P, Kyllönen T et al. Aflatoxin B1-a potential endocrine disruptor-up-regulates CYP19A1 in JEG-3 cells. Toxicol Lett 2011; 202:161-7.
Stoutenburg JP, Raftopoulos H. Antiemetic studies on the NK1 receptor antagonist aprepitant. J Natl Compr Canc Netw 2004; 2:491-7.
Stowasser M. Update in primary aldosteronism. J Clin Endocrinol Metab 2009; 94:3623-30.
Stowasser M, Taylor PJ, Pimenta E, Ahmed AH, Gordon RD. Laboratory investigation of primary aldosteronism. Clin Biochem Rev 2010; 31:39-56.
Strack DK, Leckband SG, Meyer JM. Antipsychotic prescribing practices following withdrawal of concomitant carbamazepine. J Psychiatr Pract 2009; 15:442-8.
Strack I, Schulte S, Varnholt H et al. β-Adrenoceptor blockade in sclerosing cholangitis of Mdr2 knockout mice: antifibrotic effects in a model of nonsinusoidal fibrosis. Lab Invest 2011; 91:252-61.
Strange RC, Ellison T, Ichii-Jones F et al. Cytochrome P450 CYP2D6 genotypes: association with hair colour, Breslow thickness and melanocyte stimulating hormone receptor alleles in patients with malignant melanoma. Pharmacogenetics 1999; 9:269-76.
Strange RC, Ramachandran S, Zeegers MP et al. The Multiple Sclerosis Severity Score: associations with MC1R single nucleotide polymorphisms and host response to ultraviolet radiation. Mult Scler 2010; 16:1109-16.
Straser A, Filipič M, Zegura B. Genotoxic effects of the cyanobacterial hepatotoxin cylindrospermopsin in the HepG2 cell line. Arch Toxicol 2011. doi:10. 1007/s00204-011-0716-z.
Strasky Z, Vecerova L, Rathouska J et al. Cholesterol effects on endoglin and its downstream pathways in ApoE/LDLR double knockout mice. Circ J 2011; 75:1747-55.
Strassburg CP, Manns MP, Tukey RH. Differential down-regulation of the UDP-glucuronosyltransferase 1A locus is an early event in human liver and biliary cancer. Cancer Res 1997; 57:2979-85.
Strassburg CP, Oldhafer K, Manns MP, Tukey RH. Differential expression of the UGT1A locus in human liver, biliary, and gastric tissue: identification of UGT1A7 and UGT1A10 transcripts in extrahepatic tissue. Molec Pharm 1997; 52:212-20.
Stratakis CA, Tichomirowa MA, Boikos S et al. The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes. Clin Genet 2010; 78:457-63.
Straub RE, Jiang Y, MacLean CJ et al. Genetic variation in the 6p22. 3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am J Hum Genet 2002; 71:337-48.
Strauch K, Lutz U, Bittner N, Lutz WK. Dose-response relationship for the pharmacokinetic interaction of grapefruit juice with dextromethorphan investigated by human urinary metabolite profiles. Food Chem Toxicol 2009; 47:1928-35.
Strautnieks SS, Bull LN, Knisely AS et al. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet 1998; 20:233-8.
Strautnieks SS, Thompson RJ, Gardiner RM, Chung E. A novel splice-site mutation in the gamma subunit of the epithelial sodium channel gene in three pseudohypoaldosteronism type 1 families. Nat Genet 1996; 13:248-50.
Strawbridge RJ, Kärvestedt L, Li C et al. GHR exon 3 polymorphism: association with type 2 diabetes mellitus and metabolic disorder. Growth Horm IGF Res 2007; 17:392-8.
Strazzullo P, Iacone R, Siani A et al. Relationship of the Trp64Arg polymorphism of the beta3-adrenoceptor gene to central adiposity and high blood pressure: interaction with age. Cross-sectional and longitudinal findings of the Olivetti Prospective Heart Study. J Hypertens 2001; 19:399-406.
Strehlau R, Martens L, Coovadia A et al. Absence seizures associated with efavirenz initiation. Pediatr Infect Dis J 2011; 30:1001-3.
Streit M, Göggelmann C, Dehnert C et al. Cytochrome P450 enzyme-mediated drug metabolism at exposure to acute hypoxia (corresponding to an altitude of 4,500 m). Eur J Clin Pharmacol 2005; 61:39-46.
Stresser DM, Blanchard AP, Turner SD et al. Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. Drug Metab Dispos 2000; 28:1440-8.
Stresser DM, Broudy MI, Ho T et al. Highly selective inhibition of human CYP3Aa in vitro by azamulin and evidence that inhibition is irreversible. Drug Metab Dispos 2004; 32:105-12.
Stresser DM, Kupfer D. Catalytic characteristics of CYP3A4: requirement for a phenolic function in ortho hydroxylation of estradiol and mono-O-demethylated methoxychlor. Biochemistry 1997; 36:2203-10.
Stresser DM, Kupfer D. Prosubstrates of CYP3A4, the major human hepatic cytochrome P450: transformation into substrates by other P450 isoforms. Biochem Pharmacol 1998; 55:1861-71.
Stresser DM, Mason AK, Perloff ES et al. Differential time- and NADPH-dependent inhibition of CYP2C19 by enantiomers of fluoxetine. Drug Metab Dispos 2009; 37:695-8.
Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL. Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos 2002; 30:845-52.
Stride A, Hattersley AT. Different genes, different diabetes: lessons from maturity-onset diabetes of the young. Ann Med 2002; 34:207-16.
Striepens N, Scheef L, Wind A et al. Interaction effects of subjective memory impairment and ApoE4 genotype on episodic memory and hippocampal volume. Psychol Med 2011; 2:1-10.
Stringer RA, Strain-Damerell C, Nicklin P, Houston JB. Evaluation of recombinant cytochrome P450 enzymes as an in vitro system for metabolic clearance predictions. Drug Metab Dispos 2009; 37:1025-34.
Stritesky GL, Muthukrishnan R, Sehra S et al. The transcription factor STAT3 is required for T helper 2 cell development. Immunity 2011; 34:39-49.
Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci USA 1995; 92:4724-7.
Strittmatter WJ, Saunders AM, Schmechel D et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allelein late-onset familial Alzheimer disease. Proc Nat Acad Sci USA 1993; 90:1977-81.
Strittmatter WJ, Saunders AM, Schmechel D et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993; 90:8098-102.
Strobush L, Berg R, Cross D et al. Dietary intake in the personalized medicine research project: a resource for studies of gene-diet interaction. Nutr J 2011; 10:13.
Stroeve JH, Brufau G, Stellaard F, Gonzalez FJ, Staels B, Kuipers F. Intestinal FXR-mediated FGF15 production contributes to diurnal control of hepatic bile acid synthesis in mice. Lab Invest 2010; 90:1457-67.
Stroh M, Dishy V, Radziszewski W et al. The effects of multiple doses of rolofylline on the single-dose pharmacokinetics of midazolam in healthy subjects. Am J Ther 2010; 17:53-60.
Strolin Benedetti M, Baltes EL. Drug metabolism and disposition in children. Fundam Clin Pharmacol 2003; 17:281-99.
Strug LJ, Suresh R, Fyer AJ et al. Panic disorder is associated with the serotonin transporter gene (SLC6A4) but not the promoter region (5-HTTLPR). Mol Psychiatry 2010; 15:166-76.
Struhl G, Greenwald I. Presenilin is required for activity and nuclear access of Notch in Drosophila. Nature 1999; 398:522-5.
Strushkevich N, Usanov SA, Plotnikov AN, Jones G, Park HW. Structural analysis of CYP2R1 in complex with vitamin D3. J Mol Biol 2008; 380:95-106.
Studzinski CM, Araujo JA, Milgram NW. The canine model of human cognitive aging and dementia: pharmacological validity of the model for assessment of human cognitive-enhancing drugs. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29:489-98.
Stum M, Girard E, Bangratz M et al. Evidence of a dosage effect and a physiological endplate acetylcholinesterase deficiency in the first mouse models mimicking Schwartz-Jampel syndrome neuromyotonia. Hum Mol Genet 2008; 17:3166-79.
Stumm RK, Zhou C, Schulz S et al. Somatostatin receptor 2 is activated in cortical neurons and contributes to neurodegeneration after focal ischemia. J Neurosci 2004; 24:11404-15.
Sturchler-Pierrat C, Abramowski D, Duke M et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA 1997; 94:13287-92.
Sturek JM, Castle JD, Trace AP et al. An intracellular role for ABCG1-mediated cholesterol transport in the regulated secretory pathway of mouse pancreatic beta cells. J Clin Invest 2010; 120:2575-89.
Sturgess JE, George TP, Kennedy JL, Heinz A, Müller DJ. Pharmacogenetics of alcohol, nicotine and drug addiction treatments. Addict Biol 2011; 16:357-76.
Styblo M, del Razo LM, Vega L et al. Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells. Arch Toxicol 2000; 74:289-99.
Styles JA, Davies A, Davies R, White IN, Smith LL. Clastogenic and aneugenic effects of tamoxifen and some of its analogues in hepatocytes from dosed rats and in human lymphoblastoid cells transfected with human P450 cDNAs (MCL-5 cells). Carcinogenesis 1997; 18:303-13.
Styles JA, Davies A, Lim CK et al. Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis 1994; 15:5-9.
Su B, Cai X, Hong Y, Chen S. COX-2 inhibitor nimesulide analogs are aromatase suppressors in breast cancer cells. J Steroid Biochem Mol Biol 2010; 122:232-8.
Su C, Picard P, Rathbone MP, Jiang S. Guanosine-induced decrease in side population of lung cancer cells: lack of correlation with ABCG2 expression. J Biol Regul Homeost Agents 2010; 24:19-25.
Su CR, Ueng YF, Dung NX, Vijaya Bhaskar Reddy M, Wu TS. Cytochrome P3A4 inhibitors and other constituents of Fibraurea tinctoria. J Nat Prod 2007; 70:1930-3.
Su CS, Chang WN, Huang SH et al. Cerebrotendinous xanthomatosis patients with and without parkinsonism: clinical characteristics and neuroimaging findings. Mov Disord 2010; 25:452-8.
Su EJ, Fredriksson L, Geyer M et al. Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med 2008; 14:731-7.
Su HI, Sammel MD, Velders L et al. Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors. Fertil Steril 2010; 94:645-54.
Su J, Ruan XC, Zhang YH, She SZ, Xu LX. Effects of morphine and pethidine on the expression of P-glycoprotein in mouse brain microvascular endothelial cells. Nan Fang Yi Ke Da Xue Xue Bao 2010; 30:1824-6.
Su JS, Tsai TF, Chang HM, Chao KM, Su TS, Tsai SF. Distant HNF1 site as a master control for the human class I alcohol dehydrogenase gene expression. J Biol Chem 2006; 281:19809-21.
Su L, Mruk DD, Lee WM, Cheng CY. Drug transporters and blood-testis barrier function. J Endocrinol 2011; 209:337-51.
Su S, Chen J, Zhao J et al. Angiotensin II type I receptor gene and myocardial infarction: tagging SNPs and haplotype based association study. The Beijing atherosclerosis study. Pharmacogenetics 2004; 14:673-81.
Su X, Lee L, Li X et al. Association between angiotensinogen, angiotensin II receptor genes, and blood pressure response to an angiotensin-converting enzyme inhibitor. Circulation 2007; 115:725-32.
Su X, Yee LJ, Im K et al. Association of single nucleotide polymorphisms in interferon signaling pathway genes and interferon-stimulated genes with the response to interferon therapy for chronic hepatitis C. J Hepatol 2008; 49:184-91.
Suarez-Kurtz G, Genro JP, de Moraes MO et al. Global pharmacogenomics: Impact of population diversity on the distribution of polymorphisms in the CYP2C cluster among Brazilians. Pharmacogenomics J 2010. doi:10. 1038/tpj. 2010. 89.
Suarez-Kurtz G, Perini JA, Silva-Assunção E, Struchiner CJ. Relative contribution of VKORC1, CYP2C9, and INR response to warfarin stable dose. Blood 2009; 113:4125-6.
Subauste AR, Elliott B, Das AK, Burant CF. A role for 1-acylglycerol-3-phosphate-O-acyltransferase-1 in myoblast differentiation. Differentiation 2010; 80:140-6.
Subbaramaiah K, Howe LR, Bhardwaj P et al. Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res 2011; 4:329-46.
Subbaramaiah K, Hudis CA, Dannenberg AJ. The prostaglandin transporter regulates adipogenesis and aromatase transcription. Cancer Prev Res 2011; 4:194-206.
Subbiah RN, Gollob MH, Gula LJ et al. Torsades de pointes during complete atrioventricular block: Genetic factors and electrocardiogram correlates. Can J Cardiol 2010; 26:208-12.
Subehan S, Kadota S, Tezuka Y. In vitro mechanism-based inactivation of cytochrome P450 3A4 by a new constituent of Cinnamomum burmani. Planta Med 2008; 74:1474-80.
Subehan, Usia T, Iwata H, Kadota S, Tezuka Y. Mechanism-based inhibition of CYP3A4 and CYP2D6 by Indonesian medicinal plants. J Ethnopharmacol 2006; 105:449-55.
Subehan, Usia T, Kadota S, Tezuka Y. Constituents of Zingiber aromaticum and their CYP3A4 and CYP2D6 inhibitory activity. Chem Pharm Bull 2005; 53:333-5.
Subehan, Usia T, Kadota S, Tezuka Y. Mechanism-based inhibition of human liver microsomal cytochrome P450 2D6 (CYP2D6) by alkamides of Piper nigrum. Planta Med 2006; 72:527-32.
Subehan, Zaidi SF, Kadota S, Tezuka Y. Inhibition on human liver cytochrome P450 3A4 by constituents of fennel (Foeniculum vulgare): identification and characterization of a mechanism-based inactivator. J Agric Food Chem 2007; 55:10162-7.
Subrahmanyam V, Renwick AB, Walters DG et al. Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes. Drug Metab Dispos 2001; 29:1146-55.
Subrahmanyam V, Renwick AB, Walters DG, Price RJ, Tonelli AP, Lake BG. Metabolism of a novel phosphodiesterase-IV inhibitor (V11294) by human hepatic cytochrome P450 forms. Xenobiotica 2002; 32:521-34.
Subramanian M, Low M, Locuson CW, Tracy TS. CYP2D6-CYP2C9 protein-protein interactions and isoform-selective effects on substrate binding and catalysis. Drug Metab Dispos 2009; 37:1682-9.
Subramanian M, Tam H, Zheng H, Tracy TS. CYP2C9 – CYP3A4 protein-protein interactions: Role of the hydrophobic N-terminus. Drug Metab Dispos 2010; 38:1003-9.
Suceveanu AI, Suceveanu A, Voinea F, Mazilu L, Mixici F, Adam T. Introduction of cytogenetic tests in colorectal cancer screening. J Gastrointestin Liver Dis 2009; 18:33-8.
Such E, Cervera J, Terpos E et al. CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma. Haematologica 2011; 96:1557-9.
Suchankova P, Henningsson S, Olsson M et al. Association between the AGTR1 polymorphism +1166A>C and serum levels of high-sensitivity C-reactive protein. Regul Pept 2009; 152:28-32.
Suda K, Tomizawa K, Mitsudomi T. Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev 2010; 29:49-60.
Suda N, Shibata H, Kurihara I et al. Coactivation of SF-1-mediated transcription of steroidogenic enzymes by Ubc9 and PIAS1. Endocrinology 2011; 152:2266-77.
Sudchada P, Oo-puthinan S, Kerdpin O, Saelim N. ABCB1 gene expression in peripheral blood mononuclear cells in healthy Thai males and females. Genet Mol Res 2010; 9:1177-85.
Sueyasu M, Fujito K, Shuto H, Mizokoshi T, Kataoka Y, Oishi R. Protein binding and the metabolism of thiamylal enantiomers in vitro. Anesth Analg 2000; 91:736-40.
Sueyoshi T, Kawamoto T, Zelko I, Honkakoski P, Negishi M. The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene. J Biol Chem 1999; 274:6043-6.
Sueyoshi T, Negishi M. Phenobarbital response elements of cytochrome P450 genes and nuclear receptors. Annu Rev Pharmacol Toxicol 2001; 41:123-43.
Sugahara H, Maebara C, Ohtani H et al. Effect of smoking and CYP2D6 polymorphisms on the extent of fluvoxamine-alprazolam interaction in patients with psychosomatic disease. Eur J Clin Pharmacol 2009; 65:699-704.
Sugai T, Suzuki Y, Sawamura K, Fukui N, Inoue Y, Someya T. The effect of 5-hydroxytryptamine 3A and 3B receptor genes on nausea induced by paroxetine. Pharmacogenomics J 2006; 6:351-6.
Sugatani J, Mizushima K, Osabe M et al. Transcriptional regulation of human UGT1A1 gene expression through distal and proximal promoter motifs: implication of defects in the UGT1A1 gene promoter. Naunyn Schmiedebergs Arch Pharmacol 2008; 377:597-605.
Sugatani J, Osabe M, Kurosawa M, Kitamura N, Ikari A, Miwa M. Induction of UGT1A1 and CYP2B6 by an antimitogenic factor in HepG2 cells is mediated through suppression of cyclin-dependent kinase 2 activity: cell cycle-dependent expression. Drug Metab Dispos 2010; 38:177-86.
Sugatani J, Yamakawa K, Tonda E et al. The induction of human UDP-glucuronosyltransferase 1A1 mediated through a distal enhancer module by flavonoids and xenobiotics. Biochem Pharmacol 2004; 67:989-1000.
Sugatani J, Yamakawa K, Yoshinari K et al. Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia. Biochem Biophys Res Commun 2002; 292:492-7.
Sugawara M, Okamoto K, Kadowaki T, Kusano K, Fukamizu A, Yoshimura T. The expressions of Cytochrome P450, UDP-glucuronosyltranferase and Transporter genes in monolayer carcinoma cells change in subcutaneous tumors grown as xenografts in immunodeficient nude mice. Drug Metab Dispos 2010; 38:526-33
Sugaya K, Igarashi M, Kojima Y, Tsubata M, Nagaoka I. Evaluation of the effect of flavangenol on serum lipid peroxide levels and development of atherosclerosis in spontaneously hyperlipidemic B6. KOR-Apoeshl mice. Int J Mol Med 2011; 27:33-8.
Sugie M, Asakura E, Zhao YL et al. Possible involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin. Antimicrob Agents Chemother 2004; 48:809-14.
Sugimoto K, Araki N, Ohmori M et al. Interaction between grapefruit juice and hypnotic drugs: comparison of triazolam and quazepam. Eur J Clin Pharmacol 2006; 62:209-15.
Sugimoto K, Ohmori M, Tsuruoka S et al. Different effects of St John’s wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 2001; 70:518-24.
Sugimoto M, Furuta T, Shirai N et al. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther 2004; 76:290-301.
Sugimoto M, Furuta T, Shirai N et al. Treatment strategy to eradicate Helicobacter pylori infection: impact of pharmacogenomics-based acid inhibition regimen and alternative antibiotics. Expert Opin Pharmacother 2007; 8:2701-17.
Sugimoto Y, Yamasaki A, Segi E et al. Failure of parturition in mice lacking the prostaglandin F receptor. Science 1997; 277:681-3.
Sugiyama E, Kaniwa N, Kim SR et al. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J Clin Oncol 2007; 25:32-42.
Sugiyama T, Shinozuka K, Sano A et al. Effects of various Ginkgo biloba extracts and proanthocyanidin on hepatic cytochrome P450 activity in rats. Shokuhin Eiseigaku Zasshi 2004; 45:295-301.
Sugiyama T, Shuto T, Suzuki S et al. Posttranslational negative regulation of glycosylated and non-glycosylated BCRP expression by Derlin-1. Biochem Biophys Res Commun 2011; 404:853-8.
Sugiyama Y, Mimura N, Kuwabara T, Kobayashi H, Ushiki J, Fuse E. Effect of benidipine on simvastatin metabolism in human liver microsomes. Drug Metab Pharmacokinet 2007; 22:199-205.
Suhaiman L, de-Rosas JC, Sartor T, Palmada N, Giordano OS, Lopez LA. Effect of dehydroleucodine on the reproductive tract of male mice. Andrologia 2011; 43:297-302.
Suhua W, Rongzhu L, Wenrong X et al. Induction or inhibition of cytochrome P450 2E1 modifies the acute toxicity of acrylonitrile in rats: biochemical evidence. Arch Toxicol 2010; 84:461-9.
Sui H, Wang Y, Liu X et al. COX-2 Contributes to P-glycoprotein-mediated multidrug resistance via phosphorylation of c-Jun at Ser63/73 in colorectal cancer. Carcinogenesis 2011; 32:667-75.
Sui Y, Xu J, Rios-Pilier J, Zhou C. Deficiency of PXR decreases atherosclerosis in apolipoprotein E-deficient mice. J Lipid Res 2011; 52:1652-9.
Sukumaran SM, Potsaid B, Lee MY, Clark DS, Dordick JS. Development of a fluorescence-based, ultra high-throughput screening platform for nanoliter-scale cytochrome p450 microarrays. J Biomol Screen 2009; 14:668-78.
Sulc M, Hodek P, Stiborová M. The binding affinity of carcinogenic N-nitrosodimethylamine and N-nitrosomethylaniline to cytochromes P450 2B4, 2E1 and 3A6 does not dictate the rate of their enzymatic N-demethylation. Gen Physiol Biophys 2010; 29:175-85.
Sulem P, Gudbjartsson DF, Geller F et al. Sequence variants at CYP1A1-CYP1A2 and AHR associate with coffee consumption. Hum Mol Genet 2011; 20:2071-7.
Sulkava R, Kainulainen K, Verkkoniemi A et al. APOE alleles in Alzheimer’s disease and vascular dementia in a population aged 85+. Neurobiol Aging 1996; 17:373-6.
Sulová Z, Ditte P, Kurucová T et al. The presence of P-glycoprotein in L1210 cells directly induces down-regulation of cell surface saccharide targets of concanavalin A. Anticancer Res 2010; 30:3661-8.
Sullivan AD, Wigginton J, Kirschner D. The coreceptor mutation CCR5Delta32 influences the dynamics of HIV epidemics and is selected for by HIV. Proc Natl Acad Sci USA 2001; 98:10214-9.
Sullivan GJ, Hay DC, Park IH et al. Generation of functional human hepatic endoderm from human induced pluripotent stem cells. Hepatology 2010; 51:329-35.
Sullivan KA, Castle VP, Hanash SM, Feldman EL. Insulin-like growth factor II in the pathogenesis of human neuroblastoma. Am J Pathol 1995; 147:1790-8.
Sullivan PF, Neale MC, Silverman MA et al. An association study of DRD5 with smoking initiation and progression to nicotine dependence. Am J Med Genet 2001; 105:259-65.
Sullivan PM, Mezdour H, Aratani Y et al. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem 1997; 272:17972-80.
Sullivan-Klose TH, Ghanayem BI, Bell DA et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996; 6:341-9.
Suman G, Jamil K, Suseela K, Vamsy MCh. Novel mutations of CYP3A4 in fine needle aspiration cytology samples of breast cancer patients and its clinical correlations. Cancer Biomark 2009; 5:33-40.
Sumida A, Fukuen S, Yamamoto I, Matsuda H, Naohara M, Azuma J. Quantitative analysis of constitutive and inducible CYPs mRNA expression in the HepG2 cell line using reverse transcription-competitive PCR. Biochem Biophys Res Commun 2000; 267:756-60.
Sumida A, Kinoshita K, Fukuda T et al. Relationship between mRNA levels quantified by reverse transcription-competitive PCR and metabolic activity of CYP3A4 and CYP2E1 in human liver. Biochem Biophys Res Commun 1999; 262:499-503.
Summers AM, Summers CW, Drucker DB, Hajeer AH, Barson A, Hutchinson IV. Association of IL-10 genotype with sudden infant death syndrome. Hum Immunol 2000; 61:1270-3.
Summers CM, Cucchiara AJ, Nackos E et al. Functional polymorphisms of folate-metabolizing enzymes in relation to homocysteine concentrations in systemic Lupus erythematosus. J Rheumatol 2008; 35:2179-86.
Sun A, Xu L, Wang S et al. SCN5A R1193Q polymorphism associated with progressive cardiac conduction defects and long QT syndrome in a Chinese family. J Med Genet 2008; 45:127-8.
Sun B, Hoshino J, Jermihov K et al. Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem 2010; 18:5352-66.
Sun BT, Zheng LH, Bao YL et al. Reversal effect of dioscin on multidrug resistance in human hepatoma HepG2/adriamycin cells. Eur J Pharmacol 2011; 654:129-34.
Sun C, Ji G, Liu Q, Yao M. Apolipoprotein E epsilon 4 allele and outcomes of traumatic spinal cord injury in a Chinese Han population. Mol Biol Rep 2011; 38:4793-6.
Sun C, Southard C, Olopade OI, Di Rienzo A. Differential allelic expression of c. 1568C > A at UGT2B15 is due to variation in a novel cis-regulatory element in the 3’UTR. Gene 2011; 481:24-8.
Sun CA, Wang LY, Chen CJ et al. Genetic polymorphisms of glutathione S-transferases M1 and T1 associated with susceptibility to aflatoxin-related hepatocarcinogenesis among chronic hepatitis B carriers: a nested case-control study in Taiwan. Carcinogenesis 2001; 22:1289-94.
Sun D, Chen G, Dellinger RW, Sharma AK, Lazarus P. Characterization of 17-dihydroexemestane glucuronidation: potential role of the UGT2B17 deletion in exemestane pharmacogenetics. Pharmacogenet Genomics 2010; 20:575-85.
Sun DX, Fang ZZ, Zhang YY, Cao YF, Yang L, Yin J. Inhibitory effects of curcumenol on human liver cytochrome P450 enzymes. Phytother Res 2010; 24:1213-6.
Sun DX, Lu JC, Fang ZZ et al. Reversible inhibition of three important human liver cytochrome p450 enzymes by tiliroside. Phytother Res 2010; 24:1670-5.
Sun E, Lim A, Liu X, Snellingen T, Wang N, Liu N. Apolipoprotein E gene and age-related macular degeneration in a Chinese population. Mol Vis 2011; 17:997-1002.
Sun F, Xie ML, Xue J, Wang HB. Osthol regulates hepatic PPAR alpha-mediated lipogenic gene expression in alcoholic fatty liver murine. Phytomedicine 2010; 17:669-73.
Sun H, Ehlhardt WJ, Kulanthaivel P, Lanza DL, Reilly CA, Yost GS. Dehydrogenation of indoline by cytochrome P450 enzymes: a novel “aromatase” process. J Pharmacol Exp Ther 2007; 322:843-51.
Sun H, Gong ZC, Yin JY et al. The association of adiponectin allele 45T/G and -11377C/G polymorphisms with Type 2 diabetes and rosiglitazone response in Chinese patients. Br J Clin Pharmacol 2008; 65:917-26.
Sun H, Moore C, Dansette PM, Kumar S, Halpert JR, Yost GS. Dehydrogenation of the indoline-containing drug 4-chloro-N-(2-methyl-1-indolinyl)-3-sulfamoylbenzamide (indapamide) by CYP3A4: correlation with in silico predictions. Drug Metab Dispos 2009; 37:672-84.
Sun H, Sharma R, Bauman J et al. Differences in CYP3A4 catalyzed bioactivation of 5-aminooxindole and 5-aminobenzsultam scaffolds in proline-rich tyrosine kinase 2 (PYK2) inhibitors: retrospective analysis by CYP3A4 molecular docking, quantum chemical calculations and glutathione adduct detection using linear ion trap/orbitrap mass spectrometry. Bioorg Med Chem Lett 2009; 19:3177-82.
Sun H, Yost GS. Metabolic activation of a novel 3-substituted indole-containing TNF-alpha inhibitor: dehydrogenation and inactivation of CYP3A4. Chem Res Toxicol 2008; 21:374-85.
Sun HB, Zheng Y, Ou W et al. Association between hormone receptor expression and epidermal growth factor receptor mutation in patients operated on for non-small cell lung cancer. Ann Thorac Surg 2011; 91:1562-7.
Sun J, Ma X, Chen YX et al. Attenuation of Atherogenesis via the Anti-Inflammatory Effects of the Selective Estrogen Receptor Beta Modulator 8β-VE2. J Cardiovasc Pharmacol 2011; 58:399-405.
Sun JH, Zhu HJ, Zheng YF, Zhu XQ. Study on the transcriptional modulation of cytochrome P450 3A4 expression by zearalenone. Zhonghua Yu Fang Yi Xue Za Zhi 2004; 38:411-4.
Sun N, Sun X, Chen B et al. MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer. Cancer Chemother Pharmacol 2010; 65:437-46.
Sun P, Liu W, Lin DH et al. Epoxyeicosatrienoic acid activates BK channels in the cortical collecting duct. J Am Soc Nephrol 2009; 20:513-23.
Sun QF, Sun QH, Du J, Wang S. Differential gene expression profiles of normal human parotid and submandibular glands. Oral Dis 2008; 14:500-9.
Sun RF, Zhu YS, Kuang WJ, Liu Y, Li SB. The G-712A polymorphism of brain-derived neurotrophic factor is associated with major depression but not schizophrenia. Neurosci Lett 2011; 489:34-7.
Sun T, Oh WK, Jacobus S et al. The impact of common genetic variations in genes of the sex hormone metabolic pathways on steroid hormone levels and prostate cancer aggressiveness. Cancer Prev Res 2011. doi:10. 1158/1940-6207. CAPR-11-0283.
Sun WY, Coleman MJ, Witte DP, Degen SJ. Rescue of prothrombin-deficiency by transgene expression in mice. Thromb Haemost 2002; 88:984-91.
Sun X, Marks DL, Park WD et al. Niemann-Pick C variant detection by altered sphingolipid trafficking and correlation with mutations within a specific domain of NPC1. Am J Hum Genet 2001; 68:1361-72.
Sun X, Wang Y, Qing H et al. Distinct transcriptional regulation and function of the human BACE2 and BACE1 genes. FASEB J 2005; 19:739-49.
Sun X, Yang J, Hou X, Li J, Shi Y, Jing Y. Relationship between -344T/C polymorphism in the aldosterone synthase gene and atrial fibrillation in patients with essential hypertension. J Renin Angiotensin Aldosterone Syst 2011. doi:10. 1177/1470320311417654.
Sun XF, Ahmadi A, Arbman G, Wallin A, Asklid D, Zhang H. Polymorphisms in sulfotransferase 1A1 and glutathione S-transferase P1 genes in relation to colorectal cancer risk and patients’ survival. World J Gastroenterol 2005; 11:6875-9.
Sun Y, Ren Y, Fang Z et al. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol 2010; 28:4616-20.
Sun Y, Zhu F, Wang M, Ma S, Liao Y. Association analysis about HLA-DRB1, -DQB1 polymorphism and auto-antibodies against α(1)-adrenergic receptors in Chinese patients with essential hypertension. Clin Exp Hypertens 2010; 32:532-9.
Sun YB, Li GF, Tang ZK, Wu BY. Modulation on the P-glycoprotein in the jejunum by combined use of Glycyrrhiza inflata and Kansui. Yao Xue Xue Bao 2010; 45:510-6.
Sun YJ, Long DX, Li W, Hou WY, Wu YJ, Shen JZ. Effects of avermectins on neurite outgrowth in differentiating mouse neuroblastoma N2a cells. Toxicol Lett 2010; 192:206-11.
Sun YX, Liao YH, Zhu F et al. Association between ADRA1A gene polymorphism and autoantibodies against the alpha1-adrenergic receptor in hypertensive patients. Zhonghua Xin Xue Guan Bing Za Zhi 2008; 36:883-7.
Sun Z, Chen J, Aakre J et al. Genetic variation in glutathione metabolism and DNA repair genes predicts survival of small-cell lung cancer patients. Ann Oncol 2010; 21:2011-6.
Sun Z, Milos PM, Thompson JF et al. Role of a KCNH2 polymorphism (R1047 L) in dofetilide-induced Torsades de Pointes. J Mol Cell Cardiol 2004; 37:1031-9.
Sun Z, Zhao Z, Li G et al. Relevance of two genes in the multidrug resistance of hepatocellular carcinoma: in vivo and clinical studies. Tumori 2010; 96:90-6.
Sundvall M, Iljin K, Kilpinen S, Sara H, Kallioniemi OP, Elenius K. Role of ErbB4 in breast cancer. J Mammary Gland Biol Neoplasia 2008; 13:259-68.
Suneetha KJ, Nancy KN, Rajalekshmy KR, Rama R, Sagar TG, Rajkumar T. Role of glutathione-s-transferase and CYP1A1*2A polymorphisms in the therapy outcome of south Indian acute lymphoblastic leukemia patients. Indian J Med Paediatr Oncol 2011; 32:25-29.
Sunman JA, Hawke RL, LeCluyse EL, Kashuba AD. Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes. Drug Metab Dispos 2004; 32:359-63.
Sunouchi M, Sakemi K, Kubota K et al. Network for the collection and distribution of Japanese liver tissues resected surgically for drug development and research use. Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku 2005; 68-72.
Suo Z, Cox AA, Bartelli N et al. GRK5 deficiency leads to early Alzheimer-like pathology and working memory impairment. Neurobiol Aging 2007; 28:1873-88.
Suon S, Zhao J, Villarreal SA et al. Systemic treatment with liver X receptor agonists raises apolipoprotein E, cholesterol, and amyloid-β peptides in the cerebral spinal fluid of rats. Mol Neurodegener 2010; 5:44.
Suonsyrjä T, Donner K, Hannila-Handelberg T, Fodstad H, Kontula K, Hiltunen TP. Common genetic variation of beta1- and beta2-adrenergic receptor and response to four classes of antihypertensive treatment. Pharmacogenet Genomics 2010; 20:342-5.
Suonsyrjä T, Hannila-Handelberg T, Fodstad H, Donner K, Kontula K, Hiltunen TP. Renin-angiotensin system and alpha-adducin gene polymorphisms and their relation to responses to antihypertensive drugs: results from the GENRES study. Am J Hypertens 2009; 22:169-75.
Supnet C, Bezprozvanny I. The dysregulation of intracellular calcium in Alzheimer disease. Cell Calcium 2010; 47:183-9.
Surapureddi S, Rana R, Goldstein JA. NCOA6 differentially regulates the expression of the CYP2C9 and CYP3A4 genes. Pharmacol Res 2011; 63:405-13.
Surekha D, Sailaja K, Rao DN, Padma T, Raghunadharao D, Vishnupriya S. Association of CYP1A1*2 polymorphisms with breast cancer risk: a case control study. Indian J Med Sci 2009; 63:13-20.
Surendiran A, Pradhan SC, Agrawal A et al. Influence of CYP2C9 gene polymorphisms on response to glibenclamide in type 2 diabetes mellitus patients. Eur J Clin Pharmacol 2011; 67:797-801.
Surh I, Rundhaug JE, Pavone A et al. The EP1 receptor for prostaglandin E2 promotes the development and progression of malignant murine skin tumors. Mol Carcinog 2011. doi:10. 1002/mc. 20820.
Suriapranata IM, Tjong WY, Wang T et al. Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians. BMC Med Genet 2011; 12:80.
Surowiak P, Materna V, Kaplenko I et al. ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome. Clin Cancer Res 2006; 12:7149-58.
Susa M, Choy E, Yang C et al. Multidrug resistance reversal agent, NSC77037, identified with a cell-based screening assay. J Biomol Screen 2010; 15:287-96.
Susa M, Iyer AK, Ryu K et al. Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma. PLoS One 2010. doi:10. 1371/journal. pone. 0010764.
Susce MT, Murray-Carmichael E, de Leon J. Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30:1356-8.
Sutherland RL, Musgrove EA. CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER+ disease. Breast Cancer Res 2009; 11:112.
Sutomo R, Laosombat V, Sadewa AH et al. Novel missense mutation of the UGT1A1 gene in Thai siblings with Gilbert’s syndrome. Pediatr Int 2002; 44:427-32.
Suttana W, Mankhetkorn S, Poompimon W et al. Differential chemosensitization of P-glycoprotein overexpressing K562/Adr cells by withaferin A and Siamois polyphenols. Mol Cancer 2010; 9:99.
Sutti S, Vidali M, Mombello C, Sartori M, Albano E. Conformational anti-cytochrome P4502E1 (CYP2E1) auto-antibodies contribute to necro-inflammatory injury in chronic hepatitis C. J Viral Hepat 2010; 17:685-90.
Sutti S, Vidali M, Mombello C, Sartori M, Ingelman-Sundberg M, Albano E. Breaking self-tolerance toward cytochrome P4502E1 (CYP2E1) in chronic hepatitis C: possible role for molecular mimicry. J Hepatol 2010; 53:431-8.
Suttner K, Rosenstiel P, Depner M et al. TBX21 gene variants increase childhood asthma risk in combination with HLX1 variants. J Allergy Clin Immunol 2009; 123:1062-8.
Sutton BS, Palmer ND, Langefeld CD et al. Association of SSTR2 polymorphisms and glucose homeostasis phenotypes: the Insulin Resistance Atherosclerosis Family Study Diabetes 2009; 58:1457-62.
Sutton D, Butler AM, Nadin L, Murray M. Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites. J Pharmacol Exp Ther 1997; 282:294-300.
Suzuki A, Iida I, Hirota M et al. CYP isoforms involved in the metabolism of clarithromycin in vitro: comparison between the identification from disappearance rate and that from formation rate of metabolites. Drug Metab Pharmacokinet 2003; 18:104-13.
Suzuki A, Iida I, Tanaka F et al. Identification of human cytochrome P-450 isoforms involved in metabolism of R(+)- and S(-)-gallopamil: utility of in vitro disappearance rate. Drug Metab Dispos 1999; 27:1254-9.
Suzuki A, Kondo T, Mihara K et al. The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients. Pharmacogenetics 2001; 11:545-50.
Suzuki A, Otani K, Ishida M et al. Increased plasma concentrations of bromperidol and its reduced metabolite with levomepromazine, but not with thioridazine. Ther Drug Monit 1997; 19:261-4.
Suzuki A, Yasui-Furukori N, Mihara K et al. Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol. Ther Drug Monit 2003; 25:192-6.
Suzuki H, Tanabe H, Mizukami H, Inoue M. Selective regulation of multidrug resistance protein in vascular smooth muscle cells by the isoquinoline alkaloid coptisine. Biol Pharm Bull 2010; 33:677-82.
Suzuki K, Sakiyama Y, Usui M et al. Oxidized low-density lipoprotein increases interleukin-8 production in human gingival epithelial cell line Ca9-22. J Periodontal Res 2010; 45:488-95.
Suzuki K, Yanagawa T, Shibasaki T, Kaniwa N, Hasegawa R, Tohkin M. Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes. Diabetes Res Clin Pract 2006; 72:148-54.
Suzuki M, Mizutani-Koseki Y, Fujimura Y et al. Involvement of the Polycomb-group gene Ring1B in the specification of the anterior-posterior axis in mice. Development 2002; 129:4171-83.
Suzuki M, Muto S, Hara K et al. Single-nucleotide polymorphisms in the 17beta-hydroxysteroid dehydrogenase genes might predict the risk of side-effects of estramustine phosphate sodium in prostate cancer patients. Int J Urol 2005; 12:166-72.
Suzuki N, Cheung TT, Cai X-D et al. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta-APP-717) mutants. Science 1994; 264:1336-40.
Suzuki R. Treatment of advanced extranodal NK/T cell lymphoma, nasal-type and aggressive NK-cell leukemia. Int J Hematol 2010; 92:697-701.
Suzuki T, Mihara K, Nakamura A et al. Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia. Ther Drug Monit 2011; 33:21-4.
Suzuki Y, Fujisawa M, Ando F et al. Alcohol dehydrogenase 2 variant is associated with cerebral infarction and lacunae. Neurology 2004; 63:1711-3.
Suzuki Y, Sawamura K, Someya T. The effects of a 5-hydroxytryptamine 1A receptor gene polymorphism on the clinical response to fluvoxamine in depressed patients. Pharmacogenomics J 2004; 4:283-6.
Suzuki Y, Sawamura K, Someya T. Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in japanese depressed patients. Neuropsychopharmacology 2006; 31:825-31.
Suzuki Y, Someya T, Shimoda K et al. Importance of the cytochrome P450 2D6 genotype for the drug metabolic interaction between chlorpromazine and haloperidol. Ther Drug Monit 2001; 23:363-8.
Suzuki Y, Sugai T, Fukui N et al. CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype-phenotype association study design in translational pharmacogenetics. J Psychopharmacol 2011; 25:908-14.
Suzuki Y, Wong SY, Grumet FC et al. Evidence for genetic regulation of susceptibility to toxoplasmic encephalitis in AIDS patients. J Infect Dis 1996; 173:265-8.
Svärd J, Spiers JP, Mulcahy F, Hennessy M. Nuclear receptor-mediated induction of CYP450 by antiretrovirals: Functional consequences of NR1I2 (PXR) polymorphisms and differential prevalence in whites and Sub-Saharan Africans. J Acquir Immune Defic Syndr 2010; 55:536-49.
Svartengren J, Axelsson-Lendin P, Edling N et al. The selective serotonin 5-HT6 receptor antagonist BVT-5182 decreases food intake and body weight in both rats and mice. Abstract Viewer/Itinerary Planner, Program No. 75. 8. Society for Neuroscience,Washington, DC. 2004.
Svartengren J, Fholenhag K, Modiri A et al. Preclinical in vivo pharmacology of BVT-933, a selective 5-HT2c receptor agonist. Abstract Viewer/Itinerary Planner, Program No. 509. 9. Society for Neuroscience,Washington, DC. 2003.
Svecova L, Vrzal R, Burysek L et al. Azole antimycotics differentially affect rifampicin-induced pregnane X receptor-mediated CYP3A4 gene expression. Drug Metab Dispos 2008; 36:339-48.
Svensson US, Ashton M, Trinh NH et al. Artemisinin induces omeprazole metabolism in human beings. Clin Pharmacol Ther 1998; 64:160-7.
Svensson US, Ashton M. Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin. Br J Clin Pharmacol 1999; 48:528-35.
Svensson US, Mäki-Jouppila M, Hoffmann KJ, Ashton M. Characterisation of the human liver in vitro metabolic pattern of artemisinin and auto-induction in the rat by use of nonlinear mixed effects modelling. Biopharm Drug Dispos 2003; 24:71-85.
Sverko A, Sobočanec S, Kušić B et al. Superoxide dismutase and cytochrome P450 isoenzymes might be associated with higher risk of renal cell carcinoma in male patients. Int Immunopharmacol 2011; 11:639-45.
Svobodova M, Martinkova M, Dracinska H, Frei E, Stiborova M. Rat cytochromes P450 oxidize 2-nitrophenol, a human metabolite of carcinogenic 2-nitroanisole. Neuro Endocrinol Lett 2009; 30 Suppl 1:46-51.
Swahn BM, Macsari I, Viklund J et al. Liver X receptor agonists with selectivity for LXRbeta; N-aryl-3,3,3-trifluoro-2-hydroxy-2-methylpropionamides. Bioorg Med Chem Lett 2009; 19:2009-12.
Swaisland HC, Cantarini MV, Fuhr R, Holt A. Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics. Clin Pharmacokinet 2006; 45:633-44.
Swaisland HC, Oliver SD, Morris T et al. In vitro metabolism of the specific endothelin-A receptor antagonist ZD4054 and clinical drug interactions between ZD4054 and rifampicin or itraconazole in healthy male volunteers. Xenobiotica 2009; 39:444-56.
Swaisland HC, Ranson M, Smith RP et al. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin Pharmacokinet 2005; 44:1067-81.
Swales K, Plant N, Ayrton A, Hood S, Gibson G. Relative receptor expression is a determinant in xenobiotic-mediated CYP3A induction in rat and human cells. Xenobiotica 2003; 33:703-16.
Swami S, Krishnan AV, Wang JY et al. Inhibitory effects of calcitriol on the growth of MCF-7 breast cancer xenografts in nude mice: selective modulation of aromatase expression in vivo. Horm Cancer 2011; 2:190-202.
Swanson C, Lorentzon M, Vandenput L et al. Sex steroid levels and cortical bone size in young men are associated with a uridine diphosphate glucuronosyltransferase 2B7 polymorphism (H268Y). J Clin Endocr Metab 2007; 92:3697-704.
Swanson JR, Jones GR, Krasselt W, Denmark LN, Ratti F. Death of two subjects due to imipramine and desipramine metabolite accumulation during chronic therapy: a review of the literature and possible mechanisms. J Forensic Sci 1997; 42:335-9.
Swart EL, van der Hoven B, Groeneveld AB, Touw DJ, Danhof M. Correlation between midazolam and lignocaine pharmacokinetics and MEGX formation in healthy volunteers. Br J Clin Pharmacol 2002; 53:133-9.
Swart PJ, Krauwinkel WJ, Smulders RA, Smith NN. Pharmacokinetic effect of ketoconazole on solifenacin in healthy volunteers. Basic Clin Pharmacol Toxicol 2006; 99:33-6.
Swartz-Basile DA, Goldblatt MI, Ho Choi S et al. Biliary lipids and cholesterol crystal formation in leptin-deficient obese mice. HPB 2006; 8:386-92.
Sweeney C, Ambrosone CB, Joseph L et al. Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment. Int J Cancer 2003; 103:810-4.
Sweeney JD, Blair AJ, Dupuis MP, King TC, Moulton AL. Aprotinin, cardiac surgery, and factor V Leiden. Transfusion 1997; 37:1173-8.
Sweeney MG, Bundey S, Brockington M, Poulton KR, Winer JB, Harding AE. Mitochondrial myopathy associated with sudden death in young adults and a novel mutation in the mitochondrial DNA leucine transfer RNA(UUR) gene. Q J Med 1993; 86:709-13.
Sweet DH, Miller DS, Pritchard JB, Fujiwara Y, Beier DR, Nigam SK. Impaired organic anion transport in kidney and choroid plexus of organic anion transporter 3 (Oat3 (Slc22a8)) knockout mice. J Biol Chem 2002; 277:26934-43.
Sweet RA, Pollock BG, Mulsant BH et al. Pharmacologic profile of perphenazine’s metabolites. J Clin Psychopharmacol 2000; 20:181-7.
Swellam M, Mahmoud MS, Samy N, Gamal AA. Potential influence of interleukin-1 receptor antagonist gene polymorphism on knee osteoarthritis risk. Dis Markers 2010; 28:299-305.
Swen JJ, Wessels JA, Krabben A, Assendelft WJ, Guchelaar HJ. Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus. Pharmacogenomics 2010; 11:1517-23.
Swinney DC, So OY, Watson DM et al. Selective inhibition of mammalian lanosterol 14 alpha-demethylase by RS-21607 in vitro and in vivo. Biochemistry 1994; 33:4702-13.
Swinney RM, Beuten J, Collier A 3rd et al. Polymorphisms in CYP1A1 and ethnic-specific susceptibility to acute lymphoblastic leukemia in children. Cancer Epidemiol Biomarkers Prev 2011; 20:1537-42.
Sy SK, Ciaccia A, Li W et al. Modeling of human hepatic CYP3A4 enzyme kinetics, protein, and mRNA indicates deviation from log-normal distribution in CYP3A4 gene expression. Eur J Clin Pharmacol 2002; 58:357-65.
Syamala VS, Sreeja L, Syamala V et al. Influence of germline polymorphisms of GSTT1, GSTM1, and GSTP1 in familial versus sporadic breast cancer susceptibility and survival. Fam Cancer 2008; 7:213-20.
Syamsu, Yusuf I, Budu, Patellongi I. The effect of polymorphism of the beta-2 adrenergic receptor on the response to beta-2 agonist in bronchial asthma patients. Acta Med Indones 2007; 39:8-12.
Sylvester RK, Steen P, Tate JM et al. Temozolomide-induced severe myelosuppression: analysis of clinically associated polymorphisms in two patients. Anticancer Drugs 2011; 22:104-10.
Symmans WF, Hatzis C, Sotiriou C et al. Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol 2010; 28:4111-9.
Syvälahti EK, Taiminen T, Saarijärvi S et al. Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients. J Int Med Res 1997; 25:24-32.
Szabó K, Tax G, Kis K et al. Interleukin-1A +4845(G> T) polymorphism is a factor predisposing to acne vulgaris. Tissue Antigens 2010; 76:411-5.
Szalat A, Gershkovich P, Ben-Ari A et al. Rifampicin-induced CYP3A4 activation in CTX patients cannot replace chenodeoxycholic acid treatment. Biochim Biophys Acta 2007; 1771:839-44.
Szczepankiewicz A, Breborowicz A, Sobkowiak P, Kramer L, Popiel A. Association of A/T polymorphism of the CHRM2 gene with bronchodilator response to ipratropium bromide in asthmatic children. Pneumonol Alergol Pol 2009; 77:5-10.
Szczerkowska Dobosz A, Rebała K, Szczerkowska Z, Nedoszytko B. HLA-C locus alleles distribution in patients from northern Poland with psoriatic arthritis-preliminary report. Int J Immunogenet 2005; 32:389-91.
Szczerkowska-Dobosz A, Niespodziana K, Rebała K et al. Lack of association of HLA-C alleles with late-onset psoriasis in the northern Polish population. J Appl Genet 2007; 48:273-5.
Szczesna-Skorupa E, Kemper B. Proteasome inhibition compromises direct retention of cytochrome P450 2C2 in the endoplasmic reticulum. Exp Cell Res 2008; 314:3221-31.
Szczesna-Skorupa E, Kemper B. Progesterone receptor membrane component 1 inhibits the activity of drug-metabolizing cytochromes P450 and binds to cytochrome P450 reductase. Mol Pharmacol 2011; 79:340-50.
Szczuraszek K, Materna V, Halon A et al. Positive correlation between cyclooxygenase-2 and ABC-transporter expression in non-Hodgkin’s lymphomas. Oncol Rep 2009; 22:1315-23.
Sze CI, Su M, Pugazhenthi S et al. Down-regulation of WW domain-containing oxidoreductase induces Tau phosphorylation in vitro. A potentional role in Alzheimer’s disease. J Biol Chem 2004; 279:30498-506.
Szebenyi G, Morfini G, Babcock A et al. Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport. Neuron 2003; 40:41-52.
Szekeres G, Kéri S, Juhász A et al. Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2004; 124:1-5.
Szele E, Gombos K, Kovács A, Ember I. Effects of purified glycerol from biodiesel on Cyp1a1 and Cyp2e1 expressions in CBA/CA mice. In Vivo 2011; 25:237-40.
Szeri F, Iliás A, Pomozi V, Robinow S, Bakos E, Váradi A. The high turnover Drosophila multidrug resistance-associated protein shares the biochemical features of its human orthologues. Biochim Biophys Acta 2009; 1788:402-9.
Szewczuk-Bogusławska M, Kiejna A, Beszłej JA, Orzechowska-Juzwenko K, Milejski P. Doxepin inhibits CYP2D6 activity in vivo. Pol J Pharmacol 2004; 56:491-4.
Szolnoki Z, Somogyvari F, Kondacs A et al. Specific APO E genotypes in combination with the ACE D/D or MTHFR 677TT mutation yield an independent genetic risk of leukoraiosis. Acta Neurol Scand 2004; 109:222-7.
Szotáková B, Baliharová V, Lamka J et al. Comparison of in vitro activities of biotransformation enzymes in pig, cattle, goat and sheep. Res Vet Sci 2004; 76:43-51.
Szpak Y, Vieville JC, Tabary T et al. Spontaneous retinopathy in HLA-A29 transgenic mice. Proc Natl Acad Sci USA 2001; 98:2572-6.
Szyda J, Morek-Kopeć M, Komisarek J, Zarnecki A. Evaluating markers in selected genes for association with functional longevity of dairy cattle. BMC Genet 2011; 12:30.